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Abstract 
In COPD, small airways are the main site of airflow obstruction. Neutrophil infiltration into 
small airways is significantly associated with lung function decline. This thesis investigated 
the effects of activated neutrophil products on ex vivo small airway structure and function 
using precision-cut lung slices (PCLS). 
Peripheral blood neutrophils were isolated from non-smokers, smokers and COPD patients; 
stimulated with fMLP, and supernatants obtained. Supernatant protease 
concentration/activity was assessed. There were significant increases in protease 
concentration/activity upon fMLP stimulation, but no significant differences between subject 
groups or correlations with subject demographics. 
Rat PCLS were incubated overnight with neutrophil supernatants, and small airway 
structure, function and PCLS viability assessed. Stimulated COPD neutrophil supernatants 
caused significant airway dysfunction. All neutrophil supernatants significantly reduced 
PCLS viability. There was a significant inverse correlation between supernatant active MMP-
9 concentration and maximal airway closure. Incubation of rat PCLS with H2O2 or porcine 
pancreatic elastase did not fully reproduce the effects of neutrophil supernatants: both 
reduced maximal airway closure; whilst H2O2 alone significantly reduced PCLS viability.  
Pre-incubation of COPD neutrophil supernatants with a NE inhibitor led to restoration of 
maximal airway closure only. Pre-incubation with neither an antioxidant, N-acetyl-cysteine 
(NAC), nor a MMP-9 inhibitor, had any effect on neutrophil supernatant-induced PCLS 
damage.  
Finally, small airways in PCLS from COPD lung tissue had greater maximal airway closure, 
compared with smokers and non-smokers. There were no correlations between subject 
demographics and small airway function.  
Overall, neutrophils from COPD patients induce small airway dysfunction and reduce tissue 
viability. Neither oxidative stress nor elastase reproduced these effects fully; and pre-
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incubation with neither antioxidants nor protease inhibitors restored small airway function. 
Thus, there is greater complexity in neutrophil mediation of this damage. Finally, rat small 
airways do not fully reproduce the response of small airways in COPD lung tissue, which 
exhibit evidence of hypercontractility.  
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1. Introduction 
Breathing involves the passage of air into the lungs, followed by oxygen and carbon dioxide 
exchange at the alveoli, and, finally, passage of air out of the lungs. For this process to occur 
effectively, the airways leading from the nose and mouth to the alveoli need to be open and 
offer minimal resistance to airflow. In health, this is not even considered. In respiratory 
diseases, such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, 
and other fibrotic lung diseases, the airways show increased resistance to airflow, making 
breathing difficult. The resistance to airflow can be due to blockage of the airway lumen, for 
example, by mucus, or to physical narrowing of the airway by remodelling. This thesis 
addresses the issue of remodelling of parenchymal (lung) tissue and small airways, with 
particular reference to COPD. The following sections introduce the various aspects that lead 
to the execution of the experimental work. 
1.1. The airways 
The architecture of the airways, often referred to as the tracheobronchial tree, is organised 
into a series of dichotomous branches that direct inspired air from the trachea down to the 
gas exchange region of the lung (Florens et al., 2011). Each division (branch) is referred to 
as a generation, and there are ~23-27 generations of airways in the human tracheobronchial 
tree. The branching begins at the distal end of the trachea, which splits into the two main 
bronchi. From here, branching proceeds through the lobar and segmental bronchi to the 
terminal bronchioles, which mark the end of the conducting zone (~generation 16). Beyond 
this region are the transitional and respiratory zones, which are the sites of gas exchange. 
Here, respiratory bronchioles open into a number of alveolar ducts, which then further divide 
into alveoli, of which there are ~300 million across both lungs, with an approximate cross-
sectional surface area of 50-70m2 (Weibel, 1963) (Figure 1.1). At each generation, the 
airway diameter decreases; however, due to the exponential increase in the number of 
airways, the cross-sectional area increases at each generation.  
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Figure 1.1. Diagram of the tracheobronchial tree. Airway size decreases but 
cross-sectional area increases with increasing generations. Transitional and 
respiratory zones are the sites of gas exchange. Adapted from (Weibel, 1963). 
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Hagen-Poiseuille’s law describes airflow resistance, whereby resistance is inversely 
proportional to the airway radius raised to the fourth power, which means that halving the 
radius results in a 16-fold increase in airflow resistance (Bosse et al., 2010). Airflow 
resistance is thought to be greatest between the fourth and eighth generations, and 
negligible beyond the 16th (Figure 1.2). The fourth to the 14th generations comprise the small, 
or peripheral, airways; which are defined as having a diameter of <2mm (Stewart et al., 
2013). Therefore, pathological narrowing of the small airways, as is the case in a number of 
Figure 1.2. Relationship between airway generation and resistance to airflow. 
Airway resistance peaks between generations 4-8 (the small, or peripheral, airways), 
and is negligible beyond generation 16. Adapted from Bosse et al, 2010. 
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respiratory diseases (see Section 1.2), will result in a marked increase in airflow resistance, 
which may manifest as chronic cough, difficulty in breathing, and lung function decline.  
1.2. Respiratory Diseases 
In 2012, COPD, lower respiratory tract infections, and various lung cancers were, 
respectively, the third, fourth and fifth leading causes of death worldwide (WHO, 2014), 
demonstrating the increasing global burden of lung disease. Diseases of the respiratory 
system arise due to various genetic or environmental factors, which may be acute or chronic 
in nature, and can vary from mild to debilitating and/or life threatening. 
1.2.1. Cystic Fibrosis 
One example of a genetic disease with debilitating effects on the lung is cystic fibrosis (CF). 
CF is an autosomal recessive disorder, caused by a mutation in the Cystic Fibrosis 
Transmembrane Conductance Regulator (CFTR) gene. This causes dysregulated chloride 
ion transport, and associated sodium ion and water transport at the apical epithelial cell 
membrane; which results in dehydrated, thick, viscous mucus and, consequently, impaired 
mucocilliary clearance (Collins, 1992). Symptomatically, this leads to recurrent respiratory 
infections and bacterial colonisation of the lungs; as well as disorders of the pancreas, liver 
and reproductive organs (Ratjen et al., 2003). CF is usually diagnosed at, or shortly after, 
birth, and the current life expectancy for patients is ~40 years (MacKenzie et al., 2014). 
Despite the disease affecting multiple organ systems, over 90% of CF patients die of lung 
disease, which is characterised by mucus plugging and obstruction of the airways; 
heightened inflammatory responses; persistent infection and bacterial colonization; and 
progressive bronchiectasis (Davis PB et al., 1996). The heightened inflammatory profile 
observed in CF is driven largely by neutrophils; however, there is a long-standing paradox 
that, despite the increased numbers of neutrophils, they cannot effectively control the 
colonisation of bacteria present in the CF lung.  There is thought to be innate dysfunction of 
CF neutrophils linked to the mutation in the CFTR gene that leads to impaired intracellular 
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killing of bacteria, alongside enhanced reactive oxygen species (ROS) production, granule 
enzyme activity, cytokine output, and dysfunctional apoptosis (Gifford et al., 2014). 
Current treatment strategies for CF are predominantly symptomatic, including intravenous, 
inhaled and oral antibiotics to treat infections, which are often given prophylactically to help 
control bacterial colonisation; physiotherapy to aid expectoration of mucous secretions in the 
chest; and, ultimately, lung transplantation. However, more causative therapies are being 
explored: a clinical trial has investigated the efficacy of the CFTR potentiator, Ivacaftor (VX-
770), which was found to be well-tolerated and caused significant improvements within 
patients in nasal potential difference (a measure of CFTR-mediated chloride transport) and 
lung function, and significant changes in sweat chloride levels versus the placebo group 
(Accurso FJ et al., 2010). Research and clinical trials into gene therapy to correct the 
defective receptor are also underway, which may lead to even more causative therapies to 
treat the disease in the future (Armstrong et al., 2014).  
1.2.2. Asthma 
Asthma is a heterogeneous, chronic inflammatory condition of the lungs; characterised 
symptomatically by wheezing, coughing, chest tightness, shortness of breath and airflow 
limitation that can vary in intensity and duration (GINA, 2014). The pathophysiology of 
asthma is complex and incompletely understood, but is thought to arise from a combination 
of genetic and environmental risk factors. For example, pre- and post-natal maternal 
smoking habits are associated with significantly increased risks of children developing 
asthma (Burke et al., 2012). Attacks can be triggered by a number of factors, including 
allergens, environmental pollutants, exercise, or viral infections. Stable disease is managed 
with inhaled corticosteroids, which supress the inflammation; and short-acting and long-
acting β2-adrenergic agonists, which manage the bronchial hyperresponsiveness and 
constriction (GINA 2014).  Severe asthma affects ~5% of patients, whereby their disease is 
difficult to manage with usual therapies. 
 31 
In terms of pathophysiology, allergen inhalation activates mast cells, which release a number 
of mediators, such as prostaglandins, histamine and ROS. These act as 
bronchoconstrictors, and induce mucous hypersecretion and vasodilation. Mast cells and 
airway epithelial cells release a number of cytokines that recruit other inflammatory cells to 
the airways, in particular eosinophils and TH2 cells, that further perpetuate the inflammatory 
response (Barnes, 2008). The inflammation observed in asthma is largely confined to the 
large airways; however peripheral airways have also been implicated in more severe 
phenotypes. Bronchial biopsies from asthmatic patients demonstrate structural changes, 
such as reticular basement-membrane thickening, which occurs as a result of collagen 
deposition underneath the epithelium; smooth muscle hypertrophy and hyperplasia; mucous 
hyperplasia; and an increased number of blood vessels (angiogenesis) (Barnes, 2008). 
Different treatment strategies that are currently being investigated, in particular aimed at 
severe asthmatics, include anti-IgE therapies, that prevent activation of inflammatory cells in 
response to allergens; drugs targeting inflammatory cytokines, such as TH2 cytokines, 
interleukin (IL)-4 and IL-13; and broad spectrum anti-inflammatory drugs, such as kinase 
inhibitors (Barnes, 2011).    
1.2.3. COPD 
COPD is defined as “a preventable and treatable disease that is characterised by 
progressive and persistent airflow limitation, associated with enhanced chronic inflammatory 
responses in the airways and lung to noxious particles or gases” (GOLD, 2014). Whether, in 
fact, COPD can be described as ‘treatable’ is a moot point, as will be explored below. Risk 
and frequency of exacerbations, defined as an acute worsening of symptoms beyond normal 
day-to-day variation, as well as comorbidities, also contribute to the severity of disease in 
individual patients (GOLD, 2014). The progression of COPD is divided into four stages, 
based on spirometric measurements, as defined by the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD). The main spirometric measurements used to determine 
the extent of airflow obstruction are the forced vital capacity (FVC), which is the volume of air 
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forcibly expired following maximal inspiration; and the volume of air forcibly expired in the 
first second following maximal inspiration (forced expiratory volume in one second (FEV1)). 
All patients diagnosed with airflow obstruction have an FEV1/FVC ratio of <0.7, and its 
severity defined as follows: GOLD stage 1 is considered mild, with an FEV1≥ 80% predicted; 
GOLD stage 2 is moderate, with 50%≤ FEV1<80% predicted; GOLD stage 3 is severe, with 
30%≤ FEV1<50% predicted; and GOLD stage 4 is very severe, with FEV1< 30% predicted 
(GOLD, 2014).  
Combined COPD assessments have recently been introduced to GOLD guidelines to reflect 
the heterogeneity of the disease between patients, and form the basis for more personalised 
treatment strategies. This assessment incorporates severity of symptoms, as determined by 
the COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea 
scale; spirometry data and GOLD stages, as described above; and exacerbation frequency. 
This assessment categorises patients into groups A-D: patient group A are low risk and have 
less symptoms; patient group B are low risk with more symptoms; patient group C are high 
risk with fewer symptoms; and patient group D are high risk with more symptoms (GOLD 
2014, Figure 1.3).  
Tobacco smoke has historically been considered the main risk factor pertaining to the 
development of COPD. A study by Fletcher and Peto (1977) was one of the landmark 
reports highlighting an association between cigarette smoking and lung function decline; 
however, their study cohort was limited to only men of working age (30-59 years). Kohansal 
and colleagues (2009) expanded on this by investigating the effects of lung function decline 
over time and the impact of continued cigarette smoking using the Framingham Offspring 
cohort (Kannel et al., 1979), which incorporated both men and women across a much larger 
age range (13-80 years). Their results confirmed those of Fletcher and Peto (1977): 
continued cigarette smoking results in increased lung function decline. The progressive 
nature, heterogeneity of symptoms, and differences in diagnostic criteria mean that COPD is 
often under-diagnosed (Lindberg et al., 2005). It has been previously reported that 15-20% 
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of smokers develop COPD; however, a study by Lündback and colleagues (2003) suggests 
COPD is present in approximately 50% of smokers.  
In addition, increasing evidence suggests that there are several other important risk factors 
for COPD aside from cigarette smoking. In particular, the use of biomass as the primary fuel 
source in ~50% of homes worldwide is thought to be as great a risk factor for development 
of COPD as cigarette smoking, and, in particular, is attributed to the prevalence of COPD in 
women in developing countries who have never smoked (Hu et al., 2010, Salvi, 2010).  
Figure 1.3. GOLD guidelines for COPD assessment. Patients are grouped according to 
spirometry and airflow limitation (left-hand side); symptoms, as determined by the CAT 
score, or mMRC dyspnea scale in its absence (bottom); and exacerbation frequency (right-
hand side). Adapted from GOLD 2014 report. 
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Symptoms of COPD can include chronic cough, sputum production and shortness of breath. 
Treatment guidelines include the use of short-acting and long-acting bronchodilators in mild-
to-moderate stable COPD (although these are far less effective than in asthma); and a 
combination of inhaled corticosteroids (ICS), β2-agonists and/or long-acting anticholinergics 
in patients at risk of exacerbations (Vestbo et al., 2013). However, the majority of COPD 
patients respond poorly to ICS treatment (Barnes, 2013): a recent clinical trial demonstrated 
that gradual withdrawal of ICS treatment, when being used in combination with long-acting 
beta2- agonists (LABA) and long-acting muscarinic antagonists (LAMA), did not result in 
increased risk of exacerbations (Magnussen  et al., 2014). This highlights the need for new 
(anti-inflammatory) therapeutic agents to effectively alleviate symptoms and, in particular, 
slow the progression of COPD.  
1.3. Pathophysiology of COPD 
COPD is an umbrella term that encompasses three main conditions: chronic bronchitis, 
emphysema and small airways disease; characteristics of which are exhibited 
heterogeneously between patients (Figure 1.4).  
1.3.1. Chronic bronchitis 
The definition of chronic bronchitis is “chronic cough and sputum production for at least three 
months per year for two consecutive years” (GOLD 2014). The pathophysiology of chronic 
bronchitis is overproduction and hypersecretion of mucus by goblet cells and submucosal 
glands, in response to a number of different stimuli; including cigarette smoke, viral and 
bacterial infection, and activation of mucin genes by inflammatory mediators (Kim et al., 
2013). Epithelial cells from brushings of large airways were found to have significantly higher 
mucin stores in healthy smokers and in smokers with airflow obstruction, compared with 
non-smokers, which was driven by both goblet cell hypertrophy and hyperplasia (Innes et al., 
2006).  There is also a significantly higher number of goblet cells in peripheral airways of  
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smokers with COPD, compared with non-smokers (Saetta et al., 2000), and this mucous 
metaplasia was significantly correlated with disease severity (Kim et al., 2008).  
1.3.2. Emphysema 
Emphysema is characterised by enlargement on the air spaces, caused by destruction of the 
alveolar septa, which results in reduced surface area for gas exchange. There are two main 
types of emphysema based on the areas of lung affected: centrilobular, whereby 
parenchymal destruction is predominantly in the central regions of the lung and at the 
apices; and panlobular, where destruction is more homogenously distributed across the 
CHRONIC 
BRONCHITIS 
Mucus 
hypersecretion 
EMPHYSEMA 
Destruction of 
alveolar septa and 
enlargement of air 
spaces 
SMALL AIRWAYS 
DISEASE 
Airway remodelling 
and destruction of 
parenchymal 
attachments 
Figure 1.4. The three main pathological conditions encompassing COPD: chronic 
bronchitis, emphysema and small airways disease. Patients may exhibit one, two or 
all of these conditions to a greater or lesser extent, highlighting the heterogeneity of the 
condition. Adapted from Tubby et al, 2011. 
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entire lung (Anderson et al., 1973). Generally, centrilobular emphysema has been 
associated with cigarette smoking, due to cigarette smoke reaching central areas first; 
whereas panlobular is thought to be more prevalent in non-smoking related disease, such as 
the genetic disease of alpha-1 antitrypsin (α1-AT) deficiency. As such, centrilobular 
emphysema is significantly associated with smoking history, symptoms such as dyspnea 
and shorter six-minute walk distances, and is significantly more prevalent in patients with 
severe COPD (Smith et al., 2014). In a group of 131 patients with moderate to severe 
COPD, the presence of emphysema was a significant prognostic factor regarding rapid 
decline in FEV1 (Cerveri et al., 2013). It has been postulated that emphysematous 
destruction of the lung is mediated by excessive proteolytic action, as a result of heightened 
inflammatory responses in the lung. The first evidence of this came from the observation by 
Laurell and Eriksson (1963) that patients with a deficiency in α1-AT, the main inhibitor of 
neutrophil elastase (NE), developed early-onset emphysema. This has led to the hypothesis 
that a protease-antiprotease imbalance mediates the pathogenesis of COPD, which will be 
discussed in more detail in Section 1.4.2. Centrilobular emphysema is significantly 
associated with small airway abnormalities, including smooth muscle hypertrophy, fibrosis 
and inflammatory cell infiltration, compared with panlobular emphysema, suggesting this 
form of emphysema and small airway disease may be intrinsically linked (Saetta et al., 
1994). 
1.3.3. Small airways disease  
One of the prevailing theories regarding COPD pathophysiology is that the small (or 
peripheral) airways, defined as being non-cartilaginous and <2mm in diameter, are the main 
site of airflow obstruction (Hogg et al., 1968). Small airways disease is characterised by 
remodelling of the small airways, which includes fibrosis, thickening of the airway wall layers 
and destruction of extracellular matrix proteins, all of which may contribute to aberrant 
airway function and airflow obstruction (Figure 1.5).  
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COPD progression is associated with increasing infiltration of inflammatory cells into the  
small airways, along with thickening of the airway walls and extent of luminal occlusion 
(Hogg et al., 2004). Cosio and colleagues (1980) demonstrated significant abnormalities in 
the small airways of smokers, compared with non-smokers, with respect to goblet cell 
metaplasia, inflammatory infiltrate, smooth muscle hypertrophy, and respiratory bronchiolitis. 
However, as their cohort was made up of people who died suddenly, outside of hospital, 
from non-respiratory related disease, no lung function data was available, therefore making it 
Figure 1.5. Small airway pathology in COPD. Diagram illustrates the pathophysiological 
changes in the small airways that lead to COPD and its associated symptoms. Airway 
narrowing will be a combination of increased wall thickness, due to fibrosis; and airway 
collapse, due to destruction of alveolar ‘attachments’ (emphysema). Adapted from 
(Barnes, 2004).  
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difficult to establish whether their observations are an effect of smoking, or disease, or both. 
Later studies have also found that airway wall thickness of both large and small airways is 
increased in COPD patients, compared with non-smokers and healthy smokers, and this 
was correlated positively with smoking history, and negatively with lung function (Deveci et 
al., 2004). In addition to thickening of the airway wall, there is a significant reduction in the 
amount of elastin in the walls of small airways and alveoli, compared with non-obstructed 
smokers, and the amount of elastin was significantly correlated with predicted FEV1 (FEV1 % 
predicted) (Black et al., 2008). Elastin degradation in the airway wall and surrounding 
parenchyma results in reduced elastic recoil of the airway, which may lead to partial, and 
sometimes complete, airway collapse. 
1.4. Cells and mediators in COPD 
1.4.1. Inflammatory cells 
There are a number of inflammatory cells implicated in the development and progression of 
COPD, including macrophages, T-lymphocytes, and neutrophils (Figure 1.6). All three cell 
types are significantly increased in induced sputum of COPD patients, compared with non-
smokers and asymptomatic smokers; and all are inversely correlated with lung function 
decline (Di Stefano et al., 1998). In addition, epithelial cells and fibroblasts are also involved 
in COPD pathophysiology, but are not pertinent to the subject matter of this thesis and will 
not be discussed further. 
Macrophages are ‘professional’ phagocytic cells that differentiate from circulating monocytes 
in response to inflammatory signals. Macrophages are activated by cigarette smoke, causing 
the release of pro-inflammatory mediators (Ito et al., 2001) and, thus, recruit other 
inflammatory cells, including neutrophils, to the site of inflammation. COPD macrophages 
are inherently defective at phagocytosing bacteria (Taylor et al., 2010), and appear to be 
skewed  towards a pro-inflammatory phenotype: they release increased amounts of pro-
inflammatory cytokines, e.g. tumor necrosis factor (TNF)-α and CXCL8, and demonstrate 
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reduced plasticity in differentiating towards an anti-inflammatory phenotype (Culpitt et al., 
2003, Chana et al., 2014).  
T-cells are a type of lymphocyte that is important in adaptive, rather than innate, immunity. 
There is a significant increase in number of CD8+ T-cells in bronchial biopsies and lung 
Figure 1.6. Heightened pro-inflammatory responses in COPD. Macrophage or 
epithelial cell activation by cigarette smoke triggers a cascade of pro-inflammatory 
responses that may manifest in the pathophysiogical conditions of COPD. CXCL8 = 
interleukin 8; LTB4 = leukotriene B4; TGFβ = transforming growth factor β. Solid lines = 
directly linked; dashed lines = indirectly linked. Adapted from Barnes, 2004. 
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parenchyma of COPD patients, compared with non-smokers and asymptomatic smokers; 
and this was inversely correlated with FEV1 % predicted (O'Shaughnessy et al., 1997, Saetta 
et al., 1999). In addition, over 90% of lung CD8+ cells from COPD patients express toll-like 
receptors (TLR)- 4 and -9, both of which result in signal transduction pathways involving 
downstream pro-inflammatory pathways, compared with <20% in control subjects. In 
addition, cigarette smoke condensate appeared to perpetuate this pro-inflammatory 
phenotype by significantly increasing protein expression of these TLRs on peripheral blood 
CD8+ cells, and their secretion of a number of pro-inflammatory cytokines, including TNF-α, 
IL-1β, and interferon (IFN)-γ (Nadigel et al., 2011). There is substantial interplay between 
these inflammatory cells that propagates the heightened inflammatory response 
characteristic of COPD; however, the focus of the present work is on neutrophils.  
1.4.1.2. Neutrophils 
Neutrophils, otherwise referred to as polymorphonuclear leukocytes (PMNs), are an 
essential component of the innate immune system, and are considered to be one of the “first 
responders” of host defence (Figure 1.7). Upon activation, neutrophils tether and crawl along 
inflamed blood vessels prior to extravasation (Page et al., 2013). This is accompanied by 
neutrophil polarisation and the localisation of the glycoprotein, PSGL-1, in the uropod (or 
hind edge). Neutrophils extend this PSGL-1-rich microdomain into the vessel lumen in order 
to interact with circulating activated P-selectin expressing platelets.  This interaction appears 
to be essential for neutrophil crawling and diapedesis through the endothelium: neutrophils 
in mice transiently depleted of platelets, along with mice expressing defective PSGL-1 
localisation or signalling, demonstrated virtually no crawling (Sreeramkumar et al., 2014). 
Therefore, neutrophil-platelet interactions appear to be an essential step during neutrophil 
activation and recruitment to sites of inflammation.  
Neutrophils, along with eosinophils and basophils, encompass the granulocyte fraction of 
white blood cells; which, as the name infers, pertains to the presence of granules in the 
cytoplasm (Amulic et al., 2012). There are four distinct subtypes of granule: azurophil  
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Figure 1.7. Summary of the role of neutrophils in the resolution of inflammation. (A) 
Quiescent neutrophils circulate in the blood stream. (B) In response to inflammatory 
signals e.g. Formyl-Methionyl-Leucyl-Phenylalanine (fMLP)) from bacteria acting on 
formyl peptide receptors (FPR) receptors on neutrophils, neutrophils extravasate through 
the endothelium and into the tissue, where they (C) migrate to the site of injury along 
chemotactic gradients. (D) Upon reaching the source of inflammatory signals, neutrophils 
destroy invading pathogens by degranulating, releasing granule proteins; and, via the 
respiratory burst, release reactive oxygen species (ROS). (E) Once inflammation has 
been resolved, neutrophils apoptose and are cleared by resident macrophages. F = 
fMLP. Original diagram by author.  
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(primary), specific (secondary), gelatinase (tertiary) and secretory vesicles (Figure 1.8). 
Historically, granules were defined as being either “peroxidase positive” or “peroxidase 
negative”, due to the presence of (myeloperoxidase) MPO in the former; however, further 
subdivision of granules has since been established (Borregaard et al., 1997). Azurophil 
granules are MPO positive, whilst peroxidase negative granules are further subdivided into 
specific (secondary) and gelatinase (tertiary) granules. These granules are formed 
sequentially during neutrophil maturation in the bone marrow, and differ in both their 
contents and their propensity for exocytosis. Analysis of mRNA transcripts of 16 marker 
proteins from the four granule subsets revealed that there appears to be “blockwise” 
regulation of the synthesis of many of these proteins during neutrophil maturation, from 
myeloblasts to mature PMNs; i.e. proteins incorporated in the same granule subset are 
regulated together. These results led to the “targeting-by-timing” hypothesis: the point during 
neutrophil maturation at which granule proteins are synthesised dictates the granule subset 
in which they will reside (Cowland et al., 1999) (Figure 1.9).  
 
Azurophil granules are the first to be formed at the promyelocyte stage of neutrophil 
development in the bone marrow, and are identified by their MPO content. Azurophil 
granules can be further subdivided according to their expression of α-defensins (also known 
as human neutrophil peptides (HNP)), which are important antimicrobial peptides. These 
differ in expression depending on the timing of granule formation: those formed early in the 
promyelocyte stage have low α-defensin content, whereas those formed later, near the 
promyelocyte/myelocyte transition, are rich in α-defensins. Despite these differences, both 
subtypes of azurophil granule have the same propensity for exocytosis (Faurschou et al., 
2002).  Specific granules are formed next at the myelocyte/metamyelocye stage, and contain 
high concentrations of lactoferrin; followed by gelatinase granules at the band cell stage that 
have a high gelatinase content (Faurschou et al., 2003). Secretory vesicles are the last of 
the granules to be formed, but only contain plasma proteins and so are thought to be 
endocytic in origin. These vesicles have a particularly high density of membrane proteins 
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that are incorporated in the plasma membrane of the neutrophil when secretory vesicles are 
mobilised (Faurschou et al., 2003). Granules are exocytosed in the reverse order to which 
they were formed: secretory vesicles are the first to be mobilised, followed by gelatinase, 
then specific and, finally, azurophil granules (Sengeløv et al., 1993). This is thought to reflect 
the role of each granule subset in neutrophil diapedesis: secretory vesicles contain 
membrane receptors required for neutrophil rolling and firm adhesion to the endothelium, 
whereas azurophil granules contain a number of microbicidal proteases required for 
intracellular degradation of microorganisms (Pham, 2006). In addition, this ensures that 
neutrophils are activated at the right place and the right time to avoid damage to healthy host 
tissue.  
Figure 1.8. Granule subtypes in neutrophils. Neutrophils encompass four granule 
subsets, with different propensities for exocytosis depending on the level of 
stimulation/activation. This enables appropriate responses to inflammatory signals based 
on the concentration of agonist and/or chemokines. MPO= myeloperoxidase; MMP= 
matrix metalloprotease; NGAL= neutrophil gelatinase-associated lipocalin; CD= cluster of 
differentiation; CR= complement receptor; FPR= formyl peptide receptor. Adapted from 
Pham, 2002.  
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In addition to proteases, neutrophils also release ROS and a plethora of cytokines in 
response to stimulation, which are detailed in Tecchio et al (2014). These include, but are 
not limited to, a number of CXC chemokines, including CXCL1 and -8; CC chemokines, 
including CCL2, 3 and 4; TNF-α; TGF-β; and IL-1α, -1β, -6 and -7. Therefore, as well as 
having direct antimicrobial effects, neutrophils can also augment the proinflammatory 
environment through the release of cytokines and chemokines, which may further implicate 
them in COPD pathophysiology.  
1.4.1.3. Neutrophils in COPD 
Neutrophils have been heavily implicated in the pathogenesis of COPD. There are increased 
numbers of neutrophils in the sputum (Keatings et al., 1996), bronchoalveolar lavage fluid 
(BALF) (Martin et al., 1985), and airway tissue (See section 1.4.1.4) of COPD patients, and 
Figure 1.9. Granule subset formation during neutrophil maturation. Granule 
subsets are formed by the “targeted by timing” hypothesis, whereby granule contents 
are incorporated into different subsets based on the time during neutrophil maturation in 
which they are synthesised. MB= myeolblast; PM= promyelocyte; MC=myelocyte; MM= 
metamyelocyte; BC= band cell; PMN= polymorphonuclear neutrophil; MPO= 
myeloperoxidase 
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this correlates with disease severity (Stănescu et al., 1996, Hogg et al., 2004, O'Donnell et 
al., 2004). Burnett et al (1987) posited that neutrophils from patients with emphysema exhibit 
increased proteolysis and chemotaxis, compared with control subjects. Neutrophils from 
COPD patients also exhibited increased respiratory burst and increased expression of the 
adhesion molecule, Mac-1 (CD11b/CD18), both at baseline and after stimulation with TNF-α, 
compared with non-smokers and asymptomatic smokers (Noguera et al., 2001). Neutrophils 
from patients suffering with early-onset COPD also demonstrated increased respiratory 
burst, and increased NE and CXCL8 release in response to fMLP stimulation, compared with 
non-smoker controls (Milara et al., 2012). COPD neutrophils also demonstrate aberrant 
chemotaxis, having increased speed but reduced directionality and accuracy, compared with 
non-smokers, asymptomatic smokers or patients with α1-AT deficiency (Sapey et al., 2011). 
Therefore, there is increasing evidence that the neutrophil contribution to pathophysiology of 
COPD is not only due to increased numbers, but also to inherent aberrant activity of these 
cells.  
1.4.1.4. Neutrophil infiltration of small airways in COPD 
There are significantly increased numbers of neutrophils and macrophages in the 
subepithelium in bronchial biopsies from COPD patients, compared with healthy smokers, 
and this was negatively correlated with FEV1 % predicted (Di Stefano et al., 1998). There are 
significantly increased numbers of neutrophils in the smooth muscle of small airways in 
COPD patients and smokers with normal lung function, compared with non-smokers; and 
this was also significantly negatively correlated with FEV1 % predicted and FEV1/FVC 
(Baraldo et al., 2004). The percentage of neutrophils in induced sputum was significantly 
increased in moderate to severe COPD patients, compared with non-smokers, smokers with 
normal lung function, and mild COPD patients; and this was also significantly correlated with 
evidence of small airway obstruction, as determined by the expiratory/inspiratory mean lung 
density ratio (O'Donnell et al., 2004). In the same study, increasing small airway obstruction 
was also correlated with decline in FEV1 % predicted, further validating the influence of small 
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airway obstruction on COPD progression. Isajevs et al (2011) also demonstrated significant 
neutrophil infiltration in small airways of COPD patients, compared with asymptomatic 
smokers and non-smokers; and, in addition, revealed a significant increase in nuclear factor 
(NF)-κB positive cells and a significant decrease in histone deacetylase (HDAC)-2 positive 
cells in the subepithelium and epithelium of small airways in COPD patients, which indicates 
increased expression of pro-inflammatory genes in the small airways.  
1.4.2. Proteases 
As mentioned previously, neutrophils contain a number of different proteases that enable 
them to effectively destroy invading organisms. Of particular interest are the serine 
proteases, most notably NE, matrix metalloproteases (MMPs), and MPO. 
1.4.2.1. Neutrophil elastase 
NE, Cathepsin G and Proteinase-3 are a group of proteases known as serine proteases, and 
are stored in their active form in azurophil granules (Pham, 2006).  In particular, NE has 
been heavily implicated in COPD pathophysiology (see section 1.4.2.4). The main role of NE 
is to destroy pathogens within the phagolysosome. NE has been shown to be important in 
the destruction of Gram-negative bacteria, as NE-/- knockout mice had increased mortality 
and inability to clear infection of Klebsiella pneumoniae and Escherichia coli, but not Gram 
positive Staphylococcus aureus (Belaaouaj et al., 1998). In humans, mutations in the gene 
encoding NE, ELA2/ELANE, can lead to cyclic or severe congenital neutropenia (Horwitz et 
al., 2007). NE is also important in the destruction of virulence factors on bacterial species 
such as Shigella, Salmonella and Yersinia, which otherwise cause severe enteric infections 
(Weinrauch et al., 2002).  
However, NE is also capable of destroying a number of extracellular matrix (ECM) proteins, 
including elastase, collagen, fibronectin and proteoglycans (Chua et al., 2006), and this is 
thought to mediate some of the tissue destruction observed in COPD. Yoshioka et al., (1995) 
showed that smokers with emphysema had significantly higher concentrations of NE in their 
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BALF, compared with non-smokers and asymptomatic smokers. In addition, NE significantly 
increased transforming growth factor (TGF)-β expression in airway smooth muscle cells in 
vitro, and this was downstream of NF-κB induction (Lee et al., 2006). NE has also been 
shown to induce expression of a number of mucin genes, including MUC1 (Kuwahara et al., 
2005), MUC4 (Fischer et al., 2003) and MUC5AC (Shao et al., 2005); thereby implicating it 
in the mucus hypersecretion also observed in COPD. NE has additionally been shown, in 
vitro, to be involved in the induction of proteases, such as MMP-2 and Cathepsin B 
(Geraghty et al., 2007); inflammatory cytokines, such as CXCL8 (Kuwahara et al., 2006); 
and lipid mediators, such as prostaglandin (PG) E2 (Perng et al., 2003).  
1.4.2.2. Matrix metalloproteases 
Another group of proteins that have been of particular interest in COPD is the MMPs. The 
MMPs comprise a large family of 25 related proteins that have a conserved pro-domain and 
catalytic domain, which comprises a zinc ion in their active site (Parks et al., 2004). 
Substrate specificity varies between MMPs, but they largely degrade components of the 
ECM. Neutrophils contain MMP-2 (Gelatinase A), MMP-8 (Collagenase-2), MMP-9 
(Gelatinase B), and MMP-25 (Leukolysin), which are all contained in specific or gelatinase 
granules (Parks et al., 2004). MMP-8 and MMP-9 are increased in sputum of COPD 
patients, compared with asymptomatic smokers and non-smokers (Vernooy et al., 2004, 
Culpitt et al., 2005); and this is evidenced even at very early stages of the disease 
(previously termed GOLD stage 0, whereby lung function is normal but clinical symptoms of 
COPD are present, i.e. symptomatic smokers) (Ilumets et al., 2007). The sputum 
concentration of MMP-8 and MMP-9 was also significantly negatively correlated with airflow 
obstruction (Vernooy et al., 2004). Patients with emphysema had increased concentrations 
of both MMP-8 and MMP-9 in their BALF, compared with current and ex-smokers without 
emphysema (Betsuyaku et al., 1999). MMP-9 can also induce TGF-β1 expression in human 
airway epithelial cells in vitro (Perng et al., 2011).  
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1.4.2.3. Myeloperoxidase 
MPO is another protease implicated in COPD pathophysiology. MPO is contained in 
azurophil granules, and reacts with hydrogen peroxide (H2O2), formed by nicotinamide 
adenine dinucleotide phosphate (NADP)H oxidase (see Section 1.4.3) and chloride ions, to 
create hypochlorous acid (HOCl), an extremely powerful oxidant. In a longitudinal study of 
68 Swedish males, serum levels of MPO were significantly increased in continual smokers, 
compared with never-smokers or smokers who had quit during the study period; although it 
is worth noting that, in this particular study, this was not related to lung function, and no 
subjects had clinically diagnosable COPD by the end of the study period (Andelid et al., 
2007). However, a recent meta-analysis published in the European Journal of Medical 
Research found that sputum MPO concentration is significantly higher in COPD patients, 
compared with controls; and is also significantly higher during exacerbations, compared with 
stable COPD, implicating MPO as a potential biomarker for COPD (Zhu et al., 2014). There 
are also significantly higher levels of MPO in BALF from COPD patients, compared with non-
smokers (Pesci et al., 1998). As such, MPO may be a marker of the inflammatory effects of 
smoking, with associations with COPD progression.  
1.4.2.4. Protease-antiprotease imbalance  
One of the leading hypotheses regarding the development and progression of COPD is that 
of a protease-antiprotease imbalance. As discussed in Section 1.4.2, there is an increased 
proteolytic burden in the lungs of COPD patients, due to increased numbers and aberrant 
activity of inflammatory cells. The initial evidence for this hypothesis came from the 
observation by Laurell and Eriksson (1963) that patients with a deficiency in α1-AT, the main 
inhibitor of NE, developed early-onset emphysema. A number of animal models have also 
given this hypothesis further credence: hamsters (Senior et al., 1977) and rats (Yokoyama et 
al., 1987) given in vivo instillation of NE developed emphysematous lesions and abnormal 
lung function; and NE-/- knockout mice were protected against emphysema following long-
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term cigarette smoke exposure, compared with wildtype littermates (Shapiro et al., 2003). In 
addition, α1-AT can be oxidised by H2O2, which greatly reduces its ability to inhibit NE 
(Taggart et al., 2000). In addition, this oxidised form of α1-AT can induce release of CXCL8 
and monocyte chemoattractant protein (MCP)-1 from A549 cells and human bronchial 
epithelial cells in vitro, with both chemokines being potent chemoattractants for inflammatory 
cells, such as neutrophils and monocytes (Li et al., 2009). Similarly, proline-glycine-proline 
(PGP) is a peptide formed from ECM breakdown, and is a potent neutrophil chemoattractant, 
suggesting that proteolytic degradation of the ECM can then further propagate the 
inflammatory response by recruiting more immune cells (Weathington et al., 2006). 
Therefore, there is significant evidence that an imbalance of proteases, as a result of a 
heightened pro-inflammatory environment, cannot be adequately quenched by endogenous 
antiproteases, thus leading to tissue destruction and the progression of COPD. 
1.4.3. Oxidative stress 
ROS are unstable small molecules or free radicals derived from molecular oxygen that have 
the propensity to initiate oxidation. These can be formed endogenously by metabolic 
processes, such as the mitochondrial electron transport chain, or by inflammatory cells, such 
as neutrophils; or exogenously by inhalation of cigarette smoke. Oxidative stress is the term 
used to describe a scenario where there is an imbalance of oxidants versus antioxidants. 
ROS can have a number of deleterious physiological effects: they can directly damage 
cellular deoxyribose nucleic acid (DNA), leading to mutations and/or cell death (Ryter et al., 
2007); they are involved in cellular signalling and can activate pro-inflammatory transcription 
factors, such as NF-κB (Schreck et al., 1991); and they can cause lipid peroxidation, leading 
to damage to the cell membrane and production of cytotoxic and genotoxic end-products 
(Esterbauer, 1993).  
One of the main cellular sources of ROS is NADPH oxidase, an enzyme found in a number 
of inflammatory cells, including neutrophils, which catalyses the reaction between O2 and 
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NADPH, to form superoxide ions (O2-). The enzyme is composed of five subunits: one is in 
the neutrophil cell membrane, and the other four in the cytoplasm. Upon ‘sufficient’ 
stimulation, the cytoplasmic components translocate to the membrane-bound subunit to form 
a functional enzyme, in a process often referred to as “respiratory burst” (Dahlgren et al., 
1999). As mentioned in Section 1.4.1.3, neutrophils from COPD patients demonstrate 
increased respiratory burst in vitro, which may perpetuate the oxidant imbalance in COPD if 
reproduced in vivo (Noguera et al., 2001, Milara et al., 2012). 
Evidence of oxidative stress is a common observation in COPD patients. There is a 
significantly increased concentration of H2O2 in the exhaled breath condensate of stable 
COPD patients, compared with non-smokers; and this is further increased in exacerbations 
of COPD (Dekhuijzen et al., 1996). A more recent study measured the concentrations of 
malondialdehyde (MDA), a lipid peroxide; the antioxidants, superoxide dismutase (SOD) and 
glutathione (GSH); and glutathione peroxidase (GSH-PX), an enzyme that reduces lipid 
hydroperoxides, in induced sputum of COPD patients and healthy controls. The authors 
found significant increases in MDA, and significant decreases in SOD, GSH and GSH-PX in 
stable and exacerbating COPD patients, compared with non-smokers and asymptomatic 
smokers; suggesting an imbalance of oxidants and antioxidants (Zeng et al., 2013). Nadeem 
and colleagues (2005) demonstrated evidence of systemic oxidative stress in COPD 
patients, by observing significantly increased plasma levels of MDA, GSH, and GSH-PX, but 
significantly reduced total plasma antioxidant power, compared with non-smokers; and 
significant inverse correlations between FEV1 % predicted and total blood GSH and total 
plasma antioxidant power. Therefore, there is considerable evidence to support the concept 
of an oxidant-antioxidant imbalance in COPD that may be involved in disease 
pathophysiology. 
1.4.4. Inflammatory mediators 
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As mentioned in the above sections, immune cells are recruited to the site of tissue injury by 
inflammatory signals. These signals can be released from both inflammatory cells, such as 
macrophages, and also structural cells, such as airway epithelial cells. Cigarette smoke 
activates macrophages and epithelial cells: studies show cigarette smoke extract (CSE; 
media containing the soluble components of cigarette smoke) induces the release of CXCL8, 
MCP-1 (CCL-2), leukotriene (LTB) B4 and granulocyte colony stimulating factor (G-CSF) 
from alveolar type II cells in vitro, all of which are potent neutrophil or monocyte 
chemoattractants (Masubuchi et al., 1998). CSE can also stimulate release of CXCL8 and 
TNF-α in a monocytic cell line, via activation of NF-κB (Kode et al., 2006); and BALF 
macrophages from smokers release significantly higher amounts of TNF-α and CXCL-8 in 
response to IL-1β stimulation, compared with non-smokers (Ito et al., 2001).  
A number of cells, including epithelial cells, macrophages, T-cells and airway smooth muscle 
cells, have the propensity to release TNF-α. TNF-α is stored in its membrane-bound form 
until appropriate stimulation (e.g. liposaccharide (LPS)) leads to conversion to its active 
form. Active TNF-α can activate NF-κB, a proinflammatory transcription factor that promotes 
the expression of over 150 target genes (Pahl, 1999); and p38 mitogen activated protein 
(MAP) kinase, which also has downstream proinflammatory effects (Barnes, 2004). There 
are increased concentrations of both TNF-α and CXCL8 in the sputum of COPD patients, 
compared with asymptomatic smokers and non-smokers, alluding to the heightened 
proinflammatory environment present in COPD lungs (Keatings et al., 1996).  
Cytokine-induced neutrophil chemoattractant (CINC)-1 (assessed in the present thesis) is 
the rat counterpart of human growth-regulated oncogene product (GRO); levels of which are 
elevated in sputum samples from COPD patients (Traves et al., 2002).  GROα is closely 
related to CXCL8; and CINC-1, like GRO and CXCL8, is a potent neutrophil chemoattractant 
(Handa et al., 2006). CINC-1 can be induced by LPS, IL-1β, TNF-α, ischemia/reperfusion 
and H2O2, and this is thought to be mediated by NF-κB activation (Handa et al., 2006). 
CINC-1 is released from a number of different rat cell types, including cardiac myocytes 
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(Seino et al., 1995), gastric epithelial cells (Handa et al., 2004) and alveolar epithelial cells 
(Riedemann et al., 2002).  
1.5. Investigating small airways function 
1.5.1. Smooth muscle contraction 
There are two predominant types of smooth muscle within the lung parenchyma: airway 
smooth muscle and vascular smooth muscle. As their names suggest, the former refers to 
smooth muscle surrounding the airways, and the latter refers to that surrounding the blood 
vessels. For contraction to occur, myosin light chains must be phosphorylated by myosin 
light chain kinase (MLCK), enabling interaction between actin and myosin filaments. Energy 
released by myosin ATPase enables cycling of actin-myosin cross-bridges, leading to 
functional shortening of the muscle fibers and, therefore, smooth muscle contraction.  
Contraction is calcium (Ca2+)-dependent, and increases in cytosolic Ca2+ are initiated by 
release from intracellular stores, and through voltage- and receptor-gated Ca2+ channels. 
Agonists bind to specific membrane receptors and stimulate phospholipase C (PLC). This 
catalyzes the formation of the second messengers IP3 and DAG. IP3 stimulates the release 
of Ca2+ from intracellular stores in the sarcoplasmic reticulum; whilst DAG, in conjunction 
with Ca2+, activates protein kinase C (PKC), which phosphorylates a number of downstream 
target proteins that are, generally, pro-contractile. Ca2+ combines with calmodulin, a serine-
threonine kinase, which activates MLCK. MLCK phosphorylates myosin light chains and, 
therefore, initiates contraction of smooth muscle fibers. Phosphorylation of myosin fibers is 
also regulated by myosin phosphatase. This dephosphorylates myosin fibers, therefore 
inducing relaxation of the muscle fibers. Myosin phosphatase activity is regulated by Rho 
Kinase, a downstream target of RhoA. Rho kinase phosphorylates a subunit in myosin 
phosphatase, inhibiting its action and therefore promoting contraction.  Therefore, the 
tonicity of smooth muscle is determined by the balance between these two enzymes: MLCK 
promoting contraction, and myosin phosphatase inducing relaxation (Sanderson et al. 2008).   
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G-protein coupled receptors (GPCR) are a superfamily of proteins that transduce 
extracellular signals through receptors in the plasma membrane, and initiate a plethora of 
intracellular signaling pathways vital for a diverse range of cellular functions. As such, GPCR 
are instrumental in mediating airway tone. For example, acetylcholine (or cholinergic 
mimetics, such as carbachol) acts through muscarinic receptors that initiate Gq-coupled 
receptor signaling and promote contraction; whereas β-agonists activate Gs-coupled β2-
adrenergic receptors and initiate bronchodilation (Billington & Penn, 2003). 
There are a number of receptor/agonist combinations that can initiate smooth muscle 
contraction or relaxation, including acetylcholine (or cholinergic mimetics) or 5-
Hydroxytryptamine (5-HT) acting through M2 and M3 muscarinic (see Section 1.) or 5-HT1A or 
2A (Cazzola & Materra, 2000) receptors, respectively, on airway smooth muscle; or 
endothelin-1 and angiotensin II acting through ETA and AT1 receptors (Wynne et al, 2009), 
respectively, on vascular smooth muscle.  
As described in section 1.4.1.2, neutrophils release a number of cytokines, proteases and 
ROS in response to stimulation, all of which can differentially affect both airway and vascular 
smooth muscle. The effects of some of these products are summarized in Table 1.1. It is 
clear that long-term exposure to neutrophil products may elicit many of the effects 
associated with COPD pathophysiology, including smooth muscle hypertrophy and 
hyperplasia, and airway hyperresponsiveness. With respect to the work in this thesis, the 
more chronic effects of exposure to these products, such as proliferation of the smooth 
muscle layer, may not be reflected due to the short time-frame imposed in the experiments. 
However, effects on contraction and relaxation of both airway and vascular smooth muscle 
may be pertinent in interpreting the results within this thesis. 
1.5.2. Methods used to investigate small airway function 
Tracheal and bronchial rings or strips, and parenchymal strips are used, depending of the 
generation of airway under investigation. Tracheal strips involve removing the trachealis  
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Table 1.1. Factors released by neutrophils that affect airway and vascular smooth 
muscle 
 Airway smooth muscle Vascular smooth muscle 
Neutrophil 
elastase 
Increases smooth muscle 
proliferation (Huang et al., 2004) 
Increased TGF-β expression via 
NF-κB pathway (Lee et al., 2006) 
Reduced CXCL8 mRNA 
expression (Ho et al., 2009) 
Induces apoptosis (Oltmanns et 
al., 2005) 
No specific data found 
 
Myeloperoxidase 
 
No specific data found 
Increases expression of endothelin 
receptor type B. Increases 
vasoconstriction (Lau et al., 2014) 
MMP-2, MMP-9 
Increased proliferation (Johnson et 
al., 1999) 
Increased proliferation and 
migration (Chen et al., 2013) 
CXCL8 
Increased contraction and 
migration (Govindaraju et al., 
2006) 
Increases DNA synthesis, cell 
proliferation and cell migration. 
Induces PGE2 release (Yue et al., 
1994) 
CXCL1 (GROα) 
Inhibits migration (Al-Alwan et al., 
2014) 
No specific data found 
TGFβ 
Modulates proliferation (Cohen et 
al., 1997) 
Potentiates responsiveness to 
bradykinin (Kim et al., 2005) 
Modulates proliferation (Tsai et al., 
2009) 
TNFα 
Increase DNA synthesis (Stewart 
et al., 1995) 
Induces hyperresponsiveness 
(Hunter et al., 2003) 
Induces migration (Goetze et al., 
1999) 
Induces IL-1 and PGE2 release 
(Warner et al., 1989) 
LTB4 
Increase proliferation and 
migration (Watanabe et al., 2009) 
Induces DNA synthesis (Palmberg 
et al., 1987) 
PGE2 
Bronchodilation (Benyahia et al., 
2012) 
Vasodilation (Zhu et al., 2002) 
Reactive oxygen 
species 
Modulates airway tone (see 
Chapter 5, section 5.4.1) 
 
Hypertrophy, proliferation and 
migration (Lyle et al., 2006) 
Modulates airway tone (Ardanaz et 
al., 2006) 
TGF= Transforming Growth Factor, TNF= Tumor Necrosis Factor, LTB4= Leukotrine B4, 
PGE= Prostaglandin E2, IL= Interleukin, NF= Nuclear Factor 
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smooth muscle, which runs along the posterior of the trachea in the space between the 
edges of the C-rings of cartilage, from excised trachea, and cutting strips of this muscle. 
Bronchial strips are obtained in a similar way in larger animals where the bronchi are large 
enough to manipulate; however, in small animals (e.g. mice, guinea pig and rat), bronchial 
rings may be used instead. Parenchymal strips are isolated by taking strips of parenchyma 
from the periphery of the lung lobes (Cooper et al., 2009).  
In order to assess their function, strips are held in an organ bath, a chamber containing a 
physiological salt solution; whereby one end is fixed in the organ bath, and the other end is 
fixed to a transducer that measures mechanical responses. These can either measure 
changes in muscle length given a constant force (isotonic transducers), or measure changes 
in force generated whilst maintaining the strip at a constant length (isometric transducers) 
(Cooper et al., 2009). 
The advantages of these techniques are that the dynamics of larger airways can be 
investigated from a variety of different species, and multiple strips can be obtained from one 
trachea/bronchus, allowing several conditions to be investigated. However, one of their 
disadvantages are that, as the preparation of these strips requires its removal, the influences 
of load from surrounding structures (e.g. the parenchyma) on airway smooth muscle 
contraction is not taken into account. In addition, isotonic and isometric muscle contractions 
are not necessarily indicative of in vivo lung mechanics. With regards to investigating small 
airway function, one of the main disadvantages of parenchymal strips is the heterogeneity of 
the smooth muscle within the lung tissue, as it will include vascular smooth muscle as well 
as airway smooth muscle (Cooper et al., 2009). Therefore, additional ex vivo preparations 
are required in order to address these drawbacks of the lung strip technique. 
1.5.3. Precision-cut lung slices 
Detailed examination of the function of specific airway generations is usually performed ex 
vivo. As mention previously, the small airways are thought to be the main site of airflow 
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obstruction in COPD (Hogg et al., 1968), and different ex vivo models have been utilized to 
investigate the function of these airways. Precision-cut lung slices (PCLS) are an ex vivo 
preparation of lung tissue whereby small airways are maintained in their native 
microenvironment with intact parenchymal attachments. This allows for investigation of the 
macroscopic and microscopic architecture of the lung tissue in a similar environment to in 
vivo (Sanderson, 2011). The advantages and disadvantages of PCLS are outlined in Table 
1.2. Throughout this thesis, PCLS are referred to as ex vivo, pertaining to the fact that the 
lungs, or sections of lung, are isolated and the PCLS generated outside of the host. The 
distinction between this and an in vitro preparation is subtle and possibly contentious. 
However, to remain concordant with the literature, whereby PCLS are often referred to as ex 
vivo, they will be considered and referred to as such henceforth.  
Whole lungs (small laboratory animals) or lung tissue explants (human) are inflated with low-
melting point agarose, which mimics the distension of the lung tissue and parenchymal loads 
at full inspiration (Cooper et al., 2009). Inflation with agarose is essential, firstly to enable 
slicing of the lung tissue; and, secondly, as it provides a positive alveolar pressure (which 
would be equivalent to negative pleural pressure in vivo), and this prevents collapse of the 
lung slice (Sanderson, 2011). However, the physiological implications of agarose inflation 
are a potentially confounding issue. Agarose will always remain in the lung slice, as the low-
melting point only refers to the temperature at which the agarose changes from fluid to gel, 
which is ~65°C compared with 87°C in standard agarose. Therefore, at 37°C, the 
temperature at which PCLS are maintained, the agarose will not melt and be washed from 
the slice. However, it is possible to ensure the removal of the agarose from the airway lumen 
through sequential washes following PCLS generation, therefore the agarose should not 
provide any resistance to airway closure in that respect. Different concentrations of agarose 
are used throughout the literature, from as low as 0.75% (Wohlsen et al., 2001), compared 
with the 2-3% used herein. Agarose concentration, and therefore “stiffness”, will influence 
airway contraction, as it will have a determinant effect on the mechanical properties of the  
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Table 1.2. Advantages and disadvantages of the PCLS technique 
Advantages Disadvantages 
Multiple slices can be obtained from one 
animal, therefore substantial data can be 
generated with minimal animal usage. 
This will also provide enough PCLS for 
treatments and controls.  
Inflation with agarose is essential, but 
this may impact on airway dynamics. 
This may be more or less pronounced at 
different concentrations of agarose, 
therefore intergroup comparisons may be 
difficult. 
Accessible from a number of species, 
including rat, mouse, and human.  
Analysis of airway function is potentially 
subjective, and should ideally be 
analyzed by a blinded investigator. 
Airways maintained in native 
microenvironment, therefore impact of 
surrounding structures can be 
considered. Intercellular interactions and 
cellular communications will also be 
maintained, resulting in a more 
physiological model system. 
With respect to human tissue, ability to 
obtain PCLS is largely dependent on 
quality of tissue; therefore investigation 
of severe disease states (e.g. 
emphysema) may not be possible. 
Airways contract auxotonically, which is 
more indicative of in vivo airway function. 
In comparison, organ bath preparations 
measure either isometric or isotonic 
contraction, which are not as 
physiologically applicable. 
Tissue can be damaged during the 
slicing procedure, particularly on the cut 
face of the slice. This is mostly applicable 
in thinner (100-200μm thick) PCLS, and 
this effect can be limited by a period of 
stabilization 
A number of techniques can be 
employed using PCLS, including 
functional studies, mRNA and protein 
expression, and histology.  These can 
often be utilized with the same PLCS, 
therefore enabling correlation between 
physiological responses and cellular 
data. This also maximizes the use of the 
tissue, again limiting animal/tissue 
usage. 
Vast differences in PCLS preparation 
and maintenance between groups (e.g. 
slice thickness, agarose concentration, 
media composition, PCLS culture 
conditions), which may make 
comparisons and extrapolations from 
different groups within the literature 
difficult. 
PCLS= precision-cut lung slices. 
 58 
lung tissue. In particular, relaxation of airways is impacted when using low concentrations of 
agarose (Sanderson, 2011, Schlepütz et al., 2011). However, provided that agarose 
concentration is kept consistent throughout different experiments, comparisons between 
treatments will remain valid. To the author’s knowledge, alternative methods of inflation have 
not been utilized with the PCLS technique; therefore the implications of agarose inflation will 
remain a potential drawback of the PCLS technique. 
As airways in PCLS are maintained with all parenchymal attachments intact, these airways 
contract auxotonically, i.e. parenchymal load increases as airway smooth muscle length 
decreases, which is identical to in vivo airway dynamics. In contrast, bronchial/parenchymal 
strips contract either isometrically or isotonically, depending on how individual experiments 
are set up (Cooper et al., 2009). An additional advantage to the PCLS system is that the 
effect of other structures within the parenchyma, for example blood vessels, can also be 
investigated, both independently and with respect to airway contraction. 
PCLS have a range of applications, including investigating the effects of in vivo insults, e.g. 
cigarette smoke exposure (Cooper et al., 2010) and elastase instillation (Khan et al., 2010); 
pharmacological testing of potential therapeutic targets, e.g. LABA or LAMA (Sturton et al., 
2008); identifying mechanisms of small airway dynamics (Brown et al., 2013); and, as in the 
present study, investigating ex vivo manipulation of the PCLS environment. PCLS also lend 
themselves to a wide range of laboratory techniques: small airway and vascular physiology 
can be assessed using time-lapse imaging, microscopic architecture of the tissue can be 
revealed by histology and by using immunohistochemistry, cytokine and mediator output can 
be measured in PCLS supernatant, and PCLS can be homogenized and protein expression 
detected through western blotting. Therefore, functional and cellular mechanisms can both 
be investigated in one preparation. In addition, large numbers of uniformly sized PCLS can 
be generated from one piece of tissue. To illustrate this point, in the present thesis ~50 
PCLS can be generated from one set of rat lungs, which allows for ~10 different conditions 
to be assessed. Therefore, a large amount of data can be extracted from the use of just one 
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animal, overall minimising the number of animals required. Therefore, PCLS are an 
exceptionally useful adjunct to existing in vivo and ex vivo lung preparations, in order to 
investigate small airway physiology.   
1.6. Drugs and compounds used in this thesis 
A number of different drug compounds are used in this thesis, and these are introduced 
below. 
1.6.1. Carbachol  
Carbamoylcholine chloride, or carbachol (CCh), is a cholinergic agonist that acts on both 
muscarinic and nicotinic receptors. Airways are innervated by both sympathetic (adrenergic) 
and parasympathetic (cholinergic) branches of the nervous system; however, sympathetic 
innervation of the airways is sparse, compared with the parasympathetic supply (Barnes et 
al., 1984). Adrenergic stimulation causes bronchodilation, therefore, β2-adrenergic receptors, 
the predominant adrenoreceptor subtype on airway smooth muscle, are common therapeutic 
targets in diseases with bronchial hyperreactivity, such as asthma. By contrast, cholinergic 
stimulation causes bronchoconstriction through the action of acetylcholine (ACh) on 
muscarinic receptors. There are five subtypes of muscarinic receptors, but only M1, M2 and 
M3 subtypes have been identified in human lungs. Despite the ratio of M2 to M3 receptors 
being ~ 4:1 in the lung, bronchoconstriction is mediated primarily through M3 receptors on 
airway smooth muscle in both rats and human peripheral small airways (Brown et al., 2013). 
M3 receptors activate phospholipase C (PLC) via pertussis-insensitive G-proteins (Gq), which 
in turn increase concentrations of inositol triphosphate (IP3) and diacylglycerol (DAG), 
leading to contraction of airway smooth muscle (Fryer et al., 1998). Neuronal M2 receptors 
are thought to be autoregulatory and provide a negative feedback mechanism:  ACh 
released by (vagal) cholinergic nerves acts on M2 receptors found on postganglionic nerves, 
which then inhibit further ACh release, thereby limiting the degree of airway constriction 
magnitude (Fryer et al., 1998). However, airway smooth muscle cell M2 receptors indirectly 
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mediate bronchoconstriction by inhibiting relaxation pathways of small airways in both rat 
and humans (Brown et al., 2013).   
1.6.2. fMLP 
fMLP is a bacterial peptide that activates neutrophils, initiating chemotaxis, degranulation 
and respiratory burst (Showell et al., 1976, Panaro et al., 1999). There are two types of fMLP 
receptor found on human cells that are activated by formyl peptides: formyl-peptide receptor 
(FPR) and formyl-peptide receptor like-1 (FPRL-1). The former is a high affinity receptor, 
activated at pico- to nanomolar concentrations of fMLP; whereas the latter is lower affinity 
and requires micromolar concentrations (Le et al., 2002). A difference in fMLP receptors on 
neutrophils has been posited as an explanation for the aberrant activity of neutrophils in 
COPD; however, there have been conflicting results. Stockley et al (1984) found significantly 
higher numbers of FPR receptors on neutrophils from patients with emphysema, compared 
with healthy smokers. Conversely, Matheson et al (2003) compared the numbers of fMLP 
receptors on neutrophils in healthy non-smokers and smokers, and COPD smokers and ex-
smokers, and found that current healthy smokers had the highest number of fMLP receptors, 
but that there were no significant differences in receptor number between healthy smokers 
and COPD smokers. This suggests that an increase in fMLP number may be a function of 
smoking, rather than disease state. Conversely, Sapey and colleagues (2011) found no 
difference in FPR1 receptor expression on neutrophils from COPD patients and healthy non-
smoking and smoking controls. The disparity between these results may be due to 
differences in methodology: the Stockley (1984) and Matheson (2003) papers used bound 
labeled-fMLP to quantify fMLP receptor number, whereas Sapey et al (2011) used flow 
cytometry to analyse receptor expression. It is also difficult to compare the size and 
characteristics of the subject groups: Matheson et al had only four COPD smokers, whilst 
Stockley et al had six; meanwhile, Sapey et al only had ex-smokers in their COPD group. 
Therefore, a difference in fMLP receptor expression in COPD neutrophils remains unclear.  
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1.7. Thesis hypothesis 
To briefly summarise the aforementioned background to the experimental work of this thesis, 
neutrophils have been implicated in development and progression of COPD. There is 
evidence of increased numbers of neutrophils in the lungs of COPD patients, and some 
indication that COPD neutrophils behave abnormally, compared with healthy subjects. Small 
airways are thought to be the main site of airflow obstruction in COPD, and PCLS is an ex 
vivo technique that enables investigation of the structure and function of these airways. 
However, it should be noted that the small airways in the rat PCLS of the present thesis do 
not exhibit the fibrotic characteristics of human SAD. Consequently, the present investigation 
focuses on the effect, in isolation, of neutrophil products on parenchymal structure and small 
airway function.  
As such, the hypotheses of this thesis are: 
“Released products from activated human neutrophils (hereafter referred to as neutrophil 
supernatants) will significantly affect PCLS structure and small airway function in rat PCLS, 
and the effects of neutrophils from COPD patients will be more pronounced.”  
“In addition, these effects will be mediated by neutrophil proteases and/or oxidative stress, 
and addition of exogenous inhibitors or antioxidants will attenuate these effects.” 
“Finally, small airways in human PCLS from COPD lung tissue will behave differently, 
compared with those from asymptomatic smokers and non-smokers.” 
1.8. Aims 
In order to investigate the above hypothesis and related sub-hypotheses, the aims of the 
present thesis are: 
1. Collect supernatants from peripheral blood neutrophils from non-smokers, smokers 
and COPD patients, either unstimulated or stimulated with fMLP, and store at -80°C 
until ready for use. 
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2. Measure the concentration of NE, MMP-8, MMP-9 and MPO in the neutrophil 
supernatants, and investigate any correlations with subject demographics (Chapter 
3). 
3. Incubate rat PCLS overnight with neutrophil supernatants, and investigate the effects 
on small airway closure and reopening, PCLS viability and histological appearance of 
the airways; and investigate any differences between subject groups (Chapter 4). 
4. Incubate rat PCLS in either porcine pancreatic elastase (PPE) or H2O2, to investigate 
the effects of elastolytic and oxidative stress on small airway closure, PCLS viability 
and histology; in order to determine if either/both mimic the effects observed after 
incubation with neutrophil supernatants (Chapter 5). 
5. Pre-incubate neutrophil supernatants either with an antioxidant or with protease 
inhibitors, prior to incubation on rat PCLS, in order to determine whether these 
compounds can attenuate the effects of neutrophil supernatants, and potentially 
delineate the source of the tissue destruction (Chapter 6). 
6. Investigate airway closure and reopening of small airways in PCLS from resected 
human lung tissue from COPD patients, asymptomatic smokers and non-smokers, 
and identify any differences between the subject groups and any correlations with 
subject demographics (Chapter 7). 
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Chapter 2:  
Materials & Methods 
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2. Materials & Methods 
2.1. Materials 
Amphotericin-B Gibco, Invitrogen, Paisley, UK 
Brunel BMS Video Microscope Brunel Microscopes Ltd., Wiltshire, UK 
Carbamoylcholine Chloride Sigma-Aldrich, Dorset, UK 
Cell Proliferation Reagent (WST-1)  Roche Diagnostics Ltd., West Sussex, UK 
Cytochalasin B Sigma-Aldrich, Dorset, UK 
Dextran Sigma-Aldrich, Dorset, UK 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich, Dorset, UK 
Dulbecco's Modified Eagles Medium 
(DMEM) 
Gibco, Invitrogen, Paisley, UK 
Dulbecco's Phosphate Buffered Saline 
(DPBS) 
Sigma-Aldrich, Dorset, UK 
Elastase Inhibtor III (324745) Merck Millipore, Watford, UK 
Eosin VWR International, Leicestershire, UK 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, Dorset, UK 
Euthatal® Merial Animal Health Ltd., Essex, UK 
FLUOstar Optima plate reader BMG Labtech Ltd., Bucks, UK 
Formaldehyde (10% v/v) Sigma-Aldrich, Dorset, UK 
Gentamycin Sigma-Aldrich, Dorset, UK 
Glycerol Sigma-Aldrich, Dorset, UK 
GraphPad Prism v 5.0 GraphPad Software Inc., CA, USA 
Hank's Balanced Salt Solution (HBSS) Sigma-Aldrich, Dorset, UK 
Harris Haemotoxylin VWR International, Leicestershire, UK 
HEPES Sigma-Aldrich, Dorset, UK 
Histo-clear National Diagnostics, Yorkshire, UK 
Human Active MMP-9  Fluorokine E®  kit R&D Systems, Abingdon, UK 
Human Leukocyte Elastase Sigma-Aldrich, Dorset, UK 
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Human MMP-8 (Total) Quantikine® kit R&D Systems, Abingdon, UK 
Human MPO (Total) Quantikine® kit R&D Systems, Abingdon, UK 
Hydrogen Peroxide Sigma-Aldrich, Dorset, UK 
Krumdieck Tissue Slicer  
(Model MD1100-A2) 
Alabama Specialty Products Ltd., AL, USA 
L-Glutamine Gibco, Invitrogen, Paisley, UK 
Low-melting point Type IX-A Agarose Sigma-Aldrich, Dorset, UK 
MMP-9 inhibitor I (444278) Merck Millipore, Watford, UK 
N-Acetyl- Cysteine Sigma-Aldrich, Dorset, UK 
N-Formyl-Met-Leu-Phe (fMLP) Sigma-Aldrich, Dorset, UK 
N-methoxysuccinyl-Ala-Ala-Pro-Val p-
nitroanilide 
Sigma-Aldrich, Dorset, UK 
NaOAC Sigma-Aldrich, Dorset, UK 
Neolus Needle 23Gx16mm Scientific Laboratory Supplies Ltd., Yorkshire, 
UK 
Penicillin/ Streptomycin Gibco, Invitrogen, Paisley, UK 
Percoll GE Healthcare Life Sciences, 
Buckinghamshire, UK 
Porcine Pancreatic Elastase  Merck Millipore, Watford, UK 
Prostaglandin E2 Express EIA kit Cayman Chemicals, Tallinn, Estonia 
Rat CINC-1 Duoset  R&D Systems, Abingdon, UK 
Rat TNF-α Duoset R&D Systems, Abingdon, UK 
RPMI Sigma-Aldrich, Dorset, UK 
Shandon™ Finesse™ 325 Manual 
Microtome 
Thermo Fisher  Scientific Inc., MA, USA 
Sodium Chloride (0.9% w/v) Baxter, Norfolk, UK 
Sodium Chloride (9%  w/v) Sigma-Aldrich, Dorset, UK 
Softmax Pro v 6.2 Molecular Devices Ltd., Berkshire, UK 
Spectramax Plus 384 plate reader Molecular Devices Ltd., Berkshire, UK 
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Tissue-Tek Vaccuum Infiltration 
Processor  
Sakura Finetek Europe B.V., The Netherlands 
Triton® X-100 Sigma-Aldrich, Dorset, UK 
Zeiss Axiovision KS300 v 3.0 Carl Zeiss AG, Oberkochen, Germany 
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2.2. Methods 
2.2.1. Rat precision-cut lung slices 
The general protocol for PCLS generation is outlined in Figure 2.1.  
2.2.1.1. Lung excision 
Rat incubation buffer (rat IB) comprised Dulbecco’s Modified Eagle’s Media (DMEM) 
supplemented with 100µg/ml (1% v/v) penicillin/streptomycin, 2.5µg/ml (1% v/v) amphotericin-
B, 4mM (2% v/v) L-glutamine, and 50µg/ml (0.5% v/v) gentamycin. Slicing buffer comprised 
Hank’s Balanced Salt Solution (HBSS) supplemented with 100µg/ml (1% v/v) 
penicillin/streptomycin. To make 2% (w/v) agarose, 0.6g agarose Type IX-A was dissolved in 
30ml slicing buffer, with gentle heating for 30s.  
Figure 2.1. Outline of precision cut lung slices protocol. (A) Male Sprague-Dawley 
rats were euthanized. (B) Heart and lungs with trachea were excised, and (C) inflated 
with 2% (w/v) agarose. (D) When the agarose has set, cores were cut through the lobes of 
the lung (left lung shown). (E) PCLS were cut using a Krumdieck tissue slicer. (F) Slices 
were transferred to individual wells of a 12-well plate in 1ml incubation buffer. (G) PCLS 
observed by microscopy and Zeiss software was used to capture images and analyse 
contractility of the airways. 
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The studies reported here conform to the UK Animals (Scientific Procedures) Act 1986. Male 
Sprague-Dawley rats, aged between 12 weeks and 1 year and weighing 400-700g, were 
euthanized via intraperitoneal injection of 200-300mg sodium pentobarbital (Euthatal®). 
Using dissecting scissors, an incision was made from the region of the diaphragm up to the 
jaw to remove the skin from underlying muscle. The skin was then pulled back to allow 
easier access to the body cavity. Using forceps, the salivary glands and sternohyoid muscle 
were separated to expose the trachea. The forceps were eased underneath the trachea and, 
using plain thread, a loose knot was tied around the trachea. Around a third of the way down 
the trachea, a small incision was made between two rings of cartilage and a cannula 
inserted. The knot was then tied tightly to hold the cannula secure.  To open up the thoracic 
cavity, the manubrium and sternum were dissected apart and the ribcage removed to 
expose the heart and lungs. The trachea was then cut above the cannula, and the heart, 
lungs and trachea carefully dissected out (Fig 2.1 (B)). A 50ml syringe was then filled with 
30ml agarose, attached to the cannula and the lungs inflated. When the lungs were 
adequately inflated (5ml per 100g body weight, up to 30ml) the cannula was removed and 
the trachea tied off securely to prevent leakage (Fig 2.1 (C)). The lungs were immediately 
placed on ice for 30-45min, to allow the agarose to solidify.  
2.2.1.2. Production of PCLS 
Once the agarose had set, 8mm cores were cut transversely through the left lung, and the 
middle lobe of the right lung (Fig 2.1 (D)). These cores were placed in slicing buffer prior to 
slicing. A Krumdieck Tissue Slicer was used to generate rat PLCS (Fig 2.1 (D)). All tissue 
slicing was performed at 4°C. The machine comprises three main components: the 
microtome assembly, the reservoir assembly and the electrical housing. The microtome 
assembly contains one motor that controls a rapidly oscillating disposable blade, and a 
second motor that moves the core of tissue backwards and forwards across the blade. For 
this protocol, the conditions were set so that the blade only oscillates whilst the tissue is 
moved across the blade in one direction, and remains still whilst the tissue moves back to its 
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original position. This reduces damage to the cut surface of the tissue core, compared with a 
continuously oscillating blade. The speed at which the tissue core is moved across the blade 
was set at ~40 slices/minute. The reservoir assembly was filled with ~450ml cold slicing 
buffer, and slices cut between 400-420μm thick. 
Three to 4 cores per rat lung were used, and ~12 PCLS cut per core of lung tissue to 
maximise the variation in lung tissue used for PCLS. This is to better represent a cross-
section of the lung, to ultimately limit the impact of any variability of the lung tissue itself on 
experiments. Single PCLS were placed in individual wells of a 24-well tissue culture plate 
containing 1ml rat IB (Fig 2.1 (F)). PCLS were examined using an inverted microscope and 
selected based on the following criteria: 1) slice was fully circular in shape with no major 
tears or defects, 2) full transverse face of the airway was visible, and 3) airways had intact 
walls and parenchymal attachments. Once a sufficient number of PCLS had been 
generated, they were incubated at 37°C (95% air/ 5% (v/v) CO2) for 1h. PCLS were then 
washed every 30 min for 2.5 h to remove any residual agarose from the airway lumen and 
inflammatory mediators that may have been generated during the slicing process. PCLS 
were then incubated overnight at 37°C.  
2.2.1.3. Investigating airway function in PCLS 
Airways were imaged using a Brunel BMS Video microscope (magnification x4.5) connected 
to a JVC TK-128-OE colour video camera and Zeiss Axiovision KS300 software (Fig 2.1 
(G)). Two custom-made macros were used. The first enabled sequential imaging of the 
PCLS after inputting the name of the experiment and the number of PCLS to be imaged, and 
the images generated were thus named and numbered according to the input instructions. 
The second macro calculated the number of pixels in the airway lumen after it was manually 
selected from the images. Airway closure was then determined by calculating the 
percentage difference in airway lumen size, with respect to baseline measurements (see 
Section 2.2.1.4). 
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One airway was selected on each PCLS based on fulfilment of the criteria detailed in Section 
2.2.1.2. The selected airway was imaged, and a diagram drawn so that the same airway 
could be identified throughout the experiment. PCLS were numbered and airway images 
taken sequentially.  
2.2.1.4. Protocol for measurement of airway contractility 
A summary of this protocol is shown in Figure 2.2. The cholinergic agonist, CCh (section 
1.6.1), was used to induce airway closure. CCh was dissolved in rat IB at a stock 
concentration of 10mM, and aliquots were stored at -20°C until use.  
An initial assessment of airway closure was performed to select airways for further study. 
For this initial assessment, two baseline images of the airways were taken at 5 min intervals 
before addition of 10μM CCh, and PCLS were incubated for 5 min at 37°C. Images were 
then captured of the airways following CCh addition. PCLS were washed 3 times in 1ml rat 
IB to remove CCh, and incubated for at least 1h at 37°C to allow airways to reopen. 
Airways were selected for further use based on the following criteria: 1) after addition of 
10μM CCh, airway closure was >50% with respect to baseline patency; and 2) 
DAY 0 DAY 1 DAY 2 
Rat lungs isolated and 
PCLS generated 
PCLS left to 
recover overnight 
Baseline patency and 
maximal airway closure 
are measured   
PCLS are treated and 
incubated overnight at 37°C 
Baseline patency and full 
concentration-response to CCh  
is measured, with respect to  
Day 1 baseline patency 
 
Figure 2.2. Summary of protocol for treatment of PCLS. PCLS were generated on Day 
0 and left to equilibrate overnight. Baseline measurements were then taken on Day 1, and 
used to group PCLS for treatments. PCLS were then incubated overnight under selected 
treatment conditions. Baseline airway patency and closure were then assessed on Day 2, 
following treatment, compared with baseline measurements taken on Day 1.   
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PCLS/airways still conform to criteria outlined in Section 2.2.1.2. Airways that met these 
criteria were then grouped according to the following criteria: 1) a minimum of four PCLS per 
condition, 2) approximately the same number of PCLS in each group, and 3) the average 
maximal airway closure of all airways in each group is approximately equal across all 
groups.  
PCLS were then treated as below and in subsequent chapters. Following treatment, PCLS 
were incubated overnight at 37°C. The next day, PCLS were washed once in 1ml rat IB in 
preparation for full CCh concentration-response analysis. Example images and graphs are 
shown in Figure 2.3. 
For CCh concentration-response analysis, two baseline images of airways were taken at 5 
min intervals, followed by cumulative additions of CCh at the following concentrations: 10nM, 
30nM, 100nM, 300nM, 1μM, 3μM and 10μM.  PCLS were incubated for 5 min at 37°C 
between each addition of CCh (Figure 2.3 (A)).  
Concentration-response curves were constructed by plotting log [CCh] on the x-axis, against 
the percentage airway closure on the y-axis. Non-linear regression curves were then 
constructed, a representative of which is shown in Figure 2.3 (C). From these curves, three 
parameters can be determined: maximal airway closure (% closure at 10µM CCh), EC50 to 
CCh ([CCh] that produces 50% maximal closure), and baseline airway patency (% closure of 
airways at baseline, prior to addition of CCh). 
Baseline airway patency measurements from before treatment (day 1) were used when 
calculating airway closure following treatments (day 2). This was to ensure that any 
differences in baseline airway patency that may have occurred in response to treatment 
could be identified.  
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Figure 2.3. Airway functional analyses. Representative images of (A) closure of small 
airways with cumulative additions of CCh, and (B) reopening of airways following CCh 
washout, over a 60min time-course. (C) Representative concentration-response curve 
demonstrating measurable parameters: maximal airway closure, EC
50
 to CCh, and baseline 
airway patency. (D) Representative relaxation curve demonstrating measurable parameters: 
t
1/2
 and 60min airway patency. Scale bar (red) = 100µm 
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2.2.1.5. Airway reopening 
To investigate the effects of treatment on airway reopening, PCLS were washed 3 times in 
1ml rat IB. Following the last wash, airways were immediately imaged, and this time was 
taken as 0min. Airways were then imaged every 10min for 1h (Figure 2.3 (B)). Due to the 
time constraints imposed by this experiment, a maximum of 4 airways were investigated per 
condition, up to 24 airways. Relaxation curves were constructed by plotting time after 
washout on the x-axis, and % airway closure on the y-axis. A representative curve is shown 
in Figure 2.3 (D). From this curve, a number of parameters can be determined: t1/2 (time 
taken to reopen to 50% maximal airway closure) and 60 min airway patency (% closure of 
airways at 60 min).   
2.2.2. PCLS viability 
2.2.2.1 WST-1 assay 
Viability of PCLS was determined using a Cell Proliferation Reagent WST-1. WST-1 is a 
tetrazolium salt that is cleaved to a soluble formazan product by metabolically active cells. 
Therefore, the amount of formazan produced is directly proportional to the number of viable 
cells. The stock WST-1 solution from the kit was aliquoted and stored at -20°C until ready for 
use.  
PCLS were transferred to a 48-well plate and 125µL 10% (v/v) WST-1 in rat IB was added to 
each PCLS. PCLS were then incubated at 37°C for 1 h. After this time, 50µL solution was 
pipetted, in duplicate, on to a 96-well microplate. This was then read at λ450nm, with 
reference λ690nm, on a Spectramax Plus 384 plate reader.  
Viability of PCLS is expressed as % untreated PCLS viability: WST-1 O.D of treated PCLS is 
calculated as a percentage of the WST-1 O.D of untreated PCLS. To establish the assay 
output for non-viable PCLS, as a comparison with PCLS from the experimental treatments, 
3-4 PCLS were lysed by macerating in 1ml 1% (v/v) Triton™ X-100 in rat IB for 15 min. 
These were then assayed alongside the rest of the experiment.  
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2.2.3. PCLS histology 
2.2.3.1. Generation of paraffin-embedded sections for histology 
Histological sections were generated by Miss. Lorraine Lawrence or Dr. Jie Zhu via the 
Imperial College Histology Service. 
PCLS were fixed in 1ml 4% (v/v) formaldehyde in phosphate buffered saline (PBS) for 24h 
prior to sectioning. Fixed samples were then transferred to 1ml 100% ethanol for 
transportation to the histologist. Samples were transferred to embedding cassettes between 
2 pieces of insert paper. The cassette was then processed using a Tissue-Tek Vaccuum 
Infiltration Processor, which gradually dehydrates the tissue through a series of ethanol and 
xylene washes. The tissue was then embedded in paraffin, with the surface of the PCLS 
facing the surface of the paraffin block. Sections were then cut at 5µm thickness using a 
Shandon™ Finesse™ 325 Manual Microtome. The paraffin ‘ribbon’ containing the sections 
was floated in a 45°C water bath, and then mounted on to slides. These were left to air dry 
for 30 min, and then baked overnight in a 45-50°C oven.  
2.2.3.2. Elastin Van Giesons staining 
Elastin Van Giesons (EVG) was used to stain histological sections, to allow investigation of 
the architecture of the PCLS following various treatments.  Staining was performed by Dr. 
Jie Zhu. 
EVG staining was performed as described in (Drury et al., 1967). Briefly, sections were 
washed twice for 5 min in Histo-clear, to remove paraffin wax from the section. Sections 
were then gradually rehydrated through 2 washes in 100% industrial methylated spirit (IMS), 
followed by a wash in 70% (v/v) IMS. After rinsing in tap water to remove residual IMS, 
sections were bleached in Oxalic acid for 5 min, before rinsing in tap water. Sections were 
briefly rinsed in 95% ethanol, before staining in Elastin stain for 8-24 h. To differentiate the 
staining, sections were rinsed in 1% (v/v) hydrochloric acid (HCl), followed by multiple 
washes in tap water. Sections were then counterstained in Van Giesons (VG) solution for 1 
min, and then differentiated in 95% ethanol for several seconds. Stained sections were then 
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dehydrated gradually by 30 s rinses in 70, 90 and 100% (v/v) IMS, before 3x5 min washes in 
Histo-clear. Sections were then mounted with coverslips using DPX mountant. 
 
2.2.4. PCLS pre-treatments 
PCLS were pretreated according to experimental procedures with human neutrophil 
supernatants, PPE and H2O2, and a number of inhibitor drugs, as described in Chapters 4, 5 
and 6, respectively. 
2.2.4.1. Neutrophil isolation & stimulation 
2.2.4.1.1. Subject selection 
Whole blood was obtained from non-smokers, smokers and COPD patients recruited by the 
National Heart & Lung Institute, London and the Royal Brompton Hospital, London. All 
subjects gave informed, written consent as approved by the Royal Brompton, Harefield and 
NHLI Research Ethics Committee. 
2.2.4.1.1.1. Non-smokers 
Non-smokers were aged between 48-76, with normal baseline lung function (section 
2.2.4.1.2), as predicted by age, gender and height. Subjects did not present with a history of 
respiratory disease or smoking history, and were not on any regular medications. 
2.2.4.1.1.2. Smokers 
Smokers were aged between 44-69 with normal baseline lung function, as predicted by age, 
gender and height. Subjects did not present with a history of respiratory disease and were 
not on any regular medications. Subjects presented with a smoking history of >10pack 
years, as defined by one pack year being 20 cigarettes per day for one year. 
2.2.4.1.1.3. COPD patients 
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COPD subjects were between 55-89 years old. They presented with an FEV1: FVC ratio of 
<0.7, an FEV1 % predicted of <85%, a smoking history of >10pack years, and had not 
exacerbated for at least 6 weeks prior to giving blood.  
2.2.4.1.2. Lung function assessment  
Lung function was measured by nurses based in the Asthma Laboratory, Royal Brompton 
Hospital. Spirometric measurements used to assess lung function were FEV1 and FVC. To 
obtain these measurements, subjects were required to inhale deeply before forcibly exhaling 
as quickly and for as long as possible in to a spirometer (Vitalograph). Values were 
expressed either as absolute values, or as a percentage of a predicted value based on age, 
gender and height, as determined by Vitalograph Spirotrac® software and ERS (1993) 
criteria (Quanjer et al., 1993). 
2.2.4.1.3. Leukocyte separation 
Blood was processed by members of Professor Louise Donnelly’s group as outlined below: 
Neutrophils were isolated from whole blood from non-smoker, smoker or COPD patient 
volunteers. Sixty ml blood was collected via venepuncture at the antecubital fossa in to 
3x20ml syringes containing 2.5% (v/v) 0.5M of the chelating agent ethylene-diamine-tetra-
acetic acid (EDTA). The 3x20ml syringes of blood were transferred to 3x50ml Falcon tubes, 
and each topped-up to 50ml with 20ml HBSS and 10ml 6% (w/v) dextran solution in 0.9% (w/v) 
NaCl. Red blood cells were left to sediment at room temperature for 20min. Following this, 
the white cell-rich supernatant was transferred to clean 50ml Falcon tubes, topped up with to 
50ml with HBSS and centrifuged at 350g for 10 min at room temperature.  
Different subtypes of leukocytes were separated using a discontinuous Percoll gradient. A 
100% Percoll solution was prepared using 10% (v/v) 9% (w/v) NaCl, to make an isotonic 
solution. This was then diluted in 0.9% (w/v) NaCl to make three different stock solutions: 81, 
68 and 55% (v/v) Percoll. To create the gradient, 4ml 81% (v/v) Percoll was added to 2x15ml 
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Falcon tubes, and 4ml of the 68% (v/v) Percoll was layered over the top. The cell pellet from 
above was resuspended in 3ml 55% (v/v) Percoll, and layered on the top of the pre-prepared 
gradient. The tubes were then centrifuged at 750g for 25 min at room temperature, with 
reduced acceleration and deceleration.  
The different subtypes of leukocytes were distributed along the Percoll gradient based on 
their density: peripheral blood mononuclear cells (PBMC) collect at the 55/68% (v/v) 
interphase, and PMN cells at the 68/81% (v/v) interphase. Once the Percoll gradients have 
been centrifuged, PMN were isolated from their respective layer and topped-up to 50ml with 
PBS and centrifuged at 350g for 5 min. The supernatant was aspirated and the PMN pellet 
resuspended in 2ml distilled water for 30 s to lyse any remaining erythrocytes. The cell 
suspension was then topped-up to 50ml with HBSS. To count neutrophils, the cell 
suspension was diluted 50% (v/v) in Kimura stain (Kimura et al., 1973), a differential cell stain 
that stains nuclei. A haemocytometer was used to count neutrophils, which were then 
resuspended in rat IB.  
2.2.4.1.4. Neutrophil stimulation 
Neutrophils were resuspended at 10x106 cells/ml in rat IB, and cell suspension divided into 
an appropriate number of Falcon tubes based on the number of stimuli that were to be 
administered (non-stimulated, 10 or 100µM fMLP). In all experiments, at least 1ml of the cell 
suspension was kept as a non-stimulated control sample, for comparative purposes in future 
experiments. Cells may become agitated during the isolation procedure and so, to reduce 
any priming effects that this may have, neutrophils were ‘rested’ for ~1h prior to stimulation: 
30min at 4°C and 30min at room temperature. Cytochalasin B, an actin depolymerisation 
inhibitor that aids degranulation (Honeycutt et al., 1986), was added to neutrophils at a final 
concentration of 10µM, and neutrophils were incubated for 10min in a 37°C water bath. The 
cell suspension was then stimulated with either 10 or 100µM fMLP. The cell suspension was 
incubated for 10 min in a 37°C water bath. Following this, neutrophils were centrifuged for 5  
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Figure 2.4. Summary of protocol for stimulation of neutrophils and collecting 
supernatants. 
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min at 350g. One ml of the supernatant was split into 2x500µL aliquots, for use in 
characterisation of the supernatants; whilst the remainder of the supernatant was divided 
into 1ml aliquots. Neutrophil supernatants were stored at -80°C until further use.  This is 
summarised in Figure 2.4. 
2.2.4.2. PPE 
Protocols and procedures for pre-treatment of PCLS with PPE are detailed in Chapter 4. 
2.2.4.3. H2O2 
Protocols and procedures for pre-treatment of PCLS with H2O2 are detailed in Chapter 4. 
2.2.5. Neutrophil Protease Assays 
2.2.5.1. Neutrophil elastase activity assay 
Assay was performed in HBSS supplemented with 0.1M HEPES and 0.5M NaCl, and 
adjusted to pH 7.4. HLE/NE was reconstituted in 50% (v/v) 0.02M NaOAC/glycerol at 
0.0072U/μl. Aliquots of 10μl (0.072U) were stored at -20°C. Before use, 90μl of buffer was 
added to aliquots, to make a stock of 0.0072U. N-methoxysuccinyl-Ala-Ala-Pro-Val p-
nitroanilide (N-MeO-Suc-AAPV-pNA) was reconstituted at 200mM in dimethyl sulfoxide 
(DMSO), and stored at -20°C in 10μl aliquots. 
NE dilutions, from 7.2 x 10-4 U/μl to 1.1 x 10-5 U/μl, were prepared from stock in assay buffer 
and 50μl added, in duplicate, to a 96-well plate. Neutrophil supernatants were diluted in 
assay buffer to either 50% (v/v), for non-stimulated samples, or 10% (v/v), for samples 
stimulated with fMLP, in order to ensure NE activity levels would fit on the standard curve. 
Fifty μl was then added, in duplicate, to a 96-well plate. N-MeO-Suc-AAPV-pNA was diluted 
to 1mM in assay buffer, and 50μl added to all samples/standards, at a final concentration of 
0.5mM, immediately before the plate was read on a Spectramax Plus 384 plate reader. 
Absorbance at λ405nm was measured every 10 s for 30 min, and an activity curve was 
generated using Softmax Pro software. Initial rate of reaction (Vmax) was calculated from 
the curve, and plotted against known NE concentrations to generate a standard curve 
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(Figure 2.5 (A)), and lower limit of detection determined (1.1x10-5 U/μl). Sample NE 
concentrations were then interpolated from the standard curve. 
2.2.5.2. MMP-9 activity assay 
Fluorokine E® Human Active MMP-9 kit was used to quantify the enzymatic activity of human 
MMP-9 in neutrophil supernatants. MMP-9 is secreted as a 92kDa zymogen (pro-MMP-9), 
and this is converted into an 82kDa active form by proteolytic removal of the N-terminal pro-
region. Both forms are quantified by the kit. Supernatants were thawed and all reagents 
brought to room temperature prior to use. The protocol was performed as per manufacturer’s 
instructions.  
As the assay quantifies both pro-MMP-9 and active MMP-9 activity, neutrophil supernatants 
were duplicated in each assay: half to quantify endogenous active MMP-9 in the 
supernatant, and half to quantify total active MMP-9 in the supernatant. Pro-MMP-9 
concentration can then be deduced by subtracting endogenous active MMP-9 from total 
active MMP-9. Briefly, neutrophil supernatants, diluted 1:500 in order to fit within the linear 
portion of the standard curve, and pro-MMP-9 standards serially-diluted from 16 to 
0.25ng/ml, were added to a black 96-well plate, pre-coated with anti-MMP-9 antibody. Anti-
MMP-9 antibody was specific for natural and recombinant MMP-9, and there was no 
significant cross-reactivity observed with any factors tested by the manufacturer. These were 
incubated for 2h at room temperature. The plate was then washed to remove unbound 
sample. An activation reagent, p-aminophenylmercuric acetate (AMPA), which converts pro-
MMP-9 into its active form, was added to the MMP-9 standards, and half of the duplicated 
neutrophil supernatant samples, to measure total MMP-9 in samples. The plate was 
incubated for a further 2h at 37°C in a humidified environment, protected from light. 
Following additional washes, a fluorogenic substrate linked to a quencher molecule was then 
added to all wells and incubated overnight at 37°C in a humidified environment, protected 
from light. Active MMP-9 cleaves the fluorophore from the quencher molecule, allowing a 
fluorescence signal to be emitted that is directly proportional to the amount of active MMP-9  
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Figure 2.5. Standard curves of protease assays. (A) NE concentration against Vmax 
(rate of reaction, mU/min), lower limit of detection 1.1x10
-5 
U/μl. (B) Active MMP-9 
concentration against fluorescence at excitation λ320, emission λ405nm, lower limit of 
detection 0.005ng/ml. RFU= relative fluorescent units. (C) MPO concentration against 
optical density (O.D), lower limit of detection 0.062ng/ml. (D) MMP-8 concentration 
against O.D at λ450-540nm, lower limit of detection 0.06ng/ml. Data are mean ± SEM of 
duplicate readings. 
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present in the sample. This was read the following day using a FLUOstar Optima fluorometer 
at excitation λ320nm and emission λ405nm. A standard curve was generated relating 
fluorescence to amount of active MMP-9, and sample MMP-9 concentrations were then 
interpolated from this standard curve (Figure 2.5 (B)), and lower limit of detection determined 
(0.005ng/ml). 
2.2.5.3. MPO and MMP-8 immunoassay 
Total MPO and MMP-8 were measured in neutrophil supernatants using Quantikine® 
immunoassay kits, as per manufacturer’s instructions. For MPO, supernatants were diluted 
1:100 for non-stimulated samples, and 1:2000 for fMLP-stimulated samples; and for MMP-8, 
supernatants were diluted 1:100 for non-stimulated samples, and 1:500 for fMLP-stimulated 
samples, in order to ensure that all sample MMP-8/MPO concentrations fit within the linear 
portions of the standard curve. These, along with serially-diluted recombinant MPO or MMP-
8 standards (0.156-10ng/ml), were added to a 96-well plate pre-coated with either anti-MPO 
or anti-MMP-8 antibodies. MPO antibody was specific for human MPO protein, and cross-
reacts ~1.8% with human eosinophil peroxidase protein (as determined by the manufactuer); 
and MMP-8 antibody was specific to human natural and recombinant MMP-8 and did not 
cross-react with any factors tested by the manufacturer. These were then incubated for 2h at 
room temperature. Unbound sample was washed off and either MPO or MMP-8 conjugates, 
which were enzyme-linked polyclonal antibodies specific for either protease, were added to 
the wells and incubated for a further 2 h at room temperature. Following further washes, 
substrate solution was added to the wells and incubated for 30 min at room temperature, 
protected from light. During this time, colour develops that is proportional to the amount of 
protease in the wells. Stop solution was added after 30min, and absorbance read at 
λ450nm, with a reference λ540nm. A standard curve was generated relating optical density 
(O.D) to amount of MPO/MMP-8, and sample MPO/MMP-8 concentrations were then 
interpolated from this standard curve (Figures 2.5 (C & D)), and lower limit of detections 
determined (MPO: 0.062ng/ml; MMP-8: 0.06ng/ml). 
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2.2.6. Enzyme-linked Immunosorbant assays (ELISA) 
Measurement of CINC-1, TNF-α, and PGE2 were performed as described in the Materials 
and Methods of Chapter 5 - section 5.2.6. 
 
2.2.7. Human PCLS 
2.2.7.1. Subject selection 
Subject selection for human tissue samples was undertaken as described in the Materials 
and Methods of Chapter 7 - section 7.2.1. 
2.2.7.2. Human tissue inflation and PCLS generation 
Tissue inflation and PCLS generation were performed as described in the Materials and 
Methods of Chapter 7 - section 7.2.2. 
 
2.2.8. Data Analysis 
Comparisons between groups (subject groups, PCLS treatments, protease concentrations, 
etc) were conducted using Mann-Whitney t-tests, or Kruskall-Wallis (ANOVA) tests followed 
by Dunn’s post-correctional tests. For all statistical tests, p<0.05 was considered significant. 
All statistical analysis was performed using GraphPad Prism v5.0 software. 
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3. Protease Composition of Neutrophil Supernatants 
3.1. Introduction 
In response to inflammatory signals, circulating neutrophils are activated and migrate to the 
site of injury, where they degranulate and release a plethora of proteases and ROS (Amulic 
et al., 2012). The contents of this antimicrobial armamentarium are held within four distinct 
granule subsets in the neutrophil cytoplasm, each containing different antimicrobial products 
(see Introduction, section 1.4.1.2). The formation and mobilisation of these granules is a 
tightly-regulated process: granules are formed at different stages of neutrophil maturation, 
and the timing of their formation denotes their propensity for exocytosis (Borregaard et al., 
1997). For example, secretory vesicles, the last of the granule subsets to be formed, are 
readily exocytosed upon relatively mild stimulation; whereas azurophil granules, which are 
the first to be formed, are the last granules to exocytose, and only do so upon maximal 
stimulation. This organisation of granule contents and mobilisation, firstly, prevents contents 
that may react with each other coming in to contact; and, secondly, enables neutrophils to 
elicit an appropriate response based on the level of stimulation (Borregaard et al., 1997).  
One of the leading hypotheses regarding COPD onset is that of a protease-antiprotease 
imbalance (see Introduction, Section 1.4.2.4): increased numbers and aberrant activity of 
neutrophils in the lungs results in an excess of protease activity that cannot be adequately 
quenched by endogenous antiproteases. Evidence to support this hypothesis came from the 
observation that patients with a deficiency in α1-AT, the main inhibitor of NE, develop 
COPD-like symptoms (Laurell et al., 1963). In addition, hamsters instilled with both NE 
(Senior et al., 1977) and proteinase-3 (Kao et al., 1988) developed emphysematous lesions 
in the lungs.  
In addition to in vivo evidence, there are increased concentrations of a number of neutrophil 
proteases in BALF and sputum of COPD patients, including NE (Yoshioka et al., 1995), 
MPO (Yamamoto et al., 1999), and MMP-8 and -9 (Betsuyaku et al., 1999, Vernooy et al., 
2004). NE has also been implicated in having a number of roles in development of COPD 
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pathophysiology: it potentiates mucus hypersecretion by upregulating a number of mucin 
genes (Fischer et al., 2003, Kuwahara et al., 2005, Zhou et al., 2013); it enhances the 
inflammatory response by inducing transcription and release of CXCL8 (Kuwahara et al., 
2006); and contributes to airway hyperresponsiveness and remodelling by inducing release 
of PGE2 (Perng et al., 2003), and TGF-β1 (Lee et al., 2006). The activity and concentrations 
of neutrophil proteases can, therefore, determine the balance between a supportive, 
antimicrobial attack against invading pathogens, and a detrimental assault on healthy host 
tissue that is indicative of COPD pathophysiology. 
FPRs are G-protein coupled receptors that are tightly associated with the cell membrane 
(Panaro et al., 1999). They are present on all mature neutrophils (Allen et al., 1992), and 
there are estimated to be ~53,000 ± 13,000 on resting cells (Sklar et al., 1984). fMLP binds 
to FPRs on neutrophils, and triggers a cascade of biochemical events, such as cell 
polarisation, mobilisation, respiratory burst and degranulation (Panaro et al., 1999). 
Wittmann et al., (2002) reported that stimulation with 100nM fMLP activates ~50% of 
neutrophils, and this is calcium-dependent. A number of compounds are thought to augment 
neutrophil responses to fMLP: pre-incubation with LPS results in a four-fold increase in FPR 
expression (Allen et al., 1992), and increased sensitivity and maximal responses, as 
determined by measurement of vitamin B12 binding protein, which is released by specific 
(secondary) granules (Chadwick et al., 1992). Despite some conflicting reports, there is little 
evidence of increased numbers of FPRs on neutrophils in COPD; however this line of 
investigation is often confounded by differences in time-course, level of stimulation, 
methodology and receptor internalization (see section 1.6.2). 
3.1.2. Chapter Hypothesis 
From the above introductory observations, the hypothesis for this chapter was, therefore, 
that: 
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“Stimulation of neutrophils with fMLP will induce release of proteases, and there will be 
differences in protease composition between neutrophil supernatants from non-smokers, 
smokers and COPD patients”.  
3.1.3. Aims 
In order to investigate the above hypothesis, the aims for this chapter were to: 
1. Obtain supernatants from peripheral blood neutrophils from non-smokers, smokers 
and COPD patients, both non-stimulated and stimulated with the bacterial peptide 
fMLP. 
2. Measure the activity/concentration of NE, MPO, MMP-8 and -9 in the supernatants, 
and compare levels between subject groups. 
3. Examine the relationship between protease activity/concentration and clinical 
parameters of the subjects. 
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3.2. Methods 
3.2.1. Neutrophil isolation  
Non-smokers, smokers and COPD patients were selected based on criteria outlined in 
2.2.4.1.1. Sixty ml blood was taken, and neutrophils were isolated and stimulated as 
described in section 2.2.4.1. Briefly, red blood cells were sedimented and the leukocyte 
suspension centrifuged down a discontinuous Percoll gradient. PMN were isolated from the 
68/81% (v/v) interface, and neutrophils were counted and resuspended in rat incubation 
buffer.  
3.2.2. Collection of neutrophil supernatants for PCLS experiments 
Neutrophil supernatants were isolated as described in Materials & Methods, section 
2.2.4.1.4. Aliquots (500µL) were thawed to room temperature (or 37°C for NE activity assay) 
prior to assessing protease composition. 
3.2.3. fMLP concentration-response 
Neutrophils were resuspended at 20x106 cells/ml, and rested for ~1h. Neutrophils were then 
stimulated with cytochalasin B (final concentration 10µM) for 10 min at 37°C. To make fMLP 
concentrations, stock fMLP (10mM) was diluted in 500μl rat incubation buffer to 2x the 
desired concentration for the concentration response in 1.5ml Eppendorfs. Following 
addition of cytochalasin B, 500μl neutrophil suspension was then added to the Eppendorfs. 
The concentration of fMLP was 1x the desired concentration, and the concentration of 
neutrophils was 10x106 cells/ml. Neutrophils were incubated for 10min at 37°C. Neutrophils 
were then centrifuged for 5 min at 350g and supernatant collected and stored at -80ºC.  This 
protocol is outlined in Figure 3.1. 
3.2.4. Assessment of NE activity of neutrophil supernatants 
NE activity was measured as described in Chapter 2, Section 2.2.5.1. 
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3.2.5. Assessment of MMP-9 concentration of neutrophil supernatants 
MMP-9 concentrations were measured as described in Chapter 2, Section 2.2.5.2. 
3.2.6. Assessment of MMP-8 and MPO concentration of neutrophil supernatants 
MMP-8 and MPO concentrations were measured as described in Chapter 2, Section 2.2.5.3. 
3.2.7. Data Analysis 
Figure 3.1. Protocol outlining treatment of neutrophils for fMLP concentration-
response.  
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In this chapter, patient demographics were compared using a Kruskal-Wallis with Dunn’s 
post-hoc tests. Protease concentration/activity was determined by interpolation from 
appropriate standard curves (Figure 2.5). Concentration/activity data were not all normally 
distributed, as determined by the D’Agostino-Pearson omnibus test. Consequently, the 
Kruskal-Wallis test was used, with Dunn’s post-hoc tests. For familiarity of presentation, data 
are displayed as mean ± SEM. The null hypothesis of no significant differences between 
groups was rejected at p<0.05.  
 91 
3.3. Results 
3.3.1. NE activity  
3.3.1.1. Subject demographics 
NE activity was measured in peripheral blood neutrophil supernatants from 21 non-smokers, 
18 healthy smokers and 19 COPD patients (Table 3.1). COPD patients were significantly 
older (by ~8years) and had significantly worse lung function, compared with non-smokers 
and smokers, as determined by FEV1, FEV1 % predicted and FEV1/FVC, which were 
reduced by about 30-50%. COPD patients also had significantly greater smoking history, 
compared with healthy smokers. 
Table 3.1. Subject demographics for neutrophil supernatants used to measure NE 
activity. 
 Non-smokers Smokers COPD 
N   21     18 19 
Age (years) 60 ± 2   59 ± 1           68 ± 2*/## 
Gender (m/f)   8/13     9/9 9/9 
Smoking history 
(pack years) 
N/A 34.0 ± 4.7 45.6 ± 3.6# 
FEV1 (L)   2.8 ± 0.2     2.7 ± 0.2      1.3 ± 0.1$$$ 
FEV1 predicted (%)       102.2 ± 3.9   94.7 ± 3.1    51.4 ± 4.5$$$ 
FVC (L)    3.8 ± 0.2     3.8 ± 0.3           2.7 ± 0.2**/# 
FEV1/FVC (L)    0.75 ± 0.02     0.73 ± 0.02      0.48 ± 0.04$$$ 
Data are mean ± SEM. */#p<0.05 non-smokers/smokers vs. COPD; **/##p<0.01 non-
smokers/smokers vs. COPD; $$$p<0.001 non-smokers and smokers vs. COPD. 
One pack year is defined as smoking 20 cigarettes per day for one year. NE= Neutrophil 
elastase; FEV= Forced expiratory volume; FVC= Forced vital capacity 
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3.3.1.2. fMLP concentration-response 
In order to identify the appropriate concentration to stimulate neutrophils and elicit a maximal 
response, an fMLP concentration-response was performed and NE activity measured. NE 
activity was chosen for two reasons: firstly, the assay is fast, high-throughput and 
inexpensive; and, secondly, NE is stored in azurophil granules, which are the last to 
degranulate; therefore NE activity in neutrophil supernatants will denote maximal neutrophil 
responses. 
Neutrophils from each subject group were stimulated with increasing concentrations of fMLP 
(1nM-10μM) for 10 min, prior to supernatants being isolated and assayed (Figure 3.2). NE 
activity increased in a concentration-dependent manner, and plateaued at around 1μM 
fMLP, with an overall increase of ~20-fold above non-stimulated. There were no significant 
differences in the maximal NE activity between subject groups (non-smoker 1.6 ± 0.2, n=9; 
smoker 1.6 ± 0.2, n=7; COPD 1.7 ± 0.2 x 10-3 U/μl, n=11). There was a reduction in EC50 to 
Figure 3.2. Effect of fMLP on NE activity in peripheral blood neutrophils in the three 
subject groups (concentration-response). Non-smoker (), n=9; smoker (), n=7; 
COPD patients (), n=11. NS = non-stimulated. Data are mean ± SEM. All data points 
above 100nM fMLP were significantly increased from NS (p<0.05-0.0001). 
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fMLP in neutrophils from smokers and COPD patients, compared with non-smokers; 
however this was not significant (non-smoker 193 ± 123, n=9; smoker 78 ± 21, n=7; COPD 
97 ± 17nM, n=11 fMLP).  
The fMLP concentration-response above suggests that there was maximal NE released from 
neutrophils following stimulation with 10μM fMLP. However, when incubated with rat PCLS, 
supernatants from neutrophils stimulated with 10μM fMLP had only minimal effects on small 
airway function (see Chapter 4). As such, neutrophils were also stimulated with 100µM fMLP 
to investigate whether the effects on rat small airway function could be augmented when 
incubated with these supernatants, and whether protease release in these supernatants was 
further elevated, compared with supernatants from neutrophils stimulated with 10μM fMLP. 
Therefore, proteases were measured in supernatants from non-stimulated neutrophils, and 
those from neutrophils stimulated with either 10 or 100µM fMLP. 
3.3.1.3. Neutrophil supernatants 
In non-smoker neutrophil supernatants, there was a significant increase in NE activity with 
both 10 and 100μM fMLP stimulation, compared with non-stimulated supernatants, with 
increases in activity approximately 17-fold above non-stimulated values (Figure 3.3 (A)). 
There was similar NE activity in supernatants from neutrophils stimulated with 10 and 100µM 
fMLP, therefore this was not a concentration-dependent response. A similar pattern was 
observed for smokers and COPD patients. There were, however, no significant differences 
in NE activity between 10 and 100μM fMLP stimulation in any of the subject groups. There 
were also no significant differences in NE activity between subject groups, either in non-
stimulated supernatants, or after either 10 or 100μM fMLP stimulation. 
3.3.2. MMP-8 
3.3.2.1. Subject demographics 
Compared with non-smokers and smokers, COPD patients were significantly older, by 
~8years, and had significantly worse lung function, as determined by FEV1, FEV1 % 
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predicted and FEV1/FVC, with an ~40-70% reduction in parameters (Table 3.2). COPD 
patients also had significantly greater smoking history, compared with healthy smokers, with 
an ~37% greater pack year history. 
3.3.2.2. Neutrophil supernatants 
In non-smokers, there was a significant increase in MMP-8 concentration after both 10 and 
100μM fMLP stimulation, compared with non-stimulated samples (Figure 3.3 (B)). A step-
Figure 3.3. Effect of fMLP on protease composition of neutrophil supernatants. Non-
smoker (), smoker (), COPD (). (A) neutrophil elastase (NE), non-smoker: n=12-16; 
smoker: n=13-14; COPD: n=13-17. (B) MMP-8, non-smoker: n=10-12; smoker: n=12; 
COPD: n=10-12. (C) MPO, non-smoker: n=9-12; smoker: n=12; COPD n=12. Data are 
mean ± SEM. **/*** p<0.01/p<0.001 vs. non-stimulated, as determined by Kruskal-Wallis 
and Dunn’s post-hoc tests. 
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wise increase between 10 and 100μM fMLP was observed in smokers and COPD patients, 
with an ~12-20 fold increase compared with non-stimulated values. Between subject groups, 
there was a trend for higher MMP-8 concentrations in COPD neutrophil supernatants after 
10μM fMLP stimulation (~1.5 fold increase), compared with non-smokers and smokers; 
however this did not reach significance. Similarly, there is a trend indicating higher MMP-8 
concentrations after 100μM fMLP stimulation in smoker and COPD neutrophil supernatants, 
compared with non-smoker supernatants; however, this was also not significant. 
 
Table 3.2. Subject demographics for neutrophil supernatants used to measure 
MPO and MMP-8 concentrations. 
 Non-smokers Smokers COPD 
N 21 18 18 
Age (years) 62 ± 2            60 ± 2            68 ± 2# 
Gender (m/f)    8/13   9/9               9/9 
Smoking history 
(Pack years) 
N/A 32.5 ± 4.7 44.7 ± 3.6# 
FEV1 (L)  2.8 ± 0.2    2.7 ± 0.2          1.2 ± 0.1$$$ 
FEV1 predicted (%)       102.3 ± 4.0  94.8 ± 3.1        48.9 ± 4.0$$$ 
FVC (L)   3.8 ± 0.2    3.8 ± 0.3          2.6 ± 0.2**/# 
FEV1/FVC (L)         0.74 ± 0.01    0.72 ± 0.01        0.53 ± 0.05***/# 
Data are mean ± SEM. */#p<0.05 non-smokers/smokers vs. COPD; **/##p<0.01 non-
smokers/smokers vs. COPD; $$$p<0.001 non-smokers and smokers vs. COPD. 
One pack year is defined as smoking 20 cigarettes per day for one year. MMP= Matrix 
metalloprotease; MPO= Myeloperoxidase; FEV= Forced expiratory volume; FVC= Forced 
vital capacity 
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3.3.3. Myeloperoxidase 
3.3.3.1. Subject demographics 
Subject demographics were the same as for MMP-8 (Table 3.2). 
3.3.3.2. Neutrophil supernatants 
In non-smokers, there was a significant increase in MPO concentration in neutrophil 
supernatants after both 10 and 100μM fMLP stimulation, compared with non-stimulated 
supernatants (Figure 3.3 (C)). There was a similar pattern observed for both smokers and 
COPD patients, with an approximately 30-35 fold increase compared with non-stimulated 
values. In all subject groups, the supernatant concentration of MPO was quite similar after 
10 and 100µM fMLP stimulation. There were also no significant differences in MPO 
concentration between the three subject groups, either in non-stimulated supernatants, or 
after either 10 or 100μM fMLP stimulation.  
3.3.4. MMP-9 
3.3.4.1. Subject demographics 
Compared with non-smokers and smokers, COPD patients were significantly older, by 
~8years, and had significantly worse lung function, as determined by FEV1, FEV1 % 
predicted and FEV1/FVC, with an ~50% decrease in parameters (Table 3.3). COPD patients 
also had significantly worse smoking history, by ~20 pack years, compared with healthy 
smokers. 
3.3.4.2. Pro MMP-9 
In non-smokers, there was a significant increase in pro-MMP-9 concentrations after 10μM 
fMLP stimulation, compared with non-stimulated supernatants (Figure 3.4 (A)). There was a 
similar pattern observed in smokers and COPD patients, with an approximately 3.5-7 fold 
increase, compared with non-stimulated values. When stimulated with 100µM fMLP, there 
was an increase in pro MMP-9 compared with non-stimulated supernatants; however a 35- 
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55% decrease compared with 10µM fMLP values. There were no significant differences in 
pro-MMP-9 concentration between the three subject groups, either in non-stimulated 
supernatants, or after either 10 or 100μM fMLP stimulation.  
3.3.4.3. Active MMP-9 
In contrast to pro-MMP-9, in non-smokers, there was a stepwise, significant increase in 
active MMP-9 concentration between non-stimulated supernatants, and after 10 and 100μM 
fMLP stimulation, where there was a 3-fold increase compared with non-stimulated values 
(Figure 3.4 (B)). This pattern was similar for smokers and COPD patients, where there was a 
4-12 fold increase, compared with non-stimulated values. There was significantly less active 
Table 3.3. Subject demographics for neutrophil supernatants used to measure pro- 
and active- MMP-9 concentrations. 
 Non-smokers Smokers COPD 
N 19 17 18 
Age (years) 61 ± 2             59 ± 1            67 ± 2# 
Gender (m/f)    7/12    9/8 7/11 
Smoking history 
(Pack years) 
N/A 33.2 ± 5.1 51.5 ± 5.7## 
FEV1 (L)   2.8 ± 0.2     2.7 ± 0.2    1.2 ± 0.1$$$ 
FEV1 predicted (%)       102.6 ± 4.3   95.1 ± 3.2  50.8 ± 4.3$$$ 
FVC (L)    3.8 ± 0.3     3.8 ± 0.3          2.6 ± 0.2**/## 
FEV1/FVC (L)    0.74 ± 0.02     0.72 ± 0.01    0.49 ± 0.04$$$ 
Data are mean ± SEM. */#p<0.05 non-smokers/smokers vs. COPD; **/##p<0.01 non-
smokers/smokers vs. COPD; $$$p<0.001 non-smokers and smokers vs. COPD. 
One pack year is defined as smoking 20 cigarettes per day for one year. MMP= Matrix 
metalloprotease; FEV= Forced expiratory volume; FVC= Forced vital capacity 
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MMP-9 in non-stimulated supernatants from COPD patients, compared with non-smokers 
(p<0.01 non-smokers vs. COPD patients). There were, however, no other significant 
differences in active MMP-9 concentration between subject groups.  
 
Figure 3.4. Effect of fMLP on MMP-9 isoforms in neutrophil supernatant. Non-smoker 
(), smoker (), COPD (). (A) Pro MMP-9, non-smoker: n=11; smoker: n=11; COPD 
n=11-12. (B) Active MMP-9, non-smoker: n=11; smoker: n=11; COPD n=11-12. (C) Total 
MMP-9, non-smoker: n=11; smoker: n=11; COPD: n=11-12. Data are mean ± SEM, 
**p<0.01/***p<0.001 vs. non-stimulated,
 $
p<0.05 10µM vs. 100µM,
 ##
p<0.01 non-smoker 
vs. COPD, as determined by Kruskal-Wallis and Dunn’s post-hoc tests. 
 99 
3.3.4.4. Total MMP-9 
In non-smokers, there was a significant three-fold increase in total MMP-9 concentration 
between non-stimulated supernatants, and after 10 and 100μM fMLP stimulation (Figure 3.4 
(C)). This pattern was similar for smokers, which showed a four-fold increase, and COPD 
patients, which showed a seven-fold increase, compared with non-stimulated values. There 
was significantly less total MMP-9 in non-stimulated supernatants from COPD patients, 
compared with non-smokers (p<0.01 non-smokers vs. COPD patients). There were, 
however, no other significant differences in active MMP-9 concentration between subject 
groups.  
3.3.5. Correlations with lung function 
There were no significant correlations between NE, MMP-8, and pro-MMP-9 concentrations 
of neutrophil supernatants and any lung function parameters in subjects, at any level of 
stimulation (Table 3.4). There were significant positive correlations between active MMP-9 
concentration in non-stimulated neutrophil supernatants and FEV1, FEV1 % predicted and 
FEV1/FVC ratio, and between active MMP-9 concentration in 10μM fMLP stimulated 
neutrophil supernatants and FVC (Figure 3.5, A-C); however no correlations between active 
MMP-9 concentration in 100μM fMLP stimulated neutrophil supernatants and subject lung 
function. When non-smokers and smokers were excluded from the analysis, all of these 
correlations became non-significant, albeit this is more than likely due to low numbers (Table 
3.6). However, there was a significant positive correlation between MPO concentration in 
10μM fMLP stimulated neutrophil supernatants and FVC (r=0.73, p<0.05) in COPD subjects 
(Figure 3.5 (D), Table 3.6). There was a weak negative correlation between active MMP-9 
concentration of supernatants after 100μM fMLP stimulation and FEV1 % predicted (r=-0.34), 
which continued to be a trend in COPD subjects alone, despite remaining insignificant (r=-
0.4). There were no significant correlations between protease concentrations and either age 
or smoking history. 
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Figure 3.5. Correlation between protease concentration and lung function. Non-
smoker (), smoker (), COPD (). (A) [Active MMP-9] in non-stimulated neutrophil 
supernatants vs, FEV
1
 (n=31), (B) [Active MMP-9] in non-stimulated neutrophil 
supernatants vs. FEV
1
/FVC (n=31), (C) [Active MMP-9] in 10μM fMLP-stimulated 
neutrophil supernatants vs. FVC (n=31), (D) [MPO] in 10μM fMLP-stimulated neutrophil 
supernatants from COPD patients only vs. FVC (n=10). r= Spearman rank correlation 
coefficient. 
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Table 3.4. Correlations between supernatant protease concentration, after 
different fMLP stimulations, and subject lung function: all subjects 
Protease 
[fMLP] 
(μM) 
FEV1  
FEV1 
%predicted  
FVC  FEV1/FVC  
R-value (n) 
[NE] 
NS -0.03 (43) -0.06 (43) -0.02 (43) -0.02 (43) 
10 0.17 (44) -0.02 (44) 0.14 (44) 0.08 (44) 
100 0.15 (37) 0.12 (37) 0.18 (37) 0.05 (37) 
[MMP-8] 
NS -0.15 (34) -0.03 (34) -0.33 (34) 0.26 (34) 
10 -0.23 (33) -0.20 (33) -0.28 (33) -0.09 (33) 
100 -0.17 (33) -0.18 (33) -0.06 (33) -0.14 (33) 
[Pro 
MMP-9] 
NS 0.19 (32) 0.19 (32) 0.11 (32) 0.14 (32) 
10 0.11 (31) -0.11 (31) -0.04 (31) -0.29 (31) 
100 0.19 (33) 0.24 (33) 0.24 (33) 0.03 (33) 
[Active 
MMP-9] 
NS 0.40 (31)* 0.42 (31)* 0.23 (31) 0.51 (31)** 
10 0.28 (31) 0.10 (31) 0.46 (31)** -0.11 (31) 
100 -0.24 (33) -0.34 (33) -0.20 (33) -0.16 (33) 
[MPO] 
NS -0.11 (33) -0.00 (33) -0.27 (33) 0.28 (33) 
10 0.09 (32) 0.07 (32) 0.09 (32) -0.02 (32) 
100 -0.15 (30) -0.09 (30) -0.14 (30) -0.05 (30) 
R= Spearman’s Rank Correlation Co-efficient. *p<0.05, **p<0.01.  
NE= Neutrophil elastase; MMP= Matrix metalloprotease; MPO= Myeloperoxidase; 
FEV= Forced expiratory volume; FVC= Forced vital capacity. 
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Table 3.5. Correlations between supernatant protease concentration, after 
different fMLP stimulations, and subject lung function: COPD patients 
Protease 
[fMLP] 
(μM) 
FEV1  
FEV1 
%predicted  
FVC  FEV1/FVC  
R-value (n) 
[NE] 
NS -0.02 (13) 0.32 (13) -0.14 (13) 0.24 (13) 
10 0.18 (17) 0.18 (17) 0.01 (17) 0.19(17) 
100 0.08 (10) 0.19 (10) 0.44 (10) -0.10 (10) 
[MMP-8] 
NS 0.05 (11) 0.37 (11) -0.40 (11) 0.32 (11) 
10 0.01 (11) 0.08 (11) -0.29 (11) 011 (11) 
100 -0.10 (11) -0.20 (11) 0.34 (11) -0.34 (11) 
[Pro 
MMP-9] 
NS 0.43 (10) 0.26 (10) -0.14 (10) 0.13 (10) 
10 0.05 (10) 0.26 (10) -0.25 (10) 0.44 (10) 
100 0.36 (11) 0.09 (11) 0.13 (11) 0.30 (11) 
[Active 
MMP-9] 
NS 0.14 (10) 0.28 (10) -0.24 (10) 0.41 (10) 
10 -0.24 (10) -0.43 (10) 0.36 (10) -0.58 (10) 
100 -0.11 (11) -0.41 (11) 0.03 (11) -0.10 (11) 
[MPO] 
NS -0.03 (11) 0.36 (11) -0.19 (11) 0.30 (11) 
10 0.02 (10) -0.24 (10) 0.73 (10)* -0.43 (10) 
100 -0.24 (10) 0.01 (10) -0.14 (10) -0.04 (10) 
R= Spearman’s Rank Correlation Co-efficient. *p<0.05.  
NE= Neutrophil elastase; MMP= Matrix metalloprotease; MPO= Myeloperoxidase; 
FEV= Forced expiratory volume; FVC= Forced vital capacity. 
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3.3.6. Summary of results 
 The results of the present chapter were: 
1. There were significant increases in protease concentration/activity in peripheral blood 
neutrophil supernatants from non-smokers, smokers, and COPD patients, following 
fMLP stimulation, compared with non-stimulated samples.  
2. There were no significant differences in the protease concentrations/activities 
between the three subject groups. 
3. The effects of fMLP were not concentration-responsive, except in the case of pro-
MMP-9 and active MMP-9. 
4.  There were conflicting correlations between active MMP-9 concentration and patient 
lung function, depending on the lung function parameter and level of fMLP 
stimulation, when considering all subject groups and COPD patients alone.  
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3.4. Discussion 
The results of the present chapter showed that protease concentration/activity in peripheral 
blood neutrophil supernatants increased with fMLP stimulation; however there were no 
differences between subject groups. These effects were, with the exception of MMP-9, not 
concentration-responsive, and showed some correlation with patient lung function.  
3.4.1. Differences in protease concentrations between subject groups 
One of the objectives of this chapter was to try and identify whether there are inherent 
differences in neutrophil activity, resulting in excessive or “hypersensitive” degranulation, 
between non-smokers, smokers and COPD patients; to try and reconcile whether this may 
be associate with the lung damage, and the corresponding airway dysfunction and airflow 
limitation, observed in COPD. The concentration of a number of neutrophil proteases, 
namely NE, MPO, MMP-8 and -9, were measured in neutrophil supernatants from non-
smokers, healthy smokers, and COPD patients; either non-stimulated, or stimulated with 
fMLP. This allows investigation of basal levels of protease release in non-stimulated 
neutrophil supernatants, and then how these levels increase upon neutrophil activation with 
fMLP, which stimulates degranulation. 
The proteases investigated represented a cross-section across granule subtypes: MMP-9 is 
stored in gelatinase granules, MMP-8 in secretory granules, and MPO and NE in azurophil 
granules; so any differences associated with granule mobilisation might be identified. In all 
cases, the supernatants were obtained from neutrophils at a concentration of ten million 
cells/ml, which allowed investigation of inherent differences in neutrophil activity, without the 
confounding issue of different cell numbers between subject groups.  
There were trends for higher MMP-8 and active MMP-9 concentrations in COPD patients, 
compared with non-smokers and smokers; however these were not significant. There was 
very little differences observed between the subject groups, with regards to NE and MPO. 
Previous studies have observed increased NE from fMLP-stimulated COPD neutrophils, 
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compared with non-smokers (Milara et al., 2012). The latter study used 30nM fMLP, 
whereas the present study used much higher concentrations; however an fMLP 
concentration-response was performed herein for NE activity, and there were no differences 
between subject groups at any concentration of fMLP. The latter study also measured NE 
activity in “real-time”, i.e. adding the fMLP to neutrophils resuspended with NE substrate, 
and immediately measuring activity. In the present study, NE activity was measured in 
supernatants from neutrophils already stimulated with fMLP. Therefore, differences between 
subject groups in NE activity, or, indeed, any protease release, may have temporal 
constraints that were overlooked by the methodology of the present study. Burnett et al., 
(1987) observed increased proteolytic digestion of fibronectin by neutrophils from 
emphysema patients compared with controls, which was further augmented by fMLP 
stimulation. Interestingly, the latter study did not observe any differences in total elastase 
activity between controls and emphysema patients. Therefore, there are likely other 
proteases, not measured in the present study, which may differ in activity in COPD patients. 
3.4.2. Differences in protease concentration between 10 and 100μM fMLP stimulation 
There was little difference in protease release between 10 and 100μM fMLP stimulation for 
NE and MPO. There were, however, some differences observed with the other proteases 
measured. When considering MMP-8, there was a trend towards higher MMP-8 
concentration following 100μM, compared with 10μM fMLP; however this was only observed 
in smokers. With MMP-9, there was a reduction in pro MMP-9 concentration between 10 and 
100μM fMLP, observed across all subject groups, which corresponds with a higher active 
MMP-9 concentration following 100μM fMLP stimulation. MMP-9 is synthesized and stored 
as an inactive pro- isoform, which is, upon stimulation, cleaved to its active counterpart by 
proteases, in particular other members of the MMP superfamily. Therefore, between 10 and 
100μM fMLP stimulation, more pro-MMP-9 appears to be cleaved to form active MMP-9, 
which explains the decrease in pro-MMP-9 between 10 and 100μM fMLP, and the 
corresponding increase in active MMP-9. There were almost the same concentrations of 
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total MMP-9 after 10 and 100μM fMLP, therefore it appears to be the cleavage of the 
isoforms that differs between these two stimulations.  
For NE, MPO and MMP-8, 10μM elicited maximal degranulation, whereas it was 
submaximal for MMP-9. As there are similar concentrations of total MMP-9 after both fMLP 
stimulations, and because gelatinase granules have a greater propensity for exocytosis 
compared with the other subtypes, it is unlikely that mobilisation of granules can adequately 
explain this result. Pro MMP-9 is cleaved and activated by a number of other MMPs and 
serine proteases (Van den Steen et al., 2002), therefore it may be the release of a particular 
protease after 100μM stimulation that further cleaves pro MMP-9 to form more of the active 
isoform. As there were similar concentrations of all proteases measured in this study after 
both 10 and 100μM stimulation, it is unlikely to be any of these. Alternatively, the results 
obtained may be a temporal issue. Neutrophils were stimulated with fMLP for 10min. 
However, at lower concentrations of fMLP, degranulation may be slower and, hence, less 
pro MMP-9 would be cleaved to active MMP-9. After higher concentrations of fMLP, 
however, degranulation may occur more quickly and, therefore, more pro MMP-9 could be 
cleaved. This is unlikely, however, as both 10 and 100μM fMLP are very high stimulations, 
and would most likely induce rapid degranulation in both cases. It is likely that there are 
other proteases, not measured in this chapter, that do have differing activities/concentrations 
between 10 and 100μM fMLP, which may change the relative composition of MMP-9 
isoforms (and also induce some functional differences, see Chapter 4).   
In the present thesis, fMLP was the only stimulus used to activate neutrophils. This is 
physiologically relevant, as fMLP is a bacterial product and could, therefore, mimic bacterial 
infection. However, there are a surplus of additional stimuli that could have been 
investigated that may yield differences in protease release. These include opsonized 
bacteria or LPS (Matthews et al., 2012); phorbol myristate acetate (PMA) (Noguera et al., 
2001), or CXCL8 (Dalboni et al., 2013). CSE has also been shown to prime neutrophil 
responses prior to fMLP stimulation (Koethe et al., 2000). Therefore it may be more 
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physiologically relevant to investigate different stimuli, and the priming effects of different 
mediators on neutrophil degranulation; in order to determine whether these yield any 
differences in protease activity, both between subject groups and level of stimulation. 
3.4.3. Correlations between protease concentration and subject demographics 
There were some significant correlations between protease concentration and subjects’ lung 
function. Active MMP-9 from non-stimulated neutrophils was positively correlated with FEV1, 
FEV1 % predicted, and FEV1/FVC ratio; and when non-smokers and smokers were excluded 
from the analysis, the correlation with FEV1/FVC, although now insignificant, remained a 
positive trend. However, the range of concentrations of active MMP-9 released by non-
stimulated neutrophils was very low, and would, in all likelihood, not be physiologically 
significant.  
Active MMP-9 release from neutrophils stimulated with 10μM fMLP was positively correlated 
with FVC; however, when non-smokers and smokers were excluded from the analysis, there 
were also relatively strong, but insignificant, negative correlations with FEV1 % predicted and 
FEV1/FVC ratio. Although the correlations are insignificant, there were relatively strong 
negative associations between active MMP-9 concentration in 10μM fMLP-stimulated 
neutrophil supernatants and FEV1 % predicted and FEV1/FVC ratio, and similarly between 
100μM fMLP-stimulated supernatants and FEV1 % predicted. Due to the relatively low n, the 
discordant results with different lung function parameters, and the fact that most proteases 
measured showed no correlation with lung function: on the impact of neutrophil proteases on 
lung function, no firm conclusions can be drawn from these results.  
The COPD subjects in this chapter were significantly older than the non-smokers and 
smokers, by ~8years. Age is an important issue to address, as abnormal neutrophil activity 
has been associated with increasing age (Lord et al., 2001), with regards to reduced 
chemotaxis (Sapey et al., 2014), phagocytosis and superoxide production (Wenisch et al., 
2000), and degranulation (Suzuki et al., 1983, Fülöp et al., 1986). However, despite there 
 108 
being a statistically significant difference in age, it is unlikely to have had much of an effect 
on the results herein. In the aforementioned studies, the difference in age between young 
and old subjects where differences were observed in their neutrophil activity was 
substantially larger (~50years) than that of the present chapter. In this chapter, COPD 
patients also had significantly greater smoking history than smokers, by ~10-20 pack years. 
Cigarette smoke induces CXCL8 release, NF-κB activity and intracellular ROS and nitric 
oxide (NO) production through activation of TLR-9 in human neutrophils (Mortaz et al., 
2010). However, it is unclear as to whether this effect is concentration-dependent, and this 
warrants further investigation. Nevertheless, there were no significant correlations between 
concentrations of any of the proteases measured and either age or smoking history; 
therefore it is unlikely that either of these parameters had a considerable effect on the results 
herein. 
Another potential reason for the inconsistent correlations between lung function and 
protease concentration may be that the lung function parameters used are not the most 
physiologically relevant with regards to the lung pathology being considered. The protease-
antiprotease imbalance has most often been implicated in the development of emphysema, 
whereas FEV1 and FVC, with regards to COPD diagnosis, highlight generalised airflow 
obstruction. As such, it may be more relevant to correlate protease concentration/activity 
with a measures of emphysema; such as lung volumes, including residual capacity, total 
lung capacity and diffusion capacity; or by using quantitative CT scans, as in Wang et al., 
(2014). 
3.4.4. COPD neutrophils: inherent differences? 
Overall, it was inconclusive as to whether neutrophils from COPD patients had inherent 
differences in their ability to degranulate, compared with non-smokers and smokers. COPD 
neutrophils have been shown to have aberrant functions, including chemotaxis (Sapey et al., 
2011, Milara et al., 2012), ROS production (Noguera et al., 2001), and protease release 
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(Burnett et al., 1987, Milara et al., 2012), although there is little evidence for the latter from 
the present study to support this. The obvious limitation of the present study is that, due to 
both financial and temporal constraints, only four different neutrophil proteases were 
investigated, although, as described in the Introduction (section 1.4.2), these four have 
previously been implicated in COPD pathophysiology. A high-throughput, multiplex system, 
such as Luminex or Meso Scale Discovery (MSD) technology, may be a more effective way 
to investigate a large panel of neutrophil products. It may also be of interest to further 
investigate the temporal aspect of degranulation, and how this may differ between subject 
groups. 
There is also little firm evidence in the present study to support an association between 
protease release and lung function. Sputum MMP-8 and -9 (Vernooy et al., 2004), and MMP-
12 (Demedts et al., 2006) have previously been negatively associated with lung function; 
however, in such studies, these differences in protease concentrations and subsequent 
correlation with airflow obstruction are probably a function of the increased number of 
neutrophils observed in COPD, rather than intrinsic differences in protease release between 
subject groups. A larger cohort of subjects may allow more conclusive correlations to be 
evaluated.  
3.4.5. Hypothesis: accept/reject 
The hypothesis for this chapter was: 
“Stimulation of neutrophils with fMLP will induce release of proteases, and there will be 
differences in protease composition between neutrophil supernatants from non-smokers, 
smokers and COPD patients.”  
This can only be partially accepted, as fMLP did release selected proteases from 
neutrophils, but there were no differences in the amount or composition of released 
proteases between non-smokers, smokers and COPD patients. Relatively large numbers of 
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subjects were used, and the lack of differences between groups was striking. Consequently, 
rejection of the second part of the hypothesis seems justified.  
This chapter has broadly characterised the protease composition of neutrophil supernatants. 
The next chapter will begin to investigate the effects of these neutrophil supernatants on 
small airway function, and determine whether those from COPD patients induce an 
augmented response, compared with their non-smoker and smoker counterparts. 
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Chapter 4.  
Effect of Neutrophil Supernatants on 
Small Airway Structure & Function 
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4. Effect of Neutrophil Supernatants on Small Airway Structure & Function 
4.1. Introduction 
The previous chapter (Chapter 3) showed that a number of proteases were released into 
supernatants by stimulated neutrophils. However, of the proteases measured, there were no 
significant differences between non-smokers, smokers and COPD patients. Nevertheless, 
neutrophils are considered to be important mediators of the lung damage associated with 
COPD; therefore this chapter will now investigate the consequence of neutrophil 
degranulation on small airway function. 
As described in Chapter 1 (section 1.4.1.4), there is increased neutrophil infiltration in the 
subepithelial and smooth muscle layer of COPD airways (Di Stefano et al., 1998, Baraldo et 
al., 2004), and also increased neutrophil numbers in sputum (Keatings et al., 1996) and 
BALF (Martin et al., 1985) from COPD patients. These increases in neutrophil numbers have 
been significantly correlated with lung function decline (Hogg et al., 2004, Hogg, 2004, 
O'Donnell et al., 2004). COPD neutrophils also exhibit intrinsic differences, compared with 
non-smokers and smokers; demonstrating increased cytokine release and respiratory burst, 
and abnormal chemotaxis (Noguera et al., 2001, Sapey et al., 2011, Milara et al., 2012). 
Therefore, both increased numbers and aberrant activity of neutrophils may mediate the lung 
damage that is characteristic, and symptomatic, of COPD.  
The aim of this chapter was to directly investigate evidence for the latter: to examine whether 
or not COPD neutrophils cause excessive small airway dysfunction, without the confounding 
issue of increased numbers. In order to do this, PCLS, an ex vivo preparation of lung tissue 
(section 1.5.1), were used to investigate small airway physiology and “pathophysiology” in 
response to neutrophil supernatants. As the parenchymal attachments are still intact, small 
airways in PCLS mimic in vivo airway dynamics (Cooper et al., 2009), making them an 
attractive system to examine small airway dysfunction following experimental stresses. Small 
airways are of particular interest in COPD as they are thought to be the main site of airflow 
obstruction (Hogg et al., 1968); whilst remodelling and, in some cases, hyperresponsiveness 
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of the small airways, is central to the aetiology of the disease. In addition, a cross-sectional 
analysis of patients enrolled in the GLUCOLD (Groningen Leiden Universities 
Corticosteroids in Obstructive Lung Disease) study revealed that severity of airway 
hyperresponsiveness was significantly correlated with worsening lung function, and 
increased numbers of sputum neutrophils (van den Berge et al., 2012). Therefore, there is 
accumulating evidence that abnormal neutrophil activity may contribute to the small airway 
dysfunction that is indicative of COPD pathophysiology. However, it is currently unknown 
exactly how neutrophils may impact upon the small airway obstruction observed in COPD; 
and so the aim of this chapter was to investigate this further. 
4.1.2. Hypothesis 
From the above introductory observations, the hypothesis for this chapter was, therefore, 
that: 
“The products of neutrophil activation and degranulation will affect PCLS structure and 
viability, with associated effects on small airway function, including airway closure and 
capacity for reopening”.  
4.1.3. Aims 
In order to investigate this hypothesis, the aims for this chapter were to: 
1. Incubate rat PCLS overnight in neutrophil supernatants from non-smokers, 
smokers or COPD patients, either non-stimulated or stimulated with fMLP (10 or 
100μM).  
2. Following overnight incubation with neutrophil supernatants, assess the 
histological structure and viability of PCLS, along with the function of small 
airways, including baseline patency, airway closure to CCh, and passive airway 
reopening.      
  
 114 
4.2. Methods 
4.2.1. Generation of rat PCLS and assessment of airway function 
Rat PCLS were generated and airway function assessed as described in section 2.2.1.  
4.2.2. Initial assessment of airway function and grouping of PCLS 
Airways were selected for use and grouped based on the criteria outlined in section 2.2.1.4. 
To summarise briefly, after an initial assessment of airway function, airway closure must be 
>50% at 10μM CCh. With regards to grouping PCLS for treatments: groups must contain at 
least 4 PCLS, there must be a similar number of PCLS in each group, and the average 
maximal closure of airways within each group must be approximately the same across all 
groups. Due to the large number of variables in these experiments (variation in composition 
of neutrophil supernatants, and inherent variability of lung tissue between rats) an additional 
stipulation was included for PCLS experiments in this chapter: PCLS from lungs from two 
rats were used for each neutrophil supernatant. This was to try to account for and minimize 
the effect of variation due to the lung tissue itself that may interfere with these experiments.  
As described in section 2.2.1.4, airways in PCLS were subject to an initial assessment of 
maximal airway closure by administration of 10µM CCh. Following a series of washes in rat 
IB, and a 1h recovery period to allow airways to reopen, PCLS were then grouped based on 
the criteria outlined above.  
4.2.3. Incubation of PCLS in control compounds or neutrophil supernatants 
Neutrophil supernatants, that had been stored at -80°C, were thawed and warmed to 37°C in 
a water bath. Once PCLS groups had been established (see above), 1ml neutrophil 
supernatant was added to selected groups. For control compounds, 2% DMSO (v/v), 10µM 
Cytochalasin B, or 10 or 100µM fMLP was added to PCLS in 1ml rat IB. For untreated 
controls, PCLS were incubated in 1ml rat IB. All PCLS were then incubated overnight at 
37°C. 
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4.2.4. CCh-induced airway closure and passive airway reopening  
Airway closure, in response to increasing concentrations of CCh and passive airway 
reopening were investigated as described in ‘Materials & Methods’- Sections 2.2.1.4 and 
2.2.1.5. 
4.2.5. Measurement of PCLS viability 
PCLS viability was measured by WST-1 assay, as described in section 2.2.2.1. For the 
purposes of these experiments, untreated PCLS were considered to represent 100% 
viability, and so the absorbance of all treated PCLS was presented as a percentage of the 
untreated absorbance. 
4.2.6. Data Analysis 
In this chapter, normal distributions were not assumed for any of the analyses, therefore 
patient demographics were compared using Kruskal-Wallis tests, with Dunn’s post-hoc 
comparisons; with the exception of smoking history (pack years), which were compared 
using a Mann-Whitney U-test. CCh concentration-response curves were constructed by 
plotting % airway closure (calculated with respect to Day 1 baseline airway patency), against 
the log CCh concentration, and constructing a 4-parameter logistic non-linear regression 
curve. Mean (±SEM) EC50 values to CCh were then calculated from PCLS used to generate 
each curve. Airway functional parameters and viability of PCLS treated with neutrophil 
supernatants from the three subject groups were compared using Kruskal-Wallis tests, with 
Dunn’s post-hoc comparisons. For familiarity of presentation, data are displayed as mean ± 
SEM. The null hypothesis of no significant differences between untreated airways and those 
treated with control compounds or neutrophil supernatants was rejected at p<0.05. 
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4.3. Results 
4.3.1. Temporal effect on small airway closure 
Small airway closure on PCLS was assessed at 24h (day 1) and 48h (day 2), in order to 
investigate any potential changes in airway closure with time of incubation, and to establish 
conditions for future experiments (Figure 4.1). CCh induced a concentration-dependent 
increase in airway closure in both day 1 and day 2 PCLS, with mean maximal increases of 
83.5 ± 3.4% for day 1 and 85.7 ± 5.0% for day 2 at 10µM CCh, and EC50 values of 150 ± 
52nM and 230 ± 94nM (n=3), for day 1 and day 2, respectively (Figure 4.1).  There was a 
non-significant ~10% reduction in baseline airway patency on day 2 (8.2 ± 2.5%, n=3), 
compared with day 1, and no significant differences in either maximal airway closure or EC50 
to CCh between day 1 and day 2.  
 
Figure 4.1. Temporal effect of small airway closure. Small airway closure in PCLS, in 
response to CCh, at 24h (Day 1) () and 48h (Day 2) () post generation of PCLS. N=3 
rats, 10-12 PCLS/rat.  Data shown are mean ± SEM. *p<0.05 10nM vs. 10µM CCh (Day 
1), baseline vs. 10µM CCh (Day 2). Dashed line at 0% represents Day 1 baseline patency. 
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4.3.2. Effect of control compounds on airway contractility 
PCLS were incubated overnight with diluent/control compounds that were used during 
neutrophil stimulation, in order determine whether or not these had any effects on airway 
closure that may interfere with interpretation of future experiments. 
CCh induced a concentration-dependent increase in airway closure in PCLS that had been 
pre-incubated in 2% (v/v) DMSO, 10µM Cyt B or 10 and 100µM fMLP, with maximal 
increases above baseline of 70-84% at 3-10µM CCh, and EC50 values of 150-470nM CCh 
(Figure 4.2 (A) and Table 4.1). There was a significant 15% reduction in maximal airway  
Figure 4.2. Effect of control compounds on CCh-induced small airway closure and 
PCLS viability. Untreated (UT,); 2% DMSO (open circles,); 10µM cytochalasin B (); 
10µM fMLP (open circles, ); 100µM fMLP (), lysed (). (A) CCh Concentration-
response curve of small airway closure following overnight incubation of PCLS in control 
compounds. UT n=21 rats, all compounds n=7 rats, *p<0.05 UT vs. 10µM fMLP maximal 
closure. All data sets above 30nM (UT), 100nM (all other compounds) CCh were 
significantly higher than baseline, p<0.05-0.001. (B) Viability of PCLS, assessed by WST-
1 assay, following incubation in control compounds. Untreated were considered 100% 
viable, therefore viability is expressed as % UT. N=7-9 rats, ***p<0.001 lysed vs. UT. Data 
are mean ± SEM. Dashed line at 0% represents day 1 baseline patency. 
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closure of airways on PCLS incubated in 10µM fMLP; however there were no other 
significant differences in baseline patency, maximal airway closure or EC50 to CCh when 
PCLS were incubated in any other the compounds. 
4.3.3. Effect of control compounds on PCLS viability 
There were no significant differences in viability when PCLS were incubated in either 2% (v/v) 
DMSO, Cyt B, or either concentration of fMLP, compared with untreated PCLS (Figure 4.2 
(B)). In contrast, lysed (control) PCLS showed an ~80% reduction in viability, compared with 
untreated PCLS. 
4.3.4. Effect of neutrophil supernatants on airway contractility 
4.3.4.1. Non-stimulated neutrophil supernatants 
4.3.4.1.1. Subject demographics 
Table 4.1. Effect of CCh on small airway closure in control compound pre-treated 
PCLS. 
Compound 
Baseline 
Airway 
Patency (%) 
Maximal Closure 
(%) 
[CCh] for 
maximal closure 
(µM) 
EC50 (nM) 
Untreated 
(n=21) 
10.4 ± 2.2 84.9 ± 2.1 10 471 ± 87 
2% DMSO 
(n=7) 
15.3 ± 3.4 83.0 ± 4.4 3 262 ± 125 
10µM Cyt. B 
(n=7) 
9.6 ± 3.6 73.4 ± 5.6 10 304 ± 121 
10µM fMLP 
(n=7) 
6.5 ± 3.8 70.3 ± 2.1* 3 188 ± 42 
100µM fMLP 
(n=7) 
7.5 ± 4.8 78.0 ± 3.5 3 148 ± 31 
Data are mean ±SEM. *p<0.05 vs. Untreated. DMSO= Dimethyl sulfoxide. CCh= Carbachol 
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Subject demographics for non-stimulated neutrophil supernatants are shown in Table 4.2. 
There were no significant differences in age or smoking history between subject groups; 
however, COPD patients were ~12 years older and smoked ~40% more cigarettes than the 
smoker group. COPD patients also had, as expected, significantly worse lung function than 
non-smoker and smoker volunteers, with 25-40% reductions in measured parameters.  
 
4.3.4.1.2. Effects on small airway closure 
CCh induced a concentration-dependent increase in airway closure in all four subject groups 
(untreated and those pre-incubated in non-stimulated neutrophil supernatants from non-
smokers, smokers and COPD patients), with significant increases above baseline at CCh 
Table 4.2. Subject demographics for non-stimulated neutrophil supernatants, in 
which PCLS were incubated. 
 Non-smokers Smokers COPD 
N 4 4 4 
Age 61 ± 6 60 ± 3 72 ± 1 
Gender (m/f) 1/3 1/3 2/2 
Smoking history 
(Pack years) 
N/A 32.6 ± 11.7 46.0 ± 3.1 
FEV1 (L) 3.0 ± 0.2 2.0 ± 0.3 1.5 ± 0.4* 
FEV1 predicted (%) 100.0 ± 4.2 83.4 ± 6.8 59.9 ± 10.6* 
FVC (L) 4.1 ± 0.4 2.9 ± 0.4 2.6 ± 0.7 
FEV1/FVC (L) 0.75 ± 0.04 0.71 ± 0.02 0.57 ± 0.07 
Data are mean ± SEM. *p<0.05 non-smokers vs. COPD, as determined by Kruskal-Wallis 
and Dunn’s post-hoc tests. FEV1 = Forced expiratory volume over 1sec. FVC= Forced 
vital capacity. One pack year is defined as smoking 20 cigarettes per day for 1 year. 
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concentrations of 1-10µM CCh; maximal increases above baseline of 76-90% at 10µM CCh, 
and EC50 values of 230-750nM CCh (Figure 4.3 and Table 4.3). There were no significant 
differences in the maximal airway closure, EC50 to CCh, or baseline patency of airways of 
airways on PCLS incubated in non-stimulated neutrophil supernatants from any of the three 
subject groups (Figure 4.3).  
4.3.4.2. Supernatants of neutrophils stimulated with 10μM fMLP 
4.3.4.2.1. Subject demographics 
Subject demographics for supernatants of neutrophils stimulated with 10μM fMLP are shown 
in Table 4.4. Subject groups were matched for age, but COPD patients had significantly  
Figure 4.3. Effect on CCh-induced small airway closure of overnight incubation of 
PCLS in supernatants from non-stimulated neutrophils: concentration-response 
relationships. Untreated (), n=12 rats; non-smoker (), n=4 supernatants, n=8 rats; 
smoker (), n=4 supernatants, n=8 rats; COPD (), n=4 supernatants, n=8 rats. Data 
shown are mean ± SEM. All data sets above 1µM (UT), 3µM (smoker) and 10µM (COPD) 
CCh were significantly different to baseline, p<0.05-0.01. Dashed line at 0% represents 
day 1 baseline patency. 
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greater smoking history, smoking ~128% more than smokers. COPD patients also had, as 
expected, significantly worse lung function than non-smoker and smoker volunteers, with 
~17-47% decreases in measured parameters. 
4.3.4.2.2. Effects on small airway closure 
CCh induced a concentration-dependent increase in airway closure in PCLS that had been 
incubated with neutrophil supernatants from all subjects, as well as those that were 
untreated. There were significant increases above baseline at CCh concentrations of 1-3µM 
CCh: maximal increases above baseline of 76-85% at 10µM CCh, and EC50 values of 160-
640nM CCh (Figure 4.4 and Table 4.5). 
There were no significant differences in maximal airway closure of airways in PCLS 
incubated in supernatants from any of the three subject groups (Table 4.5). There were also 
no significant differences in EC50 to CCh of airways incubated in non-smoker and smoker 
neutrophil supernatant, compared with untreated airways; however there was a four-fold 
Table 4.3. Effect of CCh on small airway closure in PCLS pre-treated with non-
stimulated neutrophil supernatants from different subject groups. 
Subject Group 
Baseline 
Airway 
Patency (%) 
Maximal Closure 
(%) 
[CCh] for 
maximal closure 
(µM) 
EC50 (nM) 
 Untreated 
(n=12 rats) 
16.7 ± 2.8 81.0 ± 3.5 10 422 ± 107 
Non-smokers 
(n=4) 
12.1 ± 2.0 90.1 ± 4.4 10 754 ± 497 
Smokers 
(n=4) 
2.7 ± 1.9 84.5 ± 1.9 10 229 ± 91 
COPD  
(n=4) 
10.2 ± 3.7 76.5 ± 8.6 10 505 ± 248 
Data are mean ± SEM. No significant differences between groups. 
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decrease in EC50 to CCh in those airways incubated with COPD supernatants, but this did 
not reach significance. There was no significant reduction in the baseline patency of airways 
incubated in supernatants from any of the subject groups (Table 4.5); however baseline 
airway patency of airways was three-fold higher in PCLS incubated with non-smoker or 
COPD neutrophil supernatants, compared with untreated airways.  
4.3.4.3. Supernatants from neutrophils stimulated with 100μM fMLP 
 4.3.4.3.1. Subject demographics 
Demographics for the subjects who provided neutrophils for this study are presented in 
Table 4.6. COPD patients were significantly older than control subjects, by ~12 years. COPD 
patients also had significantly greater smoking history, smoking ~38% more than healthy 
smokers; and, as expected, significantly worse lung function than non-smoker and smoker 
volunteers, with 27-53% decreases in measured parameters. 
Table 4.4. Subject demographics for neutrophil supernatants stimulated with 10µM 
fMLP, in which PCLS were incubated.  
 Non-smokers Smokers COPD 
N 5 6 6 
Age 64 ± 3 60 ± 3 65 ± 5 
Gender (m/f) 3/2 3/3 3/3 
Smoking history 
(Pack years) 
N/A 25.0 ± 4.8 57.0 ± 5.1# 
FEV1 (L) 3.2 ± 0.5 2.6 ± 0.4 1.4 ± 0.2* 
FEV1 predicted (%) 102.1 ± 8.4 87.9 ± 6.0 54.5 ± 6.8* 
FVC (L) 4.4 ± 0.7 3.9 ± 0.7 2.8 ± 0.4 
FEV1/FVC (L) 0.75 ± 0.01 0.73 ± 0.04 0.62 ± 0.1 
Data expressed mean ± SEM. */#p<0.05 non-smokers/smokers vs. COPD, as determined 
by Kruskal-Wallis and Dunn’s post-hoc tests. FEV1 = Forced expiratory volume over 1 
sec. FVC= Forced vital capacity. One pack year is defined as smoking 20 cigarettes per 
day for 1 year. 
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4.3.4.3.2. Effect on airway closure 
CCh induced a concentration-dependent increase in airway closure in PCLS that had been 
incubated with neutrophil supernatants from all subjects groups, and with untreated PCLS, 
with significant increases above baseline at CCh concentrations of 1-10µM CCh; maximal 
increases above baseline of 57-85% at 10µM CCh, and EC50 values of 4-382nM CCh (Fig 
4.5 and Table 4.7). 
Airways in PCLS incubated with non-smoker neutrophil supernatants had an ~13% reduction 
in maximal airway closure, compared with untreated airways, and a five-fold decrease in 
EC50 to CCh, compared with untreated airway; however none of these shifts reached 
  
Figure 4.4. Effect on CCh-induced small airway closure of overnight incubation of 
PCLS in supernatants from neutrophils stimulated with 10µM fMLP: concentration-
response relationships. Untreated (), n=20 rats; non-smoker (), n=5 supernatants, 
n=10 rats; smoker (), n=6 supernatants, n=12 rats; COPD (), n=6 supernatants, n=12 
rats. Data are mean ± SEM. All data sets above 1µM (UT) and 3µM (COPD) CCh were 
significantly higher than baseline p<0.05-0.001. No significant differences compared with 
UT airways. Dashed line at 0% represents day 1 baseline patency. 
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Table 4.5. Effect of CCh on small airway closure in PCLS pre-treated with 
supernatants from neutrophils stimulated with 10µM fMLP. 
Subject Group 
Baseline 
Airway 
Patency (%) 
Maximal Closure 
(%) 
[CCh] for 
maximal closure 
(µM) 
EC50 (nM) 
Untreated 
(n=20 rats) 
11.8 ± 4.6 84.5 ± 2.8 10 641 ± 160 
Non-smokers 
(n=5) 
31.5 ± 6.6 76.5 ± 8.3 10 283 ± 62 
Smokers 
(n=6) 
16.3 ± 11.4 78.0 ± 7.5 10 520 ± 102 
COPD  
(n=6) 
37.5 ± 9.0 82.2 ± 4.5 10 162 ± 97 
Data are mean ± SEM. No significant differences between groups.  
Table 4.6. Subject demographics for neutrophil supernatants stimulated with 100µM 
fMLP, in which PCLS were incubated.  
 Non-smokers Smokers COPD 
N 7 7 7 
Age 64 ± 3 58 ± 2 70 ± 2## 
Gender (m/f) 2/5 5/4 3/5 
Smoking history 
(Pack years) 
N/A 28.7 ± 4.9 39.5 ± 4.8# 
FEV1 (L) 2.8 ± 0.3 2.7 ± 0.3 1.2 ± 0.2$$ 
FEV1 predicted (%) 106.1 ± 9.3 99.0 ± 4.3 49.8 ± 4.9$$ 
FVC (L) 3.7 ± 0.4 3.8 ± 0.4 2.3 ± 0.3# 
FEV1/FVC (L) 0.72 ± 0.03 0.73 ± 0.02 0.53 ± 0.06$ 
Data are mean ± SEM. #p<0.05 smokers vs. COPD, ##p<0.01 smokers vs. COPD, 
$$p<0.01 non-smokers and smokers vs. COPD, as determined by Kruskal-Wallis and 
Dunn’s post-hoc tests. FEV1 = Forced expiratory volume over 1sec. FVC= Forced vital 
capacity. One pack year is defined as smoking 20 cigarettes per day for 1 year. 
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significance (Figure 4.5 () and Table 4.7). There was also no significant difference in 
baseline patency, compared with untreated airways.  
Airways in PCLS incubated with smoker neutrophil supernatants had a 30% reduction in 
maximal airway closure, and an ~10-fold reduction in EC50 to CCh, compared with untreated 
airways; however neither reached significance (Figure 4.5 () and Table 4.7). There was 
also a 2-fold decrease in baseline airway patency, compared with untreated airways, but this 
was also not significant. Maximal airway closure of airways in PCLS incubated with COPD 
neutrophil supernatants was significantly reduced by -30%, with an ~100-fold significant 
decrease in EC50 to CCh, compared with untreated airways (Figure 4.5 () and Table 4.7). 
In addition, there was a significant, 4-fold reduction in baseline airway patency, compared 
with untreated airways. 
Figure 4.5. Effect on CCh-induced small airway closure of overnight incubation of 
PCLS in supernatants from neutrophils stimulated with 10µM fMLP: concentration-
response relationships. Untreated (), n=22 rats; non-smoker (), n=7 supernatants, 
n=14 rats; smoker (), n=7 supernatants, n=14 rats; COPD (), n=7 supernatants, n=14 
rats. Data are mean ± SEM. *p<0.05 (maximal airway closure and baseline airway 
patency), ***p<0.001 (EC50) untreated vs. COPD, as determined by Kruskal Wallis and 
Dunn’s post-hoc tests. All data sets above 1µM (UT), 3µM (non-smoker) and 10µM 
(COPD) CCh were significantly higher than baseline, p<0.05-0.001. Dashed line at 0% 
represents day 1 baseline patency. 
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4.3.4.3.3. Effect on airway reopening 
Following CCh washout, airways reopened in a time-dependent manner, with an initial 
reopening of ~20-50% immediately following washout, and then a further 20-35% after 60 
min (Figure 4.6). After this time, airway closure was ~3-40%, with respect to their initial 
baseline patency. 
Untreated airways took ~30min to reopen to half the maximal airway closure (t1/2) following 
CCh washout. In contrast, airways in PCLS incubated in neutrophil supernatants reopened 
to baseline by ~90 s after washout (Figure 4.6, Table 4.8). Airways in untreated PCLS 
remained ~40% contracted after 60 min post-washout, whereas those within PCLS 
incubated with neutrophil supernatants were, on average, only 6% contracted at  the same 
time-point. There was a significant reduction in t1/2 in non-smokers and smokers, compared 
with untreated airways; and airway closure at 60 min was significantly reduced in non-
Table 4.7. Effect of CCh on small airway closure in PCLS pre-treated with 
supernatants from neutrophils stimulated with 100µM fMLP. 
Subject Group 
Baseline 
Airway 
Patency (%) 
Maximal Closure 
(%) 
[CCh] for 
maximal closure 
(µM) 
EC50 (nM) 
Untreated 
(n=22 rats) 
11.5 ± 4.6 82.5 ± 3.4 10 382 ± 172 
Non-smokers 
(n=7) 
12.4 ± 8.1 60.3 ± 8.7 10 70 ± 36 
Smokers 
(n=7) 
27.3 ± 8.1 57.5 ± 9.5 10 41 ± 19 
COPD 
(n=7)  
44.4 ± 7.4* 60.3 ± 5.6* 10 4 ± 2*** 
Data are mean ± SEM. *p<0.05, ***p<0.001 vs. untreated. 
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smokers, compared with untreated airways.  There were, however, no significant differences 
in any of the parameters of airway reopening between subject groups.  
4.3.4. Effect of neutrophil supernatants on PCLS viability 
4.3.4.1. Non-stimulated neutrophil supernatants 
When PCLS were incubated in supernatants from non-stimulated neutrophils, there was a 
significant reduction in viability to ~50% of untreated PCLS (Figure 4.7 (A)). Lysed PCLS, as 
expected, were also significantly less viable than untreated PCLS, at ~15% of untreated. 
Figure 4.6. Effect of CCh washout on small airway reopening following overnight 
incubation of PCLS in supernatants from neutrophils stimulated with 100µM fMLP. 
Untreated (), n=12 rats; non-smoker (), n=5 supernatants, n=10 rats; smoker (), n=6 
supernatants, n=12 rats; COPD (), n=6 supernatants, n=12 rats. Data are mean ± SEM. 
*p<0.05 60 min airway closure untreated vs. non-smoker, # p<0.05 t
1/2
 untreated vs. non-
smoker, $$ p<0.01 t
1/2 
untreated vs. smoker, as determined by Kruskal Wallis and Dunn’s 
post-hoc tests. All data sets are significantly different to 10µM CCh values after 40min 
(UT) and 60min (smoker), p<0.05-0.01. Data sets from non-smokers and COPD were not 
significantly different to 10µM CCh values at any time point. Dashed line at 0% represents 
day 1 baseline patency. 
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4.3.4.2. Supernatants of neutrophils stimulated with 10µM fMLP 
When PCLS were incubated in supernatants from neutrophils stimulated with 10μM fMLP, 
there was a reduction in viability to ~60% of untreated PCLS; however this was not 
significant (Figure 4.7 (B)). Again, lysed PCLS, as expected, were significantly less viable 
than untreated PCLS, at ~10% of untreated.  
4.3.4.3. Supernatants of neutrophils stimulated with 100µM fMLP 
 When PCLS were incubated in supernatants from neutrophils stimulated with 100μM fMLP, 
there was a significant reduction in viability to ~50-60% of untreated airways, across all three 
subject groups (Figure 4.7 (C)). Again, lysed PCLS were significantly less viable than 
untreated airways, at ~10% of untreated.  
4.3.4.4. Viability of PCLS incubated with fresh or frozen media 
Supernatants from both non-stimulated and stimulated neutrophils reduce PCLS viability to a 
similar extent. One consistent difference between the neutrophil supernatants and the 
Table 4.8. Effect of CCh on passive airway reopening in PCLS pre-treated with 
supernatants from neutrophils stimulated with 100µM fMLP. 
Subject Group T1/2 (min) Airway closure at 60min 
Untreated 
(n=12 rats) 
27.7 ± 1.8 40.2 ± 4.2 
Non-smokers 
(n=5) 
-1.4 ± 0.2* -8.0 ± 6.7* 
Smokers 
(n=6) 
1.2 ± 3.3** 2.1 ± 11.7 
COPD 
(n=5)  
1.3 ± 2.4 15.8 ± 9.6 
Data are mean ± SEM. *p<0.05, **p<0.01 vs. untreated, as determined by Kruskal-Wallis 
and Dunn’s post hoc tests.  
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untreated PCLS is that the media from the neutrophil supernatants has been stored at -80°C 
and thawed prior to use; whereas untreated PCLS are incubated in fresh media. In order to 
determine whether this had an effect on viability, untreated PCLS were incubated overnight 
in either fresh media, or media that had been stored at -80°C and thawed. Assuming that 
PCLS incubated in fresh media were 100% viable, there was a ~23% reduction in viability in 
Figure 4.7. Effect on viability of PCLS, as assessed by WST-1 assay, of overnight 
incubation in neutrophil supernatants. Untreated (), non-smoker (), smoker (), 
COPD (), lysed (). (A) non-stimulated neutrophil supernatants, n=6 supernatants, n=12 
rats, (B) supernatants from neutrophils stimulated with 10µM fMLP, n=4-6 supernatants, 
n=8-12 rats, and (C) supernatants from neutrophils stimulated with 100µM fMLP, n=6-7 
supernatants, n=12-14 rats. Data are % untreated PCLS, which were considered 100% 
viable. (D) Viability of PCLS following overnight incubation in either fresh or frozen media. 
N=4 rats, viability is expressed as % viability of PCLS in fresh media, which were 
considered 100% viable. Data are mean ± SEM.  *p<0.05, **p<0.01 vs. untreated, 
determined by Wilcoxon signed-rank test. 
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PCLS incubated in frozen media, compared with those incubated in fresh media, but this 
was not significant (77.6 ± 8.2% fresh, n=4, Figure 4.7 (D)).  
4.3.5. Correlations between supernatant protease composition and airway function 
There was a trend towards a weak negative correlation between maximal airway closure and 
supernatant NE concentration; however this was not significant (Figure 4.8 (A)). There was a 
significant negative correlation between maximal airway closure and supernatant active 
MMP-9 concentration (Figure 4.8 (B)). There were, however, no other correlations between 
supernatant protease composition and any other functional parameters measured. 
4.3.6. Histology of PCLS 
In order to investigate why neutrophil supernatants alter small airway function, it was 
important to determine whether overnight incubation in these supernatants had altered 
airway structure. Therefore, sections of PCLS were stained with EVG, which stains elastin 
fibres purple and collagen pink, in order to histologically assess small airways. 
Figure 4.8. Correlation between supernatant protease composition and maximal 
contraction of airways. (A) Neutrophil elastase (NE), n=46; (B) Active MMP-9, n=27, 
*p<0.05. r= Spearman rank correlation coefficient. 
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Untreated PCLS (Figure 4.9, near left panel) have a thick, pseudostratified epithelium, 
stained pink-brown, with cilia on their apical edge. Below the epithelium, there is clear elastin 
staining in purple running along the basement membrane. Collagen fibres can also be seen, 
stained in pink, running around the edge of the airway walls. 
4.3.6.1. Non-stimulated neutrophil supernatants 
PCLS incubated with non-stimulated supernatants from non-smokers, smokers and COPD 
patients show some shedding of the epithelium; however elastin and collagen in the airway 
wall appear intact (Figure 4.9, top panel). 
4.3.6.2. Supernatants from neutrophils stimulated with 10μM fMLP 
PCLS incubated with supernatants from neutrophils stimulated with 10μM fMLP show 
extensive shedding of the epithelium, particularly in those incubated with smoker or COPD 
neutrophil supernatants. There is virtually no elastin in the airway wall in PCLS incubated 
with supernatants from all subject groups; however collagen fibres remain present. There 
are also far fewer parenchymal attachments to the airways, compared with untreated PCLS, 
and those incubated with non-stimulated supernatants (Figure 4.9, middle panel).  
4.3.6.3. Supernatants from neutrophils stimulated with 100μM fMLP 
PCLS incubated with supernatants from neutrophils stimulated with 100μM fMLP show 
extensive shedding and destruction of the epithelium. This does not occur to any greater 
extent than in PCLS incubated with supernatants from neutrophils stimulated with 10μM 
fMLP, except with regards to non-smoker supernatants where there is quite a pronounced 
difference in the structure of the epithelium. Again, there is virtually no detectable elastin in 
the airway walls in PCLS incubated with supernatants from all subject groups, and 
parenchymal attachments to the airway walls are vastly diminished, compared with 
untreated PCLS and those incubated with non-stimulated supernatants. However, collagen 
fibres remain present (Figure 4.9, bottom panel). 
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Figure 4.9. Histology of PCLS following overnight incubation in neutrophil 
supernatants. Sections have been stained with EVG, which stains elastin purple and 
collagen pink. Ep= epithelium; E= elastin, P= parenchyma, Bv= blood vessel, C= 
collagen. Arrows indicate destruction of parenchymal attachments; stars indicate 
epithelial shedding, and arrow heads indicate elastin degradation in airway wall. Scale 
bar = 50µm. 
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4.3.7. Summary of results 
The main results of the present chapter were: 
1. There were no significant differences in rat small airway closure in response to CCh 
between days 1 and 2. 
2. With the exception of 10µM fMLP, which slightly reduced maximal airway closure 
compared with untreated airways, the compounds used to stimulated neutrophils had 
no significant effect on either airway function or PCLS viability. 
3. Non-stimulated neutrophil supernatants had no effect on small airway function; 
however they significantly reduced PCLS viability. 
4. Supernatants from neutrophils stimulated with 10µM fMLP had no significant effects 
on airway function; however they caused a ~60% reduction in PCLS viability. 
5.  Supernatants from neutrophils stimulated with 100µM fMLP reduced maximal 
closure of airways and, in the case of COPD, significantly reduced both EC50 to CCh 
and baseline airway patency. There was also a significant reduction in PCLS viability. 
6. There were weak negative correlations between supernatant NE and active MMP-9 
concentration and maximal airway closure; however no other correlations between 
airway function and neutrophil supernatant composition.  
7. Histological analysis of PCLS revealed extensive shedding of the epithelium and 
destruction of elastin fibres in the airway walls of PCLS incubated in supernatants 
from neutrophils stimulated with either 10 or 100µM fMLP, but with no obvious 
differences between subject groups. 
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4.4. Discussion 
In this chapter, it was demonstrated that supernatants from neutrophils stimulated with 
100µM fMLP significantly affected small airway function in rat PCLS. This was significant 
when PCLS were incubated with neutrophil supernatants from COPD patients. In addition, 
both unstimulated and stimulated neutrophil supernatants significantly reduced PCLS 
viability following overnight incubation.  
4.4.1. Concentration-responsive effects of fMLP 
The effect of supernatants from neutrophils stimulated with 100μM fMLP, compared with 
those stimulated with 10μM, was a ~20% reduction in maximal airway closure. Although this 
was only statistically significant for COPD supernatants, the mean maximal closure was 
virtually identical in all subject groups (the difference in statistical significance may be due to 
a greater range in values in non-smokers and smokers). Conversely, the mean maximal 
closure in airways treated with neutrophil supernatants stimulated with 10μM fMLP was 
<10% less than the untreated. This suggests that there are additional products released 
from neutrophils following 100μM fMLP stimulation that are not released at lower 
concentrations of fMLP. From the results obtained in Chapter 3, one candidate could be 
active MMP-9. This is supported by the observation that there was a significant negative 
correlation between concentration of active MMP-9 in the supernatant, and maximal closure 
of the airways. MMP-9 induces transforming growth factor (TGF)-β production in human 
airway epithelial cells, peaking at 6h and fading by 24h at the mRNA level, and peaking at 
24h for levels of TGFβ protein (Perng et al., 2011). TGFβ is associated with cell proliferation 
(Huang et al., 2005), and, hence, possible hypertrophy of the airway wall; however, it is 
unlikely that, even if TGFβ was produced in a similar way in rat epithelial cells, it would be 
able to elicit these effects in the time-frame in which the present PCLS were incubated in 
supernatant. As highlighted in Chapter 3, there are a plethora of additional proteases, not 
measured in this study, that may be differentially released at 10 and 100μM fMLP that may 
account for the differences observed in airway closure. Effects of individual neutrophil 
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products, namely ROS and elastase, on PCLS are investigated in Chapter 5, in order to try 
to reconcile these effects.  
4.4.2. Paracrine factors mediating reduction in baseline airway patency 
Supernatants from COPD neutrophils stimulated with 100μM fMLP significantly reduced the 
EC50 to CCh and baseline airway patency of airways on PCLS. In functional terms, airways 
became more sensitive to CCh and close at lower concentrations; however the airways are 
more contracted at baseline, prior to any addition of CCh. The effect on EC50 is therefore 
most likely an artefact caused by the reduction in maximal airway closure and reduced 
baseline patency. Airways in PCLS incubated with smoker neutrophil supernatants also 
demonstrated a slight (~20%) reduction in baseline airway patency; however this effect was 
not seen with supernatants from non-smoker neutrophils. Reduced baseline patency 
suggests that a product released by neutrophils is either directly causing bronchoconstriction 
of airways, stimulating the release of a bronchoconstrictor from the lung tissue, or inhibiting a 
bronchodilator. Lipid mediators, such as prostaglandins, are commonly associated with 
mediating airway tone. NE has been shown to stimulate release of PGE2 from human airway 
epithelial cells (Perng et al., 2003).  PGE2 activates specific G-protein coupled receptors 
(GPCR) on target cells, known as EP receptors, of which there are 4 known subtypes. 
Depending on the receptor subtype activated, PGE2 can elicit different bronchomotor effects: 
PGE2 is thought to predominantly provoke bronchodilatory effects via EP2 and EP4 receptors, 
but has been shown to have bronchoconstrictor effects via the activation of EP1 and EP3 
receptors (Clarke et al., 2009). In addition, PGE2 has been shown to mediate airway 
constriction in rat PCLS in response to epithelial injury via EP3 receptor activation (Zhou et 
al., 2013). Therefore, the reduction in baseline patency may be due to release of PGE2 from 
epithelial cells, in response to elastolytic stress, which then causes constriction of the small 
airways prior to CCh-challenge. In order to investigate this, the prostaglandin content of 
PCLS supernatants could be determined. PCLS could also be incubated in neutrophil 
supernatants in the presence of indomethacin, a non-selective cyclooxygenase (COX)-
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inhibitor. Prostanoids are derived from arachidonic acid released by the phospholipid 
membrane, and converted to various prostaglandins via COX. COX exists in 2 isoforms: 
COX-1, which is constitutively expressed; and COX-2, which is induced by cytokines during 
inflammation (Kalinski, 2012). Indomethacin inhibits both COX-1 and -2, and therefore 
inhibits the production of any prostaglandins that may modulate airway tone. Selective EP 
receptor antagonists could also be used to identify the mechanism further. 
4.4.3. Mechanical factors mediating aberrant airway function 
In addition, some of the altered functional effects may be due to reduced mechanical 
constraints imposed on the PCLS small airways in response to degradation of the 
parenchymal attachments by neutrophil proteases. Airway closure is a compound process 
mediated by airway smooth muscle fibres contracting and shortening, and the opposing 
forces exerted by parenchymal attachments to the airway wall. Khan et al., (2010) reported 
increased luminal narrowing (i.e. reduced baseline patency) in airways incubated overnight 
in elastase and/or collagenase. However, they also reported increased maximal airway 
closure to acetylcholine (Ach) and reduced reopening of airways following ACh washout, 
compared with untreated airways. These results are in direct opposition to those of the 
present study, wherein there was reduced maximal closure of airways and augmented 
reopening. Khan et al (2010) reasoned that “a loss of wall matrix proteins will both remove a 
load which opposes airway closure, thereby increasing the velocity of airway closure, as well 
as decrease the restorative force that helps the wall spring back upon relaxation (decreasing 
the velocity of relaxation)”. It is difficult to reconcile the results in the present study with those 
reported by Khan et al (2010); however, they investigated the effects of elastase and 
collagenase, which are only 2 components of the variety of neutrophil products that airways 
would have been exposed to in the present study. The results observed herein are, more 
than likely, a combination of mechanical effects due to degradation of matrix proteins; and a 
paracrine response that may involve various lipid mediators, as described above. In order to 
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investigate this further, PCLS were incubated in various inhibitors, in order to try to elucidate 
the mechanisms underlying the observed functional differences (see Chapter 6).  
4.4.4. Non-specific effects of fMLP 
The functional effects and toxicity of the compounds used to stimulate the neutrophils was 
assessed in order to determine whether any effects observed when incubating PCLS in 
neutrophil supernatants could be attributed to degranulated neutrophil products, rather than 
vehicles or stimulants. Neither DMSO (the vehicle for these compounds), Cyt B, nor 100μM 
fMLP had any significant effect on either small airway function or PCLS viability; however 
10μM significantly reduced the maximal closure of airways. Despite this statistical 
significance, it is unlikely that this result represents a true effect of 10μM fMLP on small 
airway closure. Firstly, the mean maximal closure of airways incubated in 10μM fMLP was 
only ~3% less than those incubated with 10μM Cyt. B, and this did not yield a statistically 
significant result. Secondly, the concentration-response curve for a higher concentration of 
fMLP (100μM) is almost identical to the untreated curve, with no differences in any of the 
functional parameters measured. Finally, the actual difference in maximal closure between 
untreated airways and those incubated in 10μM fMLP was only ~14%, which is unlikely to be 
physiologically significant, even if it is statistically. There is some evidence of fMLP causing 
bronchoconstriction in rabbits in vivo (Berend et al., 1986); however the authors of this study 
determined that this effect was, at least in part, mediated by a neutrophil response. The 
same group also suggested that fMLP causes bronchoconstriction in human airways in vitro 
(Armour et al., 1985, Berend et al., 1988) and in vivo (Berend et al., 1988). However, as the 
effects observed in the present study were not concentration-responsive, and also not 
markedly different from the effects of other compounds that did not produce a statistically 
significant difference in airway closure, it is possible that these results are due to inherent 
variation in airway function, which is one of the disadvantages of the PCLS system. In order 
to circumvent this when assessing future results, statistically significant (or insignificant) 
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results should be interpreted with caution, and a greater emphasis applied to the 
physiological significance of differences in airway function.  
4.4.5. Relationship between airway function and PCLS viability 
One notable observation of the results in the present chapter was that airway function and 
PCLS viability were not necessarily concordant. This was most profound in PCLS incubated 
in non-stimulated supernatants: there were no significant differences in airway function, 
compared with untreated airways; however there was a significant reduction in PCLS 
viability. This suggests that all neutrophil supernatants reduce PCLS viability, irrespective of 
fMLP stimulation and, hence, active degranulation. Although non-stimulated neutrophils 
have not, by definition, been treated with fMLP, they may still be activated to a certain 
extent. Neutrophil activation is a spectrum of processes, rather than being a discreet 
“activated”/ “not-activated” state. This begins with neutrophil “rolling” in response to adhesion 
molecules on the endothelium, followed by “firm adhesion” and transmigration to the site of 
injury. Once in the interstitial space, neutrophils continue travelling along chemotactic 
gradients until finally, when there is no longer an evident gradient of chemoattractant, 
oxidative burst and degranulation ensues (Amulic et al., 2012). Therefore, although the 
neutrophils in the “non-stimulated” samples have not been stimulated with fMLP, they may 
still be activated, albeit to a lesser extent, possibly during the isolation process.  
There was some evidence for the above activation in Chapter 3, as the concentration of 
MMP-9 was slightly elevated compared with other proteases measured. The reduction in 
viability does not appear to be augmented when PCLS were incubated in fMLP-stimulated 
neutrophil supernatants, which might be expected if the detrimental effects on viability were 
due to proteolytic or oxidative stress. The effects on viability were also not due to, nor 
caused by interference with, any of the compounds used to stimulate the neutrophils. It is 
unlikely that the supernatant is interfering with the assay because, as mentioned previously, 
none of the compounds used to treat the neutrophils (DMSO, Cyt B or fMLP) have any 
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effect; and, as the neutrophils have not been stimulated, there should not be any neutrophil 
products that could potentially impede the assay. Overall, it is unclear as to what may be 
causing the loss in viability. Oxidative stress is commonly associated with cell toxicity (Ryter 
et al. 2007), and reduces PCLS viability (see Chapter 5). As such, there may be low levels of 
ROS being released by neutrophils, even without fMLP stimulation, that detrimentally effect 
PCLS viability. 
Another possibility was that media that had been freeze/thawed may be affecting the viability 
of the PCLS. Neutrophils are resuspended in rat IB and the subsequent products are frozen 
at -80°C until ready for use; however, when performing the experiments, untreated PCLS 
are incubated in fresh media. Nevertheless, these experiments were performed (Figure 4.7 
(D)) and, despite a slight decrease in viability, there were no significant differences between 
the two conditions. 
An additional reason for the dichotomy between airway function and PCLS viability may be 
due to the PCLS representing a heterogeneous cell population that is differentially affected 
by the stresses imposed on it by the neutrophil supernatants. PCLS are, in essence, a cross-
section of the lung microenvironment, which makes them extremely useful at investigating 
airway function as, with all of the parenchymal attachments still intact, the airways contract 
as they might in vivo.  However, this does also mean that PCLS contain a number of 
different types of cell, and each may respond differently to an imposed stress. Therefore, the 
overall “net” effect on function and viability will be observed, without any regard for individual 
cell responses. This may be the case with viability: airway smooth muscle cells may be far 
more resilient to the cytotoxicity of the supernatants and, hence, continue to contract; 
whereas epithelial cells may be more sensitive. Hence, the overall effect will be a net loss of 
viability, even though the airway smooth muscle cells remain quite viable. To circumvent 
this, similar experiments could be performed in vitro on specific cell types, namely airway 
epithelial and smooth muscle cells, and viability assessed to determine if there is a 
difference in cytotoxicity. Alternatively, sections could be stained with Terminal 
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deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) to determine which cells are 
apoptotic. 
4.4.6. Hypothesis: accept/reject 
The hypothesis of this chapter was: 
“Supernatants from fMLP-stimulated neutrophils will affect PCLS structure and viability, with 
associated effects on small airway function, including airway closure and capacity for 
reopening.” 
The results of this chapter demonstrated that supernatants from neutrophils stimulated with 
fMLP did significantly affect a number of functional parameters of small airways in rat PCLS. 
In contrast, supernatants from non-stimulated neutrophil supernatants had little effect on 
small airway function, suggesting that degranulated neutrophil products mediate these 
effects. In addition, COPD neutrophil supernatants had more of an effect than supernatants 
from non-smokers and smokers. As such, this hypothesis can be accepted.  
This chapter has provided some evidence that neutrophils may be driving the aberrant small 
airway function observed in COPD, independently of the increased burden of neutrophil 
numbers. However, when activated, neutrophils release a plethora of proteolytic enzymes 
and ROS, any of which may be the driving force behind the aberrant effects induced by 
COPD neutrophils. As such, the next Chapter will investigate potential mechanisms behind 
these effects, specifically, the effects of elastase and oxidative stress.  
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Chapter 5.  
Effect of H2O2 and Elastase on Small 
Airway Structure & Function 
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5. Effect of Hydrogen Peroxide and Elastase on Small Airway Structure and Function 
5.1. Introduction 
The previous two chapters showed that a number of proteases, including elastase, were 
released from neutrophils (Chapter 3), and these products induced aberrant small airway 
function in rat PCLS (Chapter 4). The present chapter takes these observations forward by 
investigating two potential mechanisms influencing the small airway dysfunction observed 
following incubation of PCLS with COPD neutrophil supernatants: elastase treatment, using 
PPE as a substitute for NE; and oxidative stress, in the form of H2O2 treatment. 
Two of the leading hypotheses regarding the onset of COPD are those of an 
oxidant/antioxidant imbalance (Rahman et al., 2006), and a protease/antiprotease imbalance 
(Churg A et al., 2005). ROS and proteases are vital components of the neutrophil 
armamentarium that enables them to efficiently destroy invading pathogens. Under normal, 
healthy conditions, these ROS and proteases are quenched by endogenous antioxidants 
and antiproteases, which limits damage to healthy host tissue. However, under pathological 
conditions, where there is an excess of inflammatory cells and/or a chronic pro-inflammatory 
environment, endogenous antiproteases and antioxidants cannot sufficiently counteract 
these oxidative and proteolytic stresses, leading to destruction of healthy lung tissue, and 
pathological remodelling of airways (Owen, 2005).  
Oxidative stress is a common feature of COPD. The source of oxidants can either be 
exogenous, as in cigarette smoke; or endogenous, derived from immune cells in response to 
inflammatory stimuli (MacNee, 2000). H2O2 is increased in the exhaled breath condensate of 
COPD patients compared with never smokers, which is indicative of the increased oxidative 
burden in the lungs (Dekhuijzen et al., 1996). Neutrophils from COPD patients have 
increased intracellular ROS production (Milara et al., 2012) and increased respiratory burst 
(Noguera et al., 2001) in response to fMLP and PMA stimulation, respectively, compared 
with controls, which may also contribute to the perpetuated oxidative stress characteristic of 
COPD.   
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PPE is often used in animal models of elastase-induced lung damage (Tolnai et al., 1985, 
van de Lest et al., 1995, Khan et al., 2007, Khan et al., 2010). PPE and NE share 40% 
sequence homology, and are especially similar in the active site regions (Bode et al., 1989); 
however the products of digestion differ between the two elastases, irrespective of the type 
of elastin substrate. Nevertheless, PPE is a financially viable substitute for NE when 
investigating elastolytic lung damage. 
Following the results of the previous chapter (Chapter 4), whereby neutrophil supernatants, 
in particular those from COPD patients, caused aberrant small airway function, the present 
chapter set out to investigate the effects of elastolytic and oxidative stresses, to investigate 
whether either of these treatments reproduced the effects of the neutrophil supernatants. In 
addition, some of the aberrant effects on small airway function observed in the previous 
chapter may be attributed to mediator release, e.g. cytokines and/or 
bronchodilator/constrictors, from rat PCLS in response to neutrophil supernatants; therefore 
this also warranted investigation. 
5.1.2. Hypothesis 
From the above introductory observations, the hypothesis for this chapter was therefore that: 
“H2O2 or PPE will affect small airway structure and function, with associated effects on PCLS 
viability and mediator release; and will, at least in part, reproduce the effects of neutrophil 
supernatants on small airway function.”  
5.1.3. Aims 
In order to investigate this hypothesis, the aims of this chapter were to: 
1. Incubate rat PCLS overnight in increasing concentrations of either H2O2 or 
PPE and, the following day, assess the function of small airways, including 
baseline patency and airway closure to CCh assess; and the viability and 
histological structure of PCLS.      
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2. Measure CINC-1, TNF-α and PGE2 release from rat PCLS in response to 
either H2O2 or PPE. 
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5.2. Methods 
5.2.1. Generation of rat PCLS and assessment of airway function 
Rat PCLS were generated and airway function assessed as described in section 2.2.1.  
5.2.2. Initial assessment of airway function and grouping of PCLS 
As described in section 2.2.1.4, airways on PCLS were subject to an initial assessment of 
maximal airway closure by administration of 10µM CCh. Following a series of washes in rat 
IB, and a 1 h recovery period to allow airways to reopen, PCLS were then grouped based on 
the criteria outlined in section 2.2.1.4.  
5.2.3. Incubation of PCLS in H2O2 
PCLS were placed in 1ml rat IB in individual wells of a 24-well plate. H2O2 was prepared at 
the following stock concentrations in rat IB: 300mM, 100mM, 30mM, and 10mM. These were 
then added to 1ml rat IB (1% v/v), to give final concentrations of 3mM, 1mM, 0.3mM and 
0.1mM. For untreated controls, PCLS were incubated in 1ml rat IB. All PCLS were then 
incubated overnight at 37°C. Small airway CCh concentration-responses were then 
performed the following day, as described in section 2.2.1.4. 
5.2.4. Incubation of PCLS in PPE 
PCLS were placed in 1ml rat IB in individual wells of a 24-well plate. PPE was reconstituted 
at 1U/µl in rat IB. PPE was added to 1ml rat IB to give the following final concentrations: 3U, 
1U, 0.3U and 0.1U. For untreated controls, PCLS were incubated in 1ml rat IB. All PCLS 
were then incubated overnight at 37°C. CCh concentration-responses were then performed 
the following day, as described in section 2.2.1.4. 
5.2.5. Measurement of PCLS viability 
PCLS viability was measured by WST-1 assay, as described in section 2.2.2.1. For the 
purposes of these experiments, untreated PCLS were considered to be 100% viable, and so 
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the absorbance of all treated PCLS was presented as a percentage of the untreated 
absorbance. 
5.2.6. Measurement of TNF-α and CINC-1 in PCLS supernatant 
To assess release of TNF-α and CINC-1 from PCLS, the rat IB in which the PCLS were 
incubated overnight (± H2O2 or PPE) was isolated and stored at -80°C. 
TNF-α and CINC-1 were both detected using a sandwich enzyme-linked immunosorbant 
assay (ELISA). The basis of the assay was that microplates were first coated with an 
analyte-specific “capture” antibody, which forms the first layer of the “sandwich”. Samples or 
standards are then added to this microplate, and any analyte present binds to this 
immobilised capture antibody. A biotin-labelled detection antibody, which also binds to the 
analyte, is then added and forms the final layer of the “sandwich”. Streptavidin- horseradish 
peroxidase (HRP) binds to the biotin on the detection antibody, and substrate solution, a mix 
of 3,3', 5,5' tetramethylbenzidine (TMB) and H2O2, reacts with the HRP bound to the 
streptavidin, resulting in a colour change that is proportional to the amount of analyte 
present. Sulphuric acid is added to stop this reaction.   
Clear, 96-well Nunc™ microplates were coated with capture antibody at final concentrations 
of 0.4 and 4µg/ml, for CINC-1 and TNF-α respectively, and incubated overnight at room 
temperature. Manufacturers data sheets indicated that the CINC-1 antibody was specific for 
natural and recombinant rat CINC-1 and did not cross-react with other rat CINC proteins 
(CINC-2α, -2β and -3), nor related proteins in human and mouse (GRO-α, -β, or –γ in 
human, and MIP-2 in mouse); although there was 10.5% cross-reactivity with mouse KC. 
Similarly, TNF-α antibody was indicated as being specific for natural and recombinant rat 
TNF-α and did not cross-react with human and porcine TNF-α and –β homologues; however 
there was 2.4% cross-reactivity with mouse TNF-α.  
The following day, the plates were washed multiple times in wash buffer (0.05% Tween®20 
in PBS), and blocked with 1% (w/v) bovine serum albumin (BSA) in PBS for 2h, to prevent 
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non-specific binding. After several more washes, 100µL samples and standards were added 
to the microplate: standards were serially diluted from 1000pg/ml for CINC-1 and 4000pg/ml 
for TNF-α; and samples were diluted 1/50 for CINC-1, and left undiluted for TNF-α. These 
were incubated at room temperature for 2h. Plates were then washed several times in wash 
buffer, and 100µL detection antibody added to each well at 50ng/ml for CINC-1 and 
225ng/ml for TNF-α. Plates were, again, incubated at room temperature for 2h. After several 
more washes in wash buffer, 100µL Streptavidin-HRP was added at a final concentration of 
100μg/ml, and incubated in the dark for 20min. Plates were washed several times, and 
100µL TMB substrate solution added to each well, and incubated in the dark for 20min. Fifty 
µL 1M H2SO4 is added to each well to stop the reaction, and microplates read on a 
microplate reader at λ450nm, with a reference λ of 570nm.  Lower limit of detection for 
CINC-1 and TNF-α were 15.6 and 62.5pg/ml, respectively. To construct the standard curve, 
absorbance was plotted against concentration of CINC-1/TNF-α standards and a non-linear 
regression curve fit to the data (Figure 5.1 (A-B)), from which test samples were interpolated. 
5.2.7. Measurement of PGE2 in PCLS supernatant 
To assess release of PGE2 from PCLS, the rat IB in which the PCLS were incubated 
overnight (± H2O2 or PPE) was isolated and stored at -80°C. 
PGE2 was measured using PGE2 Express EIA kit. This assay is based on competition 
between PGE2 in samples and a PGE2-acetylcholinesterase (AChE) conjugate (called PGE2 
tracer) for binding to a limited amount of monoclonal PGE2 antibody. The amount of PGE2 
tracer and PGE2 monoclonal antibody are kept constant; however the amount of PGE2 in 
samples will change. Therefore, the amount of PGE2 tracer that is able to bind to the PGE2 
monoclonal antibody will be inversely proportional to the concentration of PGE2 in the 
sample. A 96-well plate is pre-coated with a goat polyclonal anti-mouse IgG antibody, which 
binds to the PGE2-antibody complex. The amount of PGE2 tracer that was able to bind to the 
PGE2 antibody, which then binds to the polyclonal antibody on the plate, was detected by 
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adding Ellman’s Reagent, which contains a substrate of AChE and reacts to form a coloured 
product that can be measured spectrophotometrically.  
The assay was performed as per the manufacturer’s instructions. Briefly, PCLS supernatants 
were diluted 1:100 in EIA buffer provided in the kit, in order to fit on the linear part of the 
Figure 5.1. Standard curves of ELISAs and EIA assays. (A) TNF-α concentration 
against optical density (O.D) at λ450-570nm, lower limit of detection 62.5pg/ml. (B) CINC-
1 concentration against O.D at λ450-570nm, lower limit of detection 15.6pg/ml. (C) Log 
PGE2 concentration against %B/B0 (% sample binding/maximum binding) , lower limit of 
detection 36pg/ml. Data are mean ± SEM of duplicate readings. 
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standard curve. PGE2 standards were serially-diluted from 2000-15.6pg/ml in EIA buffer. A 
number of controls wells were run alongside standards and samples: a maximal binding (B0) 
control, which contains 50μl each of PGE2 tracer and PGE2 monoclonal antibody alone and 
is a measure of the maximal amount of tracer able to non-competitively bind to the antibody; 
a non-specific binding (NSB) control, which contains 50μl tracer alone and measures non-
specific binding of the tracer to the antibody coated on the plate; a blank (Blk) control, which 
contains only 200μl Ellman’s Reagent at the development stage, and hence measures 
background absorbance caused by Ellman’s Reagent; and a total activity (TA) control, where 
5μl PGE2 tracer was added to 200μl Ellman’s Reagent at the development stage, which 
measures the total enzymatic activity of the tracer in an excess of substrate. Fifty μl of 
standards and samples were incubated, in duplicate, with 50μl each of PGE2 tracer and 
monoclonal antibody for 1h at room temperature on an orbital shaker. Following this, the 
plate was washed several times to remove all unbound sample/PGE2 tracer, and incubated 
with 200μl Ellman’s Reagent for 60-90min at room temperature, protected from light. The 
microplate was then read on a microplate reader at λ420nm. To prepare the data for 
constructing a standard curve, the average absorbance from the NSB wells was subtracted 
from all wells. The corrected samples and standards (B) were then divided by the average 
corrected B0, and multiplied by 100, to get a %B/B0 (% standard or sample bound/ maximum 
bound). To construct the standard curve, the %B/B0 was plotted against log concentration of 
PGE2 standards, and four-parameter logistic non-linear regression curve fit to the data 
(Figure 5.1 (C)). Sample PGE2 concentrations were then interpolated from this curve. Limit 
of detection was 36pg/ml. Monoclonal PGE2 antibody has ≥1% cross-reactivity with the 
following compounds: PGE2-ethanolamide (100%), PGE2-1-glyceryl ester (100%), PGE3 
(43%), PGE1 (18.7%), 8-iso-PGE2 (2.5%), sulprostone (1.25%), and 6-keto-PGF1α (1%).  
5.2.8. Data analysis 
In this chapter, normal distributions were not assumed for any of the analyses, therefore 
non-parametric Kruskal-Wallis tests, with Dunn’s post-hoc comparisons were performed 
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when comparing airway parameters and mediator release. CCh dose-response curves were 
constructed by plotting % airway closure (calculated with respect to Day 1 baseline airway 
patency), against the log CCh concentration, and constructing a four-parameter logistic non-
linear regression curve. Mean (±SEM) EC50 values to CCh were then calculated from the 
PCLS used to generate each curve. Airway functional parameters and viability of PCLS 
treated with H2O2 or PPE were compared using Kruskal-Wallis tests, with Dunn’s post-hoc 
comparisons. For familiarity of presentation, data are displayed as mean ± SEM. The null 
hypothesis of no significant differences between untreated airways and those treated with 
control compounds or neutrophil supernatants was rejected at p<0.05. 
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5.3. Results 
5.3.1. Effect of H2O2 on small airway closure 
CCh induced a concentration-dependent increase in small airway closure in PCLS that had 
been pre-incubated in H2O2, with maximal increases above baseline of 20-90% at 10µM 
CCh, and EC50 values of 300-850nM CCh (Fig 5.2 (A) and Table 5.1).  
At the lower concentrations of H2O2 (0.1-0.3mM), there were minimal effects on maximal 
airway closure, with decreases of <10% compared with untreated airways (Table 5.1). 
However, at higher concentrations of H2O2 (1 and 3mM), the maximal airway closure was 
Figure 5.2. Effect of H
2
O
2
 on small airway function and PCLS viability. (A) 
Concentration-response curve of small airway closure in response to overnight incubation 
of PCLS in H
2
O
2
. Untreated (), n=6 rats; 0.1mM (), n=4 rats; 0.3mM (), n=5 rats; 1mM 
(), n=6 rats; 3mM (), n=6 rats.  Data are mean ± SEM. *p<0.05 untreated vs. 3mM, as 
determined by Kruskal Wallis and Dunn’s post-hoc tests. All data sets, except for 3mM 
H2O2, above 1μM CCh were significantly higher than baseline (p<0.05-0.001). (B) Viability 
of airways, as assessed by WST-1 assay, following overnight incubation in H
2
O
2
. 
Untreated, n=6 rats; 0.1mM, n=6 rats; 0.3mM, n=4 rats; 1mM, n=6 rats; 3mM, n=6 rats; 
lysed, n=6 rats. Data are expressed as % untreated PCLS, which were considered 100% 
viable. Data are mean ± SEM.  *p<0.05, ***p<0.001 vs. untreated, as determined by 
Wilcoxon signed-rank test. 
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reduced to ~60% and 20% respectively, compared with untreated airways that were ~90% 
closed. There was a two-fold increase in baseline airway patency of airways incubated in 
3mM H2O2; however this was not significant, and there were no notable effects on baseline 
patency at any other concentration of H2O2. The CCh response of small airways on PCLS 
incubated with 3mM H2O2 showed a shift in EC50, with a ~three-fold increase compared with 
untreated airways; however this did not reach significance. There were no notable 
differences in EC50 at any other concentrations of H2O2.  
5.3.2. Effect of H2O2 on PCLS viability 
Having shown that high concentrations of H2O2 reduced maximal airway closure in response 
to CCh, it was important to determine if this was due to alterations in tissue viability. 
Table 5.1. Effect of H2O2 on small airway function  
[H2O2] (mM) 
Maximal Closure 
(%) 
[CCh] for maximal 
closure (µM) 
Baseline Airway 
Patency (%) 
EC50 (nM) 
Untreated 
(n=6) 
90.7 ± 3.2 10 8.3 ± 3.6 307 ± 48 
0.1mM H2O2 
(n=4) 
90.3 ± 2.1 10 -2.1 ± 15.0 379 ± 137 
0.3mM H2O2 
(n=5) 
83.4 ± 7.5 10 7.1 ± 3.1 320 ± 102 
1mM H2O2 
(n=6) 
59.8 ± 14.2 10 11.9 ± 5.3 378 ± 116 
3mM H2O2 
(n=6) 
20.1 ± 16.1* 10 20.1 ± 16.1 852 ± 619 
Data are mean ± SEM. *p<0.05 vs. untreated, as determined by Kruskal-Wallis test and 
Dunn’s post hoc tests. H2O2= hydrogen peroxide 
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Incubation in increasing concentrations of H2O2 resulted in a concentration-dependent 
decrease in PCLS viability (Fig 5.2 (B)). At the lower concentrations of H2O2, 0.1 and 0.3mM, 
there was ~10-20% decrease in PCLS viability, compared with untreated PCLS. However, at 
higher concentrations of H2O2, 1 and 3mM, viability of PCLS was ~40-20% of untreated 
PCLS, and this was significant at 3mM H2O2. At 3mM H2O2, PCLS viability was similar to 
that of lysed PCLS, which were, as expected, ~10% of untreated viability.  
5.3.3. Effect of PPE on small airway closure 
After determining the effects of H2O2 on small airway function and PCLS viability, it was of 
interest to investigate the role of elastolytic stress on these parameters, as this was another 
mediator potentially implicated in neutrophil supernatant-induced small airway dysfunction.   
CCh induced a concentration-dependent increase in small airway closure in PCLS that had 
been pre-incubated in PPE, with maximal increases above baseline of 40-80% at 10µM 
CCh, and EC50 values of 730-3000nM CCh (Fig 5.3 (A) and Table 5.2).  
Incubation in increasing concentrations of PPE resulted in a concentration-dependent 
decrease in maximal airway closure (Fig 5.3 (A)). At the lower concentrations of PPE (0.1 to 
0.3U) this was only ~4-10% reduction, compared with untreated airways; however, at higher 
concentrations of PPE (1 and 3U), there was an ~20-40% reduction, compared with 
untreated airways (Table 5.2). There were no significant differences in EC50 values between 
untreated airways and airways treated with PPE; however there was 1.5-4.5-fold increase in 
EC50 to CCh with PPE treatments, compared with untreated airways. There was a ~2-fold 
increase in baseline airway patency at 3U PPE, compared with untreated airways; however 
this was not significant.  
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5.3.4. Effect of PPE on PCLS viability 
PPE had no significant effect on PCLS viability (Fig. 5.3 (B)), as PCLS incubated with PPE 
were 91-107% of untreated viability. Lysed PCLS, as expected, were ~18% untreated 
viability.  
5.3.5. Effect of H2O2 and PPE on PGE2 release from PCLS 
Maximal airway closure of small airways in PCLS incubated with both H2O2 and PPE was 
reduced, compared with untreated airways. One possible mechanism behind this could be 
the release of bronchodilators from PCLS, in response to the added stresses. As such,  
Figure 5.3. Effect of PPE on small airway function and PCLS viability. (A) 
Concentration-response curve of small airway closure in response to overnight incubation 
of PCLS in PPE. Untreated (), n=5 rats; 0.1U (), n=6 rats; 0.3U (), n=6 rats; 1U (), 
n=6 rats; 3U (), n=6 rats.  Data are mean ± SEM. The only data set significantly higher 
than baseline (p<0.05) was with 0.1U PPE at 10μM CCh. (B) Viability of airways, as 
assessed by WST-1 assay, following overnight incubation in PPE. Untreated, n=8 rats; 
0.1U, n=8 rats; 0.3U, n=8 rats; 1U, n=8 rats; 3U, n=8 rats; lysed, n=8 rats. Data are 
expressed as % untreated PCLS, which were considered 100% viable. Data are mean ± 
SEM.  *p<0.05 vs. untreated, as determined by Wilcoxon signed-rank test. 
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PGE2 was measured in the supernatant of PCLS incubated with either H2O2 or PPE. There 
was a ~1.5fold decrease in PGE2 concentration in PCLS supernatant following treatment 
with H2O2 or PPE, compared with untreated PCLS; however this effect did not appear to be 
concentration-dependent. Untreated PCLS released ~12ng/ml, and all concentrations of 
H2O2 induced release of ~7-9ng/ml from PCLS, and all concentrations of PPE induced 
release of ~8.7-11.5ng/ml (Figure 5.4).  
5.3.6. Effect of H2O2 and PPE on CINC-1 release from PCLS 
Following investigation of PGE2 in PCLS supernatants, it was of interest to also investigate 
the release of other mediators, namely CINC-1 and TNF-α, to assess the nature of the 
microenvironment induced by H2O2 and PPE. Treatment of PCLS with increasing 
Table 5.2. Effect of PPE on small airway function  
[PPE] (U) 
Maximal Closure 
(%) 
[CCh] for maximal 
closure (µM) 
Baseline Airway 
Patency (%) 
EC50 (nM) 
Untreated 
(n=5) 
75.4 ± 6.0 10 7.2 ± 3.4 738 ± 309 
0.1U 
(n=6) 
65.4 ± 3.8 10 -9.5 ± 6.1 1386 ± 757 
0.3U 
(n=6) 
71.6 ± 7.5 10 6.6 ± 12.4 3376 ± 2804 
1U 
(n=6) 
52.6 ± 13.3 10 17.8 ± 9.5 2198 ± 1520 
3U 
(n=6) 
37.9 ± 12.8 10 28.3 ± 10.3 1185 ± 518 
Data are mean ± SEM. PPE = Porcine pancreatic elastase 
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concentrations of H2O2 resulted in a concentration-dependent decrease in CINC-1 release 
from PCLS (Figure 5.5). Untreated PCLS released ~4.5ng/ml CINC-1, and 0.1mM H2O2, 
released similar amounts at ~4.2ng/ml. However, this was reduced ~1.5-8 fold at 0.3, 1 and 
3mM H2O2. PPE also resulted in a concentration-dependent decrease in CINC-1 (Figure 
5.5); however, unlike with H2O2, there was a 2-fold reduction of CINC-1 at the lowest 
concentration of PPE, and ~4-11-fold decreases at 0.3-3U PPE. This reduction was 
significant at 3U PPE.  
5.3.7. Effect of H2O2 and PPE on TNF-α release from PCLS 
Levels of TNF-α were below the limit of detection (i.e. 62.5pg/ml) in supernatants from PCLS 
treated with either H2O2 or PPE. This may reflect a true lack of response, or be due merely to 
a problem with the assays. As such, PCLS TNF-α release was investigated following 
addition of LPS, a known inducer of the TNF-α pathway, either alone or in conjunction with 
H2O2 or PPE.  
 
Figure 5.4. Effect of H2O2 and PPE on PGE2 release in PCLS supernatant, following 
overnight incubation. All groups are n=4 rats. Data are mean ± SEM. 
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5.3.7.1. Effect of LPS on PCLS TNF-α release and viability 
An LPS concentration-response was performed on PCLS, and TNF-α release measured, in 
order to determine the optimal concentration of LPS to use in conjunction with H2O2 or PPE.  
As expected, increasing concentrations of LPS induced TNF-α release in a concentration-
dependent manner, with 10-15-fold increases in TNF-α release at 100 and 1000ng/ml LPS   
(Fig. 5.6 (A)). As such, 100ng/ml LPS was chosen for use in subsequent experiments. LPS 
had no significant effect on PCLS viability (data not shown). 
5.3.7.2. Effect of LPS, in conjunction with H2O2 and PPE, on TNF-α release from 
PCLS 
In response to 100ng/ml LPS, there was a 6.5-fold increase in TNF-α release from PCLS, 
compared with untreated PCLS (Fig. 5.6 (B)). However, in conjunction with increasing 
concentrations of H2O2, there was a concentration-dependent decrease in TNF-α release, 
with a 9-fold decrease at 1mM H2O2, and a 100-fold decrease at 3mM H2O2. In conjunction 
with PPE, there were ~100-fold decreases in TNF-α release at 0.1U PPE, and levels were 
virtually undetectable at higher concentrations of PPE (Fig. 5.6 (B)).  
Figure 5.5. Effect of H2O2 and PPE on CINC-1 in PCLS supernatant, following 
overnight incubation. All groups are n=4 rats. Data are mean ± SEM. *p<0.05 vs. 
untreated, as determined by Kruskall-Wallis test and Dunn’s post hoc comparisons 
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5.3.8. Effect of H2O2 and PPE on mediator levels in rat IB ‘spiked’ with either CINC-1 or 
TNF-α 
The previous section (Section 5.3.7.2) showed that H2O2 and PPE reduced LPS-induced 
TNF-α concentrations in rat PCLS supernatants. Consequently, in order to assess whether 
H2O2 or PPE alone had any direct effect on CINC-1 or TNF-α detection, rat IB was “spiked” 
Figure 5.6. Effect of H
2
O
2
 or PPE on LPS-induced TNF-α release. (A) LPS 
concentration-response. All groups n=4 rats. (B) TNF-α release in response to 100ng/ml 
LPS and increasing concentrations of either H
2
O
2
 or PPE. All groups n=3 rats. Data are 
mean ± SEM.  
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with either 500pg/ml CINC-1 or 1000pg/ml TNF-α and incubated overnight with either 0.1-
3mM H2O2 or 0.1-3U PPE.  
There was a ~1.2-2-fold decrease in TNF-α and CINC-1 levels in untreated (UT) rat IB, and 
those incubated with increasing concentrations of H2O2, with respect to the 500pg/ml CINC-1 
“spike” (Figure 5.7 (A)) or 1000pg/ml TNF-α ‘spike’ (Figure 5.7 (B)). However, H2O2 did not 
appear to have any effect on CINC-1 or TNF-α levels (Fig. 5.7). In contrast, in rat IB treated 
with PPE, there were virtually undetectable levels of CINC-1 and TNF-α at all concentrations 
of PPE (Figure 5.7). 
Figure 5.7. Effect of overnight incubation in H2O2 and PPE on measurement of 
“spiked” concentrations of (A) CINC-1 and (B) TNF-α levels in rat IB. Data were a 
single measurement. 
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5.3.9. Histology of PCLS 
As small airway function and mediator release from PCLS in response to H2O2 and PPE 
treatment had already been assessed, it was important to also assess the architecture of the 
small airways in response to these stresses, and to elucidate any abnormalities that may be 
associated with the previous results in this chapter. As such, histological analysis of small 
airways in PCLS treated with either H2O2 or PPE was performed. 
Untreated PCLS (Figure 5.8 and 5.9, near left panel) have a thick, pseudostratified 
epithelium, stained pink-brown, with cilia on their apical edge. Below the epithelium, there is 
clear elastin staining in purple running along the basement membrane. Collagen fibres can 
also be seen, stained in pink, running around the edge of the airway walls. 
5.3.9.1. H2O2 
PCLS that were incubated with 0.1-1mM H2O2 show little destruction to the epithelium; 
however, at the highest concentration of H2O2 (3mM), there is clear destruction of the 
epithelium as it appears to be only ~1 cell thick, compared with the epithelium of untreated 
airways, which appears more pseudo-stratified. At 0.1 and 0.3mM, there are clear, intact    
parenchymal attachments, which are reduced at 1 and 3mM H2O2. Elastin and collagen in 
the airway wall appears to be intact at all concentrations of H2O2 (Figure 5.8). 
5.3.9.2. PPE 
PCLS incubated with all concentrations of PPE have no detectable elastin in the airway 
walls. At all concentrations, there is some evidence of epithelial detachment, with portions of 
the epithelium missing around the airway wall. Parenchymal attachments are only visible in 
3U PPE; however they appear to be intact. Collagen staining is evident at all concentrations 
of PPE. Unlike with other treatments, damage to the airway is not particularly consistent with 
increasing concentration of PPE; i.e. is not concentration-responsive (Figure 5.9).  
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Figure 5.8. Histology of small airways in PCLS incubated overnight with increasing 
concentrations of H
2
O
2
. Sections have been stained with Elastin Van Giesons (EVG), 
which stains elastin purple and collagen pink. UT= untreated; Ep= epithelium; E= elastin; 
P= parenchyma; Bv= blood vessel; C= collagen. Stars indicate epithelial shedding, 
arrows indicate parenchymal destruction. Scale bar = 50µm. 
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Figure 5.9. Histology of PCLS incubated overnight with increasing concentrations 
of PPE. Sections have been stained with Elastin Van Giesons (EVG). Ep= epithelium; E= 
elastin; P= parenchyma; C= collagen. Arrowheads indicate loss of elastin in airway wall. 
Scale bar = 50µm.  
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5.3.10. Summary of results 
The results of the present chapter were: 
1. Increasing concentrations of H2O2 caused concentration-dependent decreases in 
maximal closure of small airways in rat PCLS; however had no notable effects on 
either EC50 to CCh or baseline airway patency. Increasing concentrations of H2O2 
also caused concentration-dependent decreases in PCLS viability. 
2. Increasing concentrations of PPE caused concentration-dependent decreases in 
maximal closure of small airways in rat PCLS; however had no notable effects on 
either EC50 to CCh or baseline airway patency. Increasing concentrations of PPE had 
no effect on PCLS viability. 
3. Both H2O2 and PPE had no significant effect on PGE2 release, but caused 
concentration-dependent decreases in CINC-1 release from PCLS.  
4. There were no detectable levels of TNF-α from PCLS following overnight incubation 
in either H2O2 or PPE; however LPS could concentration-dependently induce TNF-α 
release from PCLS. H2O2 caused concentration-dependent decreases in LPS-
induced TNF-α release from PCLS; however all concentrations of PPE abolished 
LPS-induced TNF-α release from PCLS. 
5. H2O2 had no effect on recovery of either CINC-1 or TNF-α from “spiked” media; 
however all concentrations of PPE virtually abolished both proteins. 
6. Histological analysis of PCLS revealed that with increasing concentrations of H2O2 
there is increasing epithelial damage; however elastin and collagen appear to remain 
intact. All concentrations of PPE resulted in complete obliteration of elastin staining 
and epithelial damage; however collagen remained intact. 
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5.4. Discussion 
The results of the previous chapter (Chapter 4) demonstrated that incubation of rat PCLS in 
supernatants from stimulated neutrophils resulted in aberrant airway function and a 
reduction in PCLS viability. Exactly why neutrophil products should elicit these responses is 
unclear. In order to investigate some putative mechanisms, this chapter examined the effect 
of oxidative and elastolytic stresses, as they are important components of the neutrophil 
arsenal against invading pathogens. Therefore, the present chapter investigated the effects 
of H2O2 and PPE on small airway function, viability and mediator release.  
5.4.1. Effects of H2O2 on small airway closure 
Both H2O2 and PPE caused concentration-dependent decreases in maximal small airway 
closure. In the case of H2O2, this reduction in maximal airway closure was concomitant with 
reduced PCLS viability, suggesting a link between these two parameters. There are a 
number of different ways in which oxidants can damage cells: they can directly damage 
structural components, for example collagen (Curran et al., 1984); they can initiate lipid 
peroxidation of membrane phospholipids (Gutteridge, 1995); and can inhibit ATP synthesis 
and cause direct DNA damage (Cochrane, 1991). H2O2 can initiate apoptosis pathways 
(Ryter et al., 2007), and has previously been shown to cause cell death in rat lung explants 
(Martin et al., 1981); therefore the result on PCLS viability is concordant with the literature.  
H2O2 has also been shown to mediate contractile responses of airways. Treatment with 1mM 
H2O2 alone has been shown to initiate transient contractile responses in rat tracheal explants 
(Szarek et al., 1990) and in lung parenchymal strips (Kramer et al., 1987). This response 
was attenuated by indomethacin, a non-selective COX inhibitor, and abolished by mianserin, 
a 5-HT antagonist, suggesting a role for both prostaglandins and 5-HT in H2O2-induced 
contraction of rat trachea (Szarek et al., 1990). Pre-treatment with H2O2 has also been 
shown to significantly reduce cholinergic contractions in tracheal explants (Kramer et al., 
1987, Szarek et al., 1990) and lung parenchymal strips, and, in addition, attenuate relaxation 
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via isoprenaline (Kramer et al., 1987); suggesting both muscarinic and/or contractile 
pathways, as well as adrenergic and/or relaxant pathways, are affected by H2O2. Similar 
observations have been found in other species: in strips from rabbit intrapulmonary 
bronchioles, high concentrations of H2O2 (>30μM) attenuated ACh-induced contractions, and 
this effect was further attenuated in strips with their epithelium removed (Asano et al., 2001), 
indicating H2O2-induced “removal” of an epithelial airway dilatory factor (e.g. PGE2); and 
H2O2 induced relaxation of ACh-contracted canine bronchial strips, and indomethacin 
attenuated these relaxations (Gao et al., 1992), thereby further implicating prostaglandins in 
the response. In the latter study, ACh significantly increased release of PGE2 and PGI2, and 
this was further augmented in the presence of H2O2. These results suggest that, at high 
concentrations, H2O2 can attenuate cholinergic contraction of airways, and this effect is 
mediated by bronchodilatory prostaglandins. With respect to the results of the present 
chapter, the effects observed may be a combination of both loss of viability, and direct 
effects of H2O2 on modulating airway tone. One important aspect here may be the time-
frame: the experiments herein were all performed following overnight incubation in H2O2, 
whereas those discussed from the literature were all following much shorter exposures to 
H2O2. Prostaglandins are potentially important mediators of H2O2-induced small airway 
responses. PGE2 release was measured in this chapter; however the results were 
inconclusive (see section 5.4.4). Therefore, in order to reconcile these results, the present 
contractile experiments could be repeated in the presence of indomethacin, to see if the 
reduction in maximal airway closure is attenuated and, thereby, implicate any involvement of 
prostaglandins. A time-course of H2O2 exposure could also be performed investigating both 
airway function and PCLS viability, to determine the effect of H2O2 at shorter time-points, and 
whether there is a temporal factor that mediates the effects of H2O2 on PCLS viability and/or 
paracrine responses.  
5.4.2. Effects of PPE on small airway closure 
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With regards to PCLS incubated overnight with PPE, this had no effect on PCLS viability; 
therefore the reduction in maximal airway closure, unlike that of H2O2, cannot be attributed to 
a loss of viability. Similar experiments have been performed previously with mice PCLS and 
showed that in vivo treatment with a single exposure to PPE followed, 14 days later, by 
sacrifice and subsequent PCLS generation, caused a significant and concentration-
dependent reduction in the magnitude of response to ACh; however overnight treatment of 
PCLS from naïve mice with PPE in vitro caused larger and faster contractile responses to 
ACh (Khan et al., 2010). Ex vivo preparations of tracheal and parenchymal strips from 
guinea pigs also demonstrated hyperresponsiveness to cholinergic stimulation following in 
vivo elastase instillation for 24 or 48h (Willet et al., 1988). However, ex vivo preparations of 
trachea and bronchi from hamsters that were given a single instillation of elastase in vivo 
and sacrificed 4-weeks later, demonstrated reduced contraction to ACh; although 
parenchymal strips from the same animals demonstrated increased contraction (Qian et al., 
1989), indicating a possible differential response between proximal and distal airways.  
The results demonstrated in the present chapter are concordant with the in vivo data from 
the (Khan et al., 2007) study, whereby overnight incubation of PPE caused concentration-
dependent decreases in maximal airway closure; however they are in conflict with the in vitro 
results. Similarly, the results with respect to the trachea and bronchi from the Qian & Mitzner 
(1989) study were also concordant with those in the present chapter. Some of the 
differences observed here might be due to species differences, as the experiments in the 
present chapter were performed in rats, whereas those in the literature were performed in 
mice, guinea pigs and hamsters. It is also difficult to reconcile the concentrations of PPE 
used between the experiments herein and those in the literature; therefore this may also be 
a confounding factor. The effects of PPE seem to be largely attributed to mechanical 
alterations in the contractile apparatus of the airway; however, NE has been shown to induce 
the release of PGE2 from human airway epithelial cells, therefore there may also be a 
paracrine response involved that warrants investigation. In addition, according to histological 
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analysis of PCLS treated with PPE, there appeared to be complete loss of elastin fibres at all 
concentrations of PPE, thereby being not concentration-dependent, as the functional results 
may suggest. This indicates that the mechanical alterations caused by elastin destruction 
would be uniform across all PPE treatments, therefore further implicates paracrine factors 
released in response to PPE treatment that may help explain the concentration-dependent 
loss of airway function. 
As discussed in section 5.1, PPE is widely used in the literature in animal models of 
emphysema or COPD-like symptoms. However, there are quite substantial differences 
between PPE and NE, particularly with regards to their substrate specificity. This made it 
difficult to establish a concentration, or activity, of PPE that would accurately mimic the 
levels of NE found within the neutrophil supernatants; and therefore maintain consistency 
across the experiments. Despite the financial constraints, in the experiments herein it may 
have been more physiologically relevant, and consistent with the experiments in Chapter 4, 
to use NE rather than PPE; particularly as the PCLS system accommodates relatively small 
volumes of drug/treatment.  
5.4.3. Comparative effects of H2O2 and PPE with those of neutrophil supernatants 
One of the objectives of the present chapter was to elucidate whether H2O2 or PPE could 
reproduce the effects of neutrophil supernatants on small airway function that were observed 
in Chapter 4. To recap, neutrophil supernatants from COPD patients caused significant 
reductions in maximal closure, EC50 to CCh and baseline patency of airways in rat PCLS, 
and also significantly reduced PCLS viability. The highest concentrations of both H2O2 and 
PPE caused reductions in maximal airway closure; therefore oxidative and/or elastolytic 
stresses may contribute to the decreased maximal airway closured caused by neutrophil 
supernatants. However, neither H2O2 nor PPE had any notable effects on either EC50 or 
baseline airway patency, suggesting other mechanisms are at play with regards to these 
supernatant-induced effects. The highest concentrations of H2O2, but not PPE, significantly  
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reduced PCLS viability, suggesting that oxidative stress may be involved in neutrophil 
supernatant-induced reduction in PCLS viability. Therefore, H2O2 (or oxidative stress) may 
be implicated in neutrophil supernatant-induced reduced maximal airway closure and PCLS 
viability (however, it is worth noting here that the former may be a consequence of the latter, 
as described above in Section 5.4.1). PPE, or neutrophil elastase, may also be implicated in 
neutrophil supernatant-induced reduced maximal airway closure, but had no effect on any 
other functional parameters or PCLS viability. Neither H2O2 nor PPE had any significant 
effect on baseline airway patency or EC50 to CCh, although this was non-significantly 
increased at both the highest concentration of H2O2 and with all PPE treatments, suggesting 
other mechanisms are involved. With regards to baseline airway patency, this may include 
the release of bronchoconstrictors, either from neutrophils themselves, or induced from the 
lung epithelium in response to neutrophil products. Conversely, this may be due to inhibition 
of bronchodilators, again, either directly by neutrophil products, or via an epithelial response 
Table 5.3. Summary of the effects of neutrophil supernatants, H2O2 and PPE on 
small airway function and PCLS viability 
 Stimulated (100μM fMLP) 
neutrophil supernatants 
H2O2 PPE 
Maximal airway 
closure 
   
EC50 to CCh 
 
 No effect 

(NS) 
Baseline airway 
patency 
 No effect No effect 
PCLS viability 
 
  No effect 
 and  denote increased and reduced, respectively. NS= non-significant 
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to neutrophil products. The effect on EC50 may be mediated by the destruction of 
parenchymal attachments on the airways, which thus facilitates small airway closure by 
minimising the load opposing smooth muscle contraction. This may be more pronounced in 
PCLS incubated with neutrophil supernatants, as these airways are exposed to more 
proteases than just PPE alone. This is summarised in Table 5.3. 
5.4.4. Mediator release in response to H2O2 and PPE treatment 
In order to investigate potential mechanisms mediating the effects observed in the present 
chapter, mediator release from PCLS following treatment with H2O2 and PPE was 
investigated. PGE2 release was investigated, due to its role as a bronchodilator, which has 
been shown to be released from airway smooth muscle in response to both H2O2 (Szarek et 
al., 1990, Gao et al., 1992, Asano et al., 2001) and elastase treatment (Perng et al., 2003). 
The results of this were inconclusive. There appeared to be no significant effect of either 
H2O2 or PPE on PGE2 release; however this is more than likely due to problems with the 
assay. The assay measures PGE2 directly; however this is rapidly metabolized, with a very a 
short half-life (Samuelsson et al., 1975). Therefore, it is possible that any PGE2 released by 
the PCLS had already been metabolized. In addition, PGE2 in the PCLS supernatants was 
measured at two different dilutions, and there was little agreement between the final PGE2 
concentrations at these two dilutions (data not shown). This suggests some 
interference/contamination between the samples and the assay, as the assay is sensitive to 
contamination with organic solvents and rat antibodies that may be found in the PCLS 
supernatant. To remedy this in future, samples could be purified prior to running them on this 
assay. Alternatively, measuring a more stable PGE2 metabolite may yield more conclusive 
results. 
CINC-1 and TNF-α were chosen due to their inductive roles in inflammation and in response 
to a variety of stresses, in order to evaluate the inflammatory environment induced by H2O2 
or PPE. CINC-1 mRNA expression and protein secretion is induced in vitro in rat C6 glioma 
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cells by a number of different stresses, including LPS, H2O2 and TNF-α (Uehara et al., 
1998); and CINC-1 protein levels are elevated in BALF, lung tissue homogenates and serum 
from rats following in vivo exposure to nickel oxide nanoparticles (Nishi et al., 2009), diesel 
exhaust particles (DEP) (Yokota et al., 2005), and LPS (Mitsuhashi et al., 1999). TNF-α is an 
important pro-inflammatory cytokine heavily implicated in a plethora of inflammatory 
diseases, including COPD (Barnes, 2009) , and causes bronchial hyperresponsiveness in 
rats (Kips et al., 1992) and guinea pigs (Makwana et al., 2012). In addition, rat alveolar 
epithelial cells release TNF-α in vitro in response to LPS stimulation (McRitchie et al., 2000). 
The results of the present chapter showed that neither H2O2 nor PPE treatment had any 
inductive properties for these cytokines, either with or without LPS treatment, but caused 
concentration-dependent decreases in both CINC-1 and TNF-α. Neither H2O2 nor PPE alone 
induced TNF-α secretion, therefore LPS was used, firstly to confirm that PCLS had the 
propensity to release TNF-α; and, secondly, to investigate how this was affected by H2O2 or 
PPE treatment. LPS induced TNF-α secretion from PCLS in a concentration-dependent 
manner; however both H2O2 and PPE caused concentration-dependent decreases in LPS-
induced TNF-α secretion.  With respect to PPE, this was most likely due to the observation 
that PPE most probably degrades both CINC-1 and TNF-α protein, as demonstrated by the 
spiking experiments in Figure 5.5. The same experiments demonstrated that H2O2 did not 
affect either CINC-1 or TNF-α proteins; therefore the reduction in their expression in PCLS 
treated with H2O2 may be due to other mechanisms, as, at low concentrations, H2O2 has 
been shown to mediate signalling pathways (reviewed by (Gough et al., 2011)). Therefore, 
an explanation of the results of the present chapter may be due to the concurrent reduction 
in PCLS viability with increasing concentrations of H2O2. In order to investigate this further, 
lower, non-lethal concentrations of H2O2 could be used to treat PCLS, and cytokine output 
measured. 
One profound pitfall in the aforementioned experiments was the observation that PPE most 
probably degraded both CINC-1 and TNF-α proteins, therefore measuring their release from 
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PCLS using ELISA was not possible. It may, therefore, be better to measure mRNA 
expression of these cytokines, as this may not be as susceptible to degradation compared 
with protein secretion. However, this result may allude to a potential anti-inflammatory 
mechanism, whereby the release of proteases by inflammatory cells, such as neutrophils, 
regulates the concentration of pro-inflammatory cytokines, such as TNF-α. In vivo, this could 
represent a self-limiting mechanism of inflammatory cell recruitment and maintenance of a 
pro-inflammatory environment, which may be dysregulated in chronic inflammatory 
conditions. 
5.4.5. Hypothesis: accept/reject 
The hypothesis at the beginning of this chapter was: 
“Addition of H2O2 or PPE will affect small airway structure and function, with associated 
effects on PCLS viability and mediator release; and will, at least in part, reproduce the 
effects of neutrophil supernatants on small airway physiology.” 
The results of the chapter showed that H2O2 and PPE did indeed affect small airway function 
in that they both reduced maximal airway closure to CCh. Consequently, this part of the 
hypothesis can be accepted. However, as neither stress was able to completely reproduce 
the effects of neutrophil supernatants in Chapter 4, this part of the hypothesis can be 
rejected. 
This aim of this chapter was to investigate potential mechanisms that may mediate 
neutrophil supernatant-induced small airway dysfunction and loss of PCLS viability. The 
results allude to potential roles of both H2O2 and PPE in certain aspects of this, namely 
reduced maximal airway closure and PCLS viability; however much remains unclear. The 
next chapter will attempt to reconcile this using an alternative approach: inhibiting particular 
components of the neutrophil supernatants, to determine whether or not small airway 
dysfunction and PCLS viability can be restored. 
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6. Effect of Pre-Incubation with Antioxidants and Protease Inhibitors on Neutrophil 
Supernatant-Mediated Small Airway Dysfunction 
6.1. Introduction 
In the previous two chapters (Chapters 4 and 5), neutrophil supernatants, H2O2 and PPE 
have all been shown to induce small airway dysfunction and, with the exception of PPE, 
reduction in PCLS viability. It was, therefore, of interest to ascertain whether or not the 
aberrant effects induced by these stresses can be inhibited, using antioxidants or inhibitors 
of various proteases. 
There have been numerous clinical attempts at utilizing protease inhibitors and antioxidants 
in the treatment of COPD, but with very limited success. Patients enrolled in clinical trials 
investigating the efficacy of AZD9668, a neutrophil elastase inhibitor, over a three-month 
period demonstrated no significant improvements in lung function or quality of life, either in 
conjunction with treatment with the LAMA tiotropium (Vogelmeier et al., 2012), or without 
(Kuna et al., 2012).  Clinical trials investigating the efficacy of a selective inhibitor for MMP-9 
and MMP-12 demonstrated that the drug did not have any significant effects on lung 
function; however there was a trend for a reduction in levels of plasma and urinary 
desmosine, an indicator of elastolytic degradation in the lung (Dahl et al., 2012).  
N-acetyl-cysteine (NAC) elicits both direct and indirect antioxidant properties: it has a free 
thiol group that directly interacts with ROS, and can also be utilized as a precursor for GSH, 
which is an important endogenous antioxidant (Dekhuijzen, 2004).  Treatment with NAC 
protects against cigarette smoke-induced lung damage in rats in vivo (Balansky et al., 1992, 
Cai et al., 2009) and in vitro (Fu et al., 2010); and daily NAC treatment significantly reduced 
concentration of H2O2 in exhaled breath condensate of COPD patients after one year 
(Kasielski et al., 2001).  
Chapter 3 of this thesis showed that supernatants of neutrophils from COPD patients 
stimulated with 100μM fMLP contain a number of different proteases, including MMP-8, 
MMP-9, MPO and NE (Section 3.3). These supernatants had adverse effects on small 
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airway function and viability when incubated overnight with rat PCLS (Section 4.3). In order 
to investigate what may be causing these adverse effects, the present chapter pre-incubated 
neutrophil supernatants with NAC or inhibitors of NE or MMP-9, in order to determine 
whether the effects on small airway function and/or PCLS viability could be attenuated, and 
thereby assess the contribution of oxidants and proteases to the supernatant-induced effects 
on small airways and PCLS. 
6.1.2. Hypothesis 
From the above introductory observations, the hypothesis for this chapter was therefore: 
“The antioxidant NAC, and/or inhibitors of NE and/or MMP-9 will inhibit small airway 
dysfunction and reduced PCLS viability in PCLS incubated in stimulated neutrophil 
supernatants from COPD patients.” 
6.1.3. Aims 
In order to investigate this hypothesis, the aims of this chapter were to: 
1. Investigate the conditions for NAC pre-incubation of PCLS pre-treatment with 1mM 
H2O2, with respect to small airway function and PCLS viability, in order to optimise 
conditions for pre-incubation with neutrophil supernatants. 
2. Pre-incubate NAC in neutrophil supernatants, as per conditions identified in (1), and 
investigate small airway function and PCLS viability after neutrophil supernatant 
treatment. 
3. Optimize conditions (i.e. pre-incubation time and concentration) for the pre-incubation 
of NE inhibitor in neutrophil supernatants, using neutrophil supernatants and a NE 
activity assay. 
4. Pre-incubate NE inhibitors in neutrophil supernatants, as per conditions identified in 
(3), and then incubate rat PCLS overnight with neutrophil supernatants, and measure 
small airway function and PCLS viability. 
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5. Optimize conditions for pre-incubation with MMP-9 inhibitor (i.e. pre-incubation time 
and concentration) using neutrophil supernatants and MMP-9 activity assay. 
6. Pre-incubate MMP-9 inhibitor in neutrophil supernatants, as per conditions identified 
in (5), and then incubate rat PCLS overnight with neutrophil supernatants, and 
measure small airway function and PCLS viability.  
  
 176 
6.2. Methods 
6.2.1. Generation of rat PCLS and assessment of airway function 
Rat PCLS were generated and airway function assessed as described in section 2.2.1.  
6.2.2. Initial assessment of airway function and grouping of PCLS 
As described in section 2.2.1.4, airways on PCLS were subject to an initial assessment of 
maximal airway closure by administration of 10µM CCh. Following a series of washes in rat 
IB, and a 1h recovery period to allow airways to reopen, PCLS were then grouped based on 
the criteria outlined in section 2.2.1.4. As in Chapter 4, in order to minimize the impact of 
lung tissue variability on the results, a mix of PCLS from 2 different rats were used when 
investigating the effect of neutrophil supernatants in conjunction with protease inhibitors or 
NAC.   
6.2.3. Optimization of NE inhibitor 
A selective, non-reversible inhibitor of NE (324745; Table 6.1) was reconstituted at 10mM in 
DMSO. Aliquots were stored at -20°C. Neutrophil supernatants were thawed to 37°C in a 
water bath prior to use in the following experiments.  
To determine the concentration of inhibitor to use, a selection of COPD patient neutrophil 
supernatants were pre-incubated with varying concentrations of inhibitor, ranging from 
100nM to 1mM, for 30min at 37°C. NE activity assay was then performed as described in 
chapter 2, section 2.2.5.1.   
To determine pre-incubation time with inhibitor, a selection of COPD patient neutrophil 
supernatants were pre-incubated with 10μM inhibitor for varying amounts of time, ranging 
from 10min to 4h. NE activity assay was then performed as described in section 3.2.2. 
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To determine if inhibition was maintained overnight, a selection of COPD patient neutrophil 
supernatants were pre-incubated overnight at 37°C in varying concentrations of inhibitor, 
ranging from 1nM to 10μM. The following day, NE activity assay was performed as 
described in section 3.2.2. 
6.2.4. Optimisation of MMP-9 inhibitor 
A selective inhibitor of MMP-9 (444278; Table 6.2) was reconstituted at 10mM in DMSO. 
Aliquots were stored at -20°C.  
To determine the concentration of inhibitor to use, a selection of neutrophil supernatants 
were pre-incubated in varying concentrations of inhibitor, ranging from 10nM to 100μM (v/v), 
for 30min or overnight, at 37°C. MMP-9 concentration in supernatants was then determined, 
as described in section 2.2.5.2. 
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6.2.5. Incubation of PCLS in H2O2 and NAC 
To assess the concentration of NAC that would likely be appropriate to inhibit oxidant activity 
in neutrophil supernatants, PCLS were pre-incubated for 30min at 37°C with varying 
concentrations of NAC, ranging from 1μM to 1mM. Following this, 1mM H2O2 was added and 
PCLS were then incubated overnight at 37°C. CCh concentration-responses were then 
performed the following day, as described in section 2.2.1.4. This protocol is summarized in 
Figure 6.1. 
6.2.6. Incubation of PCLS in neutrophil supernatants with inhibitors or NAC 
Neutrophil supernatants, that had been stored in 1ml aliquots, were thawed and warmed to 
37°C in a water bath. Once PCLS groups had been established, 1ml neutrophil supernatant 
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was added to selected groups. For those groups for investigation of the effects of protease 
inhibitors or NAC, neutrophil supernatants were pre-incubated for 30min at 37°C in 10μM NE 
inhibitor (324745) or MMP-9 inhibitor (444278), or 1mM NAC, prior to their addition to PCLS. 
For untreated controls, PCLS were incubated in 1ml rat IB.  All PCLS were then incubated 
overnight at 37°C. CCh concentration-responses were then performed the following day, as 
described in section 2.2.1.4. This protocol is summarized in Figure 6.2. 
6.2.7. Measurement of PCLS viability 
PCLS viability was measured by WST-1 assay, as described in section 2.2.2.1. For the 
purposes of these experiments, untreated PCLS were considered to be 100% viable, and so 
the absorbance of all treated PCLS was presented as a percentage of the untreated 
absorbance. 
6.2.8. Data analysis 
In this chapter, normal distributions were not assumed for any of the analyses, therefore 
patient demographics were compared using Kruskal-Wallis tests, with Dunn’s post-hoc 
comparisons. CCh dose-response curves were constructed by plotting % airway closure 
(calculated with respect to Day 1 baseline airway patency), against the log CCh 
concentration, and constructing a 4-parameter logistic non-linear regression curve. Mean 
(±SEM) EC50 values to CCh were then calculated from the PCLS used to generate each 
Figure 6.1. Summary of protocol for pre-incubation of PCLS with NAC, prior to 
addition of H2O2. 
 180 
curve. Airway functional parameters and viability of PCLS treated with neutrophil 
supernatants from the three subject groups were compared using Kruskal-Wallis tests, with 
Dunn’s post-hoc comparisons. For familiarity of presentation, data are displayed as mean ± 
SEM. The null hypothesis of no significant differences between untreated airways and those 
treated with control compounds or neutrophil supernatants was rejected at p<0.05 
 
 
 
  
Figure 6.2. Summary of the protocol for pre-incubation of inhibitors/NAC with 
neutrophil supernatants, prior to overnight incubation with PCLS. 
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6.3. Results 
6.3.1. Effect of pre-incubation with NAC on H2O2-induced small airway dysfunction  
In order to determine an appropriate concentration of NAC to use with neutrophil 
supernatants, its activity against 1mM H2O2-induced airway/PCLS effects were investigated. 
This concentration of H2O2 was selected as its effects on small airway function and PCLS 
viability (see Section 5.3.1 & 5.3.2) were comparable with those induced by supernatants 
from neutrophils stimulated with 100μM fMLP (see Section 4.3.4.3).  
PCLS were pre-incubated with NAC for 30 min prior to overnight incubation with 1mM H2O2 
treatment. The following day, small airway closure in response to CCh and PCLS viability 
was assessed, to determine whether NAC could attenuate the effects of H2O2. CCh induced 
a concentration-dependent increase in small airway closure in PCLS that had been treated 
with H2O2, with or without NAC pre-incubation, with maximal increases above baseline of 
~65-90% at 10μM CCh, and EC50 values of ~240-490nM CCh (Figure 6.3 (A), Table 6.3).  
Treatment with 1mM H2O2 alone resulted in ~20% reduction in the maximal airway closure, 
but had little effect on either EC50 or baseline airway patency, compared with untreated 
airways (Table 6.3). Pre-incubation with NAC at 1, 10 and 100μM prior to H2O2 treatment 
had little effect on maximal airway closure, as there were significant ~25-30% decreases in 
maximal airway closure, compared with untreated airways. However, pre-incubated with 
1mM NAC prior to H2O2 treatment significantly restored maximal airway closure to 95% of 
that of untreated airways. There were no effects on EC50 to CCh or baseline airway patency 
at any concentration of NAC. In response to the results of these experiments, 1mM NAC 
was chosen for use in subsequent experiments. 
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Figure 6.3. Effect of NAC on H
2
O
2
-induced small airway closure and PCLS 
viability. (A) Effect on small airway closure of pre-treatment with NAC on overnight 
incubation with 1mM H
2
O
2
. Untreated (), n=8 rats; 1mM H
2
O
2
 (), n=8 rats; 1μM 
NAC+1mM H
2
O
2
 (), n=6 rats; 10μM NAC+1mM H
2
O
2
 (), n=7 rats; 100μM 
NAC+1mM H
2
O
2
 (), n=5 rats; 1mM NAC+1mM H
2
O
2
 (), n=6 rats. *p<0.05 1, 10 
and 100μM NAC vs. untreated. Data are mean ± SEM. All data sets above 1μM 
CCh were significantly higher than baseline (p<0.05-0.0001). (B) Effect on PCLS 
viability, as determined by WST-1 assay, of pre-incubation with NAC and overnight 
incubation with 1mM H
2
O
2
. Lysed (), n=6-7 rats per group. Data are mean ± SEM. 
*p<0.05, ***p<0.001 vs, untreated. (C) Effect of NAC on reduction of WST-1 
solution. Optical density of an example untreated PCLS shown as a reference point.  
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6.3.2. Effect of pre-incubation with NAC prior to H2O2 treatment on PCLS viability 
Treatment with 1mM H2O2 resulted in a loss of PCLS viability to ~40% that of untreated 
airways (Figure 6.3 (B)). Pre-treatment with 1, 10 or 100μM NAC did not inhibit this H2O2-
induced loss of viability, with significant reductions in PCLS viability of ~35-40% that of 
untreated airways. Pre-incubation with 1mM NAC slightly attenuated this loss of viability to 
~50% that of untreated airways. As, expected, viability of lysed PCLS was ~25% that of 
untreated airways. 
Table 6.3. Effect of pre-incubation with NAC on treatment with 1mM H2O2 on small 
airway function  
Treatment 
Maximal 
Closure (%) 
[CCh] for 
maximal 
closure (µM) 
Baseline 
Airway 
Patency (%) 
EC50 (nM) 
Untreated  
(n=8) 
91.0 ± 4.1 10 20.3 ± 5.0 277 ± 45 
1mM H2O2 alone 
(n=8) 
70.1 ± 8.3 10 17.4 ± 4.8 373 ± 130 
1μM NAC 
(n=6) 
64.5 ± 10.6* 10 11.6 ± 7.0 240 ± 62 
10μM NAC 
(n=7) 
66.1 ± 7.8* 10 10.3 ± 2.9 491 ± 235 
100μM NAC 
(n=5) 
68.0 ± 8.6* 10 13.6 ± 5.2 314 ± 60 
1mM NAC 
(n=6) 
85.9 ± 4.1 10 9.6 ± 3.8 331 ± 167 
Data are mean ± SEM.  *p<0.05 vs. untreated, as determined by Kruskal-Wallis test and 
Dunn’s post hoc comparisons. n= number of rats. NAC= N-acetyl cysteine; CCh= 
carbachol. 
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The lack of any marked effect of NAC on viability was inconsistent, at least for 1mM NAC, 
with its reversal of airway contractility. It was possible that the apparent lack of effect was 
due to NAC interfering with the viability assay. The basis of the viability assay is that WST-1 
is reduced by mitochondrial enzymes to form a coloured tetrazolium salt. As NAC is an 
antioxidant, and therefore is a reducing agent, its effect on reduction of WST-1 was 
investigated to determine any potential assay interference (Figure 6.3. (C)). Low 
concentrations of NAC (1-100μM) did not appear to additionally reduce WST-1 solution, as 
there were decreases in optical density comparable with WST-1 solution alone. However, 
1mM NAC caused a four-fold increase in optical density, compared with WST-1 solution 
alone. This optical density was comparable to that caused by incubation of WST-1 solution 
with untreated (i.e. viable) PCLS. This suggests that, at a concentration of 1mM, NAC 
reduces WST-1 solution, and therefore may interfere with assessment of PCLS viability. 
However, concentrations <1mM do not appear to interfere with the WST-1 assay; therefore it 
can be assumed that the loss of viability at these concentrations represents an accurate 
reflection of experimental outcomes. 
6.3.3. Pre-incubation of neutrophil supernatants with NAC, an NE inhibitor or an MMP-
9 inhibitor 
6.3.3.1. Subject demographics 
The COPD patients from whom neutrophils were isolated for the following experiments are 
shown in Table 6.4. Subjects were all, on average, 68 years-old, and had very similar lung 
function, with FEV1/FVC ratios of ~0.6L. However, smoking history varied between the 
groups, with those patients used in the NE inhibitor experiments smoking significantly over 
double those used in the NAC experiments. There were no other significant differences in 
demographics between any of the experimental groups.  
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6.3.3.2. Effect of pre-incubation with 1mM NAC on supernatant-induced small 
airway dysfunction 
Supernatants from neutrophils from COPD patients that were stimulated with 100μM fMLP 
were pre-incubated with 1mM NAC for 30min, prior to overnight incubation in the continued 
presence of NAC with PCLS. The following day, small airway function was assessed. CCh 
induced a concentration-dependent increase in small airway closure in untreated PCLS and 
in those that had been pre-incubated in 1mM NAC alone, with maximal increases above 
baseline of ~75% at 10μM CCh, and EC50 values of ~200-1000nM CCh (Figure 6.4, Table 
6.5). However, in PCLS that were incubated with COPD neutrophil supernatants, either with 
or without pre-incubation with NAC, the maximal increase above baseline was ~7-27%, 
which was a significant ~65-90% reduction in maximal airway closure compared with 
Table 6.4. Subject demographics: Neutrophil supernatants pre-incubated with 
NAC, NE inhibitor, or MMP-9 inhibitor 
 NAC 
NE Inhibitor 
(324745) 
MMP-9 inhibitor 
(444278) 
N 4 7 5 
Age 68 ± 3 68 ± 2 68 ± 3 
Gender (m/f) 2/2 2/5 3/2 
Pack years 24.8 ± 4.2* 53.9 ± 11.6 32.4 ± 6.5 
FEV1 (L) 1.6 ± 0.2 1.5 ± 0.1 1.5 ± 0.2 
FEV1 predicted (%) 60.3 ± 4.7 68.4 ± 4.4 62.0 ± 6.4 
FVC (L) 2.8 ± 0.1 2.7 ± 0.2 2.5 ± 0.2 
FEV1/FVC (L) 0.62 ± 0.1 0.59 ± 0.1 0.58 ± 0.1 
Data are mean ± SEM. *p<0.05 vs. NE inhibitor.  
NAC= N-acetylcysteine, NE= neutrophil elastase, MMP= matrix metalloprotease, FEV= 
forced expiratory volume, FVC= forced vital capacity. 
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untreated airways. There was a five-fold increase in EC50 to CCh between untreated airways 
and those incubated in NAC alone; however this was not significant and there were no other 
significant effects on EC50 to CCh between untreated airways and those incubated in COPD 
neutrophil supernatants alone. The EC50 to CCh for airways incubated in neutrophil 
supernatants and NAC could not be calculated due to the shallowness of the curve. There 
was a ~50% reduction in the baseline airway patency of airways incubated with the 
neutrophil supernatants, with or without NAC pre-incubation; however this was not 
significant. Therefore, NAC did not inhibit the effect of neutrophil supernatants on small 
airway closure. 
Due to the aforementioned interference between 1mM NAC and WST-1 solution (Section 
6.3.2), PCLS viability was not assessed in these experiments. 
Figure 6.4. Effect of NAC on small airway contractility induced by neutrophil 
supernatants. Rat PCLS were pretreated with NAC prior to overnight incubation in 
supernatants from COPD neutrophils stimulated with 100μM fMLP. Untreated (), 
n=6 rats; 1mM NAC alone (), n=4 rats; COPD supernatants alone (), n=5 
supernatants, n=10 rats; COPD supernatant + 1mM NAC (), n=5 supernatants, n=10 
rats. Untreated data sets above 1μM CCh are significantly higher than baseline (p<0.01). 
Data are mean ± SEM, **p<0.01 vs. untreated. 
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6.3.4. Efficacy of NE inhibitor in neutrophil supernatants: time-course and 
concentration-response 
In order to determine the appropriate concentration and pre-incubation time for the NE 
inhibitor (324745), a time-course and concentration-response was performed in 
supernatants from neutrophils from COPD patients that had been stimulated with 100μM 
fMLP (Figure 6.5). After 30 min pre-incubation, there was a step-wise decrease in NE activity 
in neutrophil supernatants with increasing concentrations of inhibitor. There was ~50% 
decrease in NE activity at 1μM inhibitor, and, at concentrations above 10μM, the inhibitor 
almost completely abolished NE activity, with levels below the limit of detection at 100μM 
and 1mM (Figure 6.5 (A)). After overnight incubation, there was also a step-wise reduction in 
NE activity with increasing concentrations of inhibitor, with an ~50% decrease at 100nM of 
inhibitor, and complete abolishment of NE activity at concentrations above 1μM of inhibitor, 
with levels being below the limit of detection (Figure 6.5 (B)). There was a 75-fold decrease 
Table 6.5. Effect of pre-incubation of COPD neutrophil supernatants with NAC on 
small airway function  
Treatment 
Maximal 
Closure (%) 
[CCh] for 
maximal 
closure (µM) 
Baseline 
Airway 
Patency (%) 
EC50 (nM) 
Untreated  
(n=6) 
77.1 ± 5.8 10 8.8 ± 6.0 200 ± 48.8 
NAC alone 
(n=4) 
75.6 ± 6.6 10 1.5 ± 4.9 1075 ± 652 
COPD  
(n=5 supernatants) 
27.7 ± 7.3 10 16.1 ± 7.8 521 ± 309 
COPD + NAC 
(n=5 supernatants) 
7.2 ± 9.0** 1 4.2 ± 8.8 - 
Data are mean ± SEM.  NAC= N-acetyl cysteine. **p<0.01 vs. untreated, as determined 
by Kruskall-Wallis test and Dunn’s post-hoc comparisons 
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in IC50 to inhibitor following overnight incubation with inhibitor (11.4 ± 0.2nM), compared with 
30 min pre-incubation (919 ± 107nM); however this was not significant (Figure 6.6). 
NE activity was markedly reduced following 10 min pre-incubation with 10μM inhibitor, and 
completely abolished after 30 min (Figure 6.5 (C)). Following these results, the conditions 
chosen for subsequent experiments were 10μM inhibitor, and a 30min pre-incubation time.  
 
 
Figure 6.5. Optimization of concentration and pre-incubation time of NE inhibitor 
(324745) in neutrophil supernatants. (A-B) Concentration-response of inhibition of NE 
in neutrophil supernatants following (A) 30 min and (B) overnight incubation with NE 
inhibitor (324745), n=3 supernatants. (C) Time-course of pre-incubation with 10μM NE 
inhibitor, n=3 supernatants. Data are mean ± SEM.  
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6.3.5. Effect of pre-incubation of neutrophil supernatants with NE inhibitor on small 
airway function and PCLS viability 
Supernatants from neutrophils from COPD patients that were stimulated with 100μM fMLP 
were pre-incubated for 30min with 10μM NE inhibitor (324745), prior to overnight incubation 
with PCLS. The following day, small airway function was assessed. CCh induced a 
concentration-dependent increase in small airway closure in PCLS that had been treated 
with neutrophil supernatants, with or without NE inhibitor, with maximal increases above 
baseline of ~50-85% at 10μM CCh, and EC50 values of ~160-370nM CCh (Figure 6.7 (A), 
Table 6.6). Treatment with NE inhibitor alone had no significant effect on small airway 
function. Incubation with neutrophil supernatants without NE inhibitor resulted in an ~40% 
decrease in maximal airway closure and ~30% decrease in EC50 to CCh, compared with 
untreated airways. Pre-incubation of neutrophil supernatants with NE inhibitor restored the 
maximal airway closure to ~90% that of untreated airways; although there was still a >two-
fold decrease in EC50 to CCh, compared with untreated airways. There was an ~15%, non-
Figure 6.6. Measurement of NE activity in COPD neutrophil supernatants following 
pre-incubation with increasing concentrations of NE inhibitor. Supernatants pre-
incubated for A) 30 min and B) overnight. Note different axes scales. Data are mean ± 
SEM, n=3-4 supernatants. 
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significant reduction in baseline airway patency in PCLS treated with neutrophil supernatants 
pre-incubated with NE inhibitor; however no other significant effects were observed.  
NE inhibitor alone had no significant effects on PCLS viability (Figure 6.7 (B)). However, 
PCLS incubated with neutrophil supernatants, both with and without inhibitor, were ~41-46% 
viable, compared with untreated airways. Therefore, pre-incubation with NE inhibitor did not 
appear to restore PCLS viability. As expected, lysed PCLS were ~15% viable, compared 
with untreated airways. 
Figure 6.7. Effect of pre-incubation with NE inhibitor (324745) on neutrophil 
supernatant-induced small airway dysfunction and PCLS viability. (A) Effect on 
small airway closure. Untreated (), n=10 rats; NE inhibitor alone (), n=4 rats; COPD 
neutrophil supernatant alone (), n=7 supernatants, n=14 rats; COPD neutrophil 
supernatants + pre-incubation with 10μM NE inhibitor (), n=7 supernatants, n=14 rats. 
All data sets above 1μM CCh were significantly higher than baseline (p<0.05-0.0001) (B) 
Effect on PCLS viability. Untreated (), n=4 rats; NE inhibitor alone (), n=4 rats; COPD 
neutrophil supernatant alone (), n=7 supernatants, n=14 rats; COPD neutrophil 
supernatants + pre-incubation with 10μM NE inhibitor (), n=7 supernatants, n=14 rats; 
lysed (), n=4 rats. Data are mean ± SEM. **p<0.01 vs. untreated, as determined by 
Kruskal-Wallis and Dunn’s post-hoc tests; *p<0.05 vs. untreated, as determined by 
Wilcoxon Signed Rank test. 
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6.3.6. Efficacy of MMP-9 inhibitor on neutrophil supernatants 
 In order to determine the efficacy of the MMP-9 inhibitor (444278), concentration-responses 
were performed in supernatants from neutrophils from COPD patients stimulated with 
100μM fMLP (Figure 6.8). After 30 min pre-incubation, active MMP-9 was not inhibited at 
any concentration tested (Figure 6.8. (A)); however, following overnight incubation, there 
was a step-wise decrease in active MMP-9 concentration with increasing concentrations of 
MMP-9 inhibitor, with ~92% inhibition at 10μM and an IC50 of ~11nM (Figure 6.8 (B) and 
(C)). The protocol for the MMP-9 assay made it difficult to perform a time-course, as “active” 
samples (i.e. supernatants + inhibitor) incubate on the plate for 2h, with no step to stop the 
inhibition before adding the samples. Therefore, due to the temporal constraints of the MMP-
9 activity assays, it was not possible to investigate multiple time-points for this inhibitor. It 
would be unfeasible to pre-incubate the inhibitor with the neutrophil supernatants overnight, 
prior to then commencing experiment with PCLS, as it is unclear how this might affect the 
Table 6.6. Effect of pre-incubation of COPD neutrophil supernatants with NE 
inhibitor on small airway function  
Treatment 
Maximal 
Closure (%) 
[CCh] for 
maximal 
closure (µM) 
Baseline 
Airway 
Patency (%) 
EC50 (nM) 
Untreated  
(n=10 rats) 
85.7 ± 2.1 10 -3.1 ± 3.8 367 ± 78.6 
NE inhibitor alone 
(n=4 rats) 
82.9 ± 8.9  10 -4.1 ± 6.8  234 ± 115  
COPD  
(n=7 supernatants) 
52.5 ± 8.8** 10 1.3 ± 9.7 262 ± 93 
COPD + NE inhibitor 
(n=7 supernatants) 
76.6 ± 7.7 10 14.7 ± 4.9 161 ± 47 
Data are mean ± SEM.  **p<0.01 vs. untreated, as determined by Kruskal-Wallis test and 
Dunn’s post hoc comparisons. NE= Neutrophil Elastase.  
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composition of the neutrophil supernatants, and there would likely be some degradation of 
products after this length of time. Therefore, 10μM inhibitor with a 30 min pre-treatment with 
neutrophil supernatants before overnight incubation with PCLS was chosen for subsequent 
experiments.   
Figure 6.8. Effect of pre-incubation with an MMP-9 inhibitor (444278) on active 
MMP-9 concentration in neutrophil supernatants. (A) 2.5h (30min pre-incubation + 2h 
on plate) and (B) overnight incubation with supernatants from neutrophils stimulated with 
100μM fMLP. (C) Concentration-response of active MMP-9 concentration in neutrophil 
supernatants following overnight incubation with increasing concentrations of MMP-9 
inhibitor. N=7 supernatants per group, data are mean ± SEM. *p<0.05, **p<0.01, 
***p<0.001 vs. untreated, as determined by Kruskal-Wallis and Dunn’s post-correctional 
tests. 
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6.3.7. Effect of pre-incubation of neutrophil supernatants with MMP-9 inhibitor on 
small airway function and PCLS viability 
Supernatants from neutrophils from COPD patients that were stimulated with 100μM fMLP 
were pre-incubated for 30 min with MMP-9 inhibitor, prior to overnight incubation with PCLS. 
The following day, small airway function and PCLS viability was assessed.  CCh induced a 
concentration-dependent increase in small airway closure in untreated PCLS and those 
incubated in MMP-9 inhibitor alone, with maximal increases above baseline of ~78% at 
10μM CCh, and EC50 values between 200-500nM (Figure 6.9 (A), Table 6.7). However, 
maximal airway closure of small airways in PCLS incubated with neutrophil supernatants, 
either with or without inhibitor, was ~17-24%, which was an ~70-80% decrease compared 
Figure 6.9. Effect of an MMP-9 inhibitor (444278) on neutrophil supernatant-
induced small airway dysfunction and PCLS viability. (A) Effect on small airway 
closure. Untreated (), n=6 rats; MMP-9 inhibitor alone (), n=6 rats; COPD neutrophil 
supernatant alone (), n=5 supernatants, n=10 rats; COPD neutrophil supernatants + 
pre-incubation with 10μM MMP-9 inhibitor (), n=5 supernatants, n=10 rats. *p<0.05 vs. 
untreated, as determined by Kruskal-Wallis and Dunn’s post-hoc tests. All untreated and 
MMP-9 inhibitor alone data sets above 1μM CCh were significantly higher than baseline 
(p<0.05-0.01). (B) Effect on PCLS viability, expressed as % untreated, which were 
considered 100% viable. Lysed, all groups n=4-5 supernatants; n=8-10 rats. Data are 
mean ± SEM. *p<0.05 vs. Untreated, as determined by Wilcoxon Signed Rank tests.  
 194 
with untreated airways. There was a ~two-fold increase in EC50 to CCh in airways incubated 
with neutrophil supernatants and inhibitor, but this was not significant. There were no 
significant differences in the baseline airway patency between any groups. Therefore, MMP-
9 inhibitor (444278) did not inhibit small airway dysfunction.  
MMP-9 inhibitor alone had no significant effect on PCLS viability (Figure 6.9 (B)); however 
PCLS incubated with neutrophil supernatants, either with or without MMP-9 inhibitor, had 
~48-58% the viability of untreated PCLS. Pre-incubation with MMP-9 inhibitor did not restore 
PCLS viability. As expected, lysed PCLS were significantly less viable than untreated PCLS, 
at ~ 25% untreated viability.  
 
 
 
Table 6.7. Effect of pre-incubation of COPD neutrophil supernatants with MMP-9 
inhibitor (444278) on small airway function  
Treatment 
Maximal 
Closure (%) 
[CCh] for 
maximal closure 
(µM) 
Baseline 
Airway 
Patency (%) 
EC50 (nM) 
Untreated  
(n=6) 
77.1 ± 5.8 10 8.7 ± 3.5 200 ± 48.8 
MMP-9 
inhibitor alone 
(n=5) 
78.2 ± 6.4  10 -9.1 ± 7.7 488 ± 171  
COPD  
(n=5) 
16.9 ± 9.4 10 7.8 ± 17.1 541 ± 299 
COPD + MMP-9 
inhibitor 
(n=5) 
23.7 ± 12.5 10 8.5 ± 15.1 1068 ± 400 
Data are mean ± SEM.  MMP= Matrix metalloprotease.  
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6.3.8. Summary of results 
The results of the present chapter were: 
1. NAC (1mM) was able to restore maximal airway closure following overnight treatment 
with 1mM H2O2. Lower concentrations of NAC had no notable effects. At 1mM, NAC 
appeared to interfere with WST-1 viability assay, therefore it was inconclusive as to 
whether PCLS viability was also restored. 
2. At 1mM, NAC did not inhibit neutrophil-supernatant induced small airway dysfunction. 
PCLS viability was not assessed due to aforementioned interference between NAC 
and WST-1 assay. 
3. At 10μM, NE inhibitor (324745) was able to abolish NE activity after 30min pre-
incubation with neutrophil supernatants. 
4. Pre-incubation of NE inhibitor in neutrophil supernatants, in the conditions outlined 
above, prior to overnight incubation with PCLS resulted in restoration of the maximal 
closure of small airways in PCLS; however there was no significant restoration of 
PCLS viability.  
5. Pre-incubation of MMP-9 inhibitor (444278) in neutrophil supernatants prior to 
overnight incubation with PCLS did not inhibit supernatant-induced small airway 
dysfunction or loss of PCLS viability. 
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6.4. Discussion 
In order to assess the contribution of oxidants and proteases present in neutrophil 
supernatants on rat small airway function and PCLS viability, the present chapter 
investigated the effect of the antioxidant, NAC, and inhibitors of NE and MMP-9, to 
determine whether or not these could attenuate the effects of supernatants from COPD 
neutrophils stimulated with 100μM fMLP on small airway dysfunction and loss of PCLS 
viability. 
6.4.1. NAC could attenuate H2O2-induced small airway dysfunction, but not that 
induced by neutrophil supernatants. 
Prior to pre-treating neutrophil supernatants with NAC, a series of experiments were 
performed with H2O2 in order to optimise the concentration of NAC that may be appropriate 
to inhibit ROS in neutrophil supernatants. Treatment with 1mM H2O2 was chosen, as the 
maximal airway closure in response to this treatment was ~60%; similar to that observed 
when PCLS were incubated in supernatants from COPD neutrophils stimulated with 100μM 
fMLP. Therefore, it was postulated that if the effects of the neutrophil supernatants were due 
to oxidative stress, then this concentration of H2O2 would most closely mimic that.   
Pre-incubation with 1mM NAC appeared to attenuate H2O2-induced reduction in maximal 
airway closure. Despite this result being non-significant, there was an ~18% increase in 
maximal airway closure with 1mM NAC pre-incubation, compared with 1mM H2O2 treatment 
alone. However, the effects of NAC on H2O2-induced reductions in maximal airway closure 
were not concentration-dependent: at all other concentrations of NAC tested, the maximal 
airway closure was lower than that of H2O2 alone. When incubated alone, 1mM NAC did not 
augment maximal airway closure, which suggests that there are not any off-target effects of 
NAC that increase maximal airway closure independent of its effects on H2O2. Therefore, 
these results suggest that there is a threshold level of NAC that can attenuate small airway 
dysfunction induced by H2O2; and that below this level, NAC is ineffective. This may be 
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explained by the observation that the reaction between NAC and H2O2 is slow, with a small 
reaction rate constant (Aruoma et al., 1989); which suggests that high concentrations of both 
reactants may be required to react. In addition, NAC must be in considerable excess of H2O2 
for the reaction between them to occur at any significant rate (Moldéus et al., 1986). NAC 
attenuates H2O2-induced apoptosis in rat alveolar type II cells in vitro at similarly high 
concentrations: cells were pre-treated for 30min with 5mM NAC prior to treatment with 
500μM H2O2 (Fu et al., 2010). This supports the notion that high concentrations of NAC are 
required to elicit any effects when using H2O2 as an oxidative stress. 
One of the issues encountered with using high concentrations of NAC was the interference 
of this antioxidant with the viability assay used herein. The basis of the viability assay is the 
reduction of the tetrazolium salt, WST-1, by cellular dehydrogenases, to the coloured 
compound formazan. However, as NAC is a reducing agent, this resulted in interference at 
high NAC concentrations. A similar effect has also been reported by Bruggisser et al., 
(2002). In order to circumvent this, a viability assay that does not rely on reduction of 
tetrazolium salts would need to be utilized in future experiments. One way may be to 
homogenize PCLS into a single cell suspension and use flow cytometry to detect early and 
late apoptotic/necrotic cells by staining for Annexin-V and 7- Amino-Actinomycin (AAD). A 
foreseeable problem with this approach may be that the homogenizing procedure could 
further damage cells in the PCLS, resulting in an underestimate of PCLS viability. Other 
methods utilized in the literature have been to use confocal microscopy to examine PCLS 
stained with propidum idodide (PI) and/or calcein acetoxymethyl/ethidium homodimer-1 
(calcein AM/EthD-1), which stain the nuclei of dead cells (Henjakovic et al., 2008, Nassimi et 
al., 2010); although it is worth noting that the PCLS used in those experiments were 
approximately half the thickness of those used in the present study, which may be an 
important factor to consider.  
Pre-incubating neutrophil supernatants with 1mM NAC did not attenuate the effects of 
maximal airway closure, which suggests that oxidative stress is not involved to any great 
 198 
extent in neutrophil supernatant-induced small airway dysfunction. This is not altogether 
unsurprising, as reactive oxygen species are highly unstable, so it is unlikely that they will 
remain present in neutrophil supernatants throughout their storage. However, it is possible 
that NAC was required in greater excess in order to be effective, therefore neutrophil 
supernatants could be pre-incubated with even higher concentrations of NAC in order to 
establish whether or not oxidative stress is involved. To the author’s knowledge, there is not 
a validated way to measure the concentration of ROS in supernatant; therefore it is difficult 
to establish whether or not oxidative stress is a feasible target. Due to the interference with 
the assays, it was not possible to establish whether or not NAC could attenuate neutrophil 
supernatant-induced loss of PCLS viability; therefore alternative viability assays, as 
described above, could be utilized in order to investigate this. However, the current data 
suggest that oxidative stress does not contribute significantly to small airway dysfunction in 
rat PCLS associated with neutrophil supernatants. 
6.4.2. NE inhibition could attenuate reduction in maximal airway closure caused by 
neutrophil supernatants 
The results of the current chapter suggest that inhibition of NE may attenuate the reduction 
in maximal airway closure caused by incubation with neutrophil supernatants. Although not 
significant, there was a ~45% increase in maximal airway closure when supernatants were 
pre-incubated with NE inhibitor (324745), compared with COPD supernatant alone. The 
effects of elastolytic activity on small airway dynamics were discussed in detail in Section 
5.4; however, as the results from Chapter 5 are somewhat discordant with the literature, it is 
difficult to reconcile the effect that elastase inhibition may have on small airway function. 
One possible explanation may be that NE has been shown to induce PGE2 release from 
bronchial epithelial cells, and PGE2 is a known bronchodilator (Perng et al., 2003). As such, 
inhibition of NE may reduce this release of PGE2, and thus increase maximal airway closure. 
In order to validate this hypothesis, levels of PGE2 in the PCLS supernatant could be 
measured. Alternatively, neutrophil supernatants could be pre-incubated with indomethacin, 
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a non-selective prostaglandin inhibitor, to investigate whether this also attenuates small 
airway dysfunction. 
NE inhibition did not have any significant protective effects against loss of PCLS viability. 
This result is concordant with the results of Chapter 5, where elastase was shown to have no 
effect on PCLS viability (section 5.3.4), and, therefore, does not appear to be involved in 
neutrophil supernatant-induced loss of PCLS viability.  
6.4.3. MMP-9 inhibition had no effect on neutrophil supernatant-induced small airway 
dysfunction and loss of PCLS viability 
Inhibition of MMP-9 had no protective effects against the reduction in maximal airway 
closure, nor the loss of PCLS viability caused by incubation with neutrophil supernatants. 
However, this may be because the inhibitor used was not adequately inhibiting MMP-9. The 
results of the present chapter suggest that after 30 min there was no inhibition of MMP-9 in 
the sample; however there is an ~three-fold reduction in MMP-9 activity following overnight 
incubation. Neutrophil supernatants were pre-incubated with the inhibitor for 30 min, 
therefore it is possible that MMP-9 activity in the sample was still high and, thus, continued 
to damage PCLS.  
One of the reasons why the inhibitor may have been so ineffective is that it was a reversible 
inhibitor, therefore may not be permanently inhibiting MMP-9 throughout the incubation 
period. In addition, the assay used to determine MMP-9 activity may not have been 
appropriate to optimise the inhibitor. The assay used to measure active MMP-9 in 
supernatants is a fluorometric assay that measures the enzyme activity of active MMP-9, 
and is described in detail in Section 3.2.3. The assay utilizes a plate coated with a 
monoclonal antibody that binds to MMP-9 in the sample; therefore binding of the inhibitor 
may alter the conformation of MMP-9 so it no longer effectively binds to the antibody coated 
on the plate. However, as there was observable inhibition following overnight incubation with 
the inhibitor, this is unlikely. It is difficult to perform a time-course using this assay, as 
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samples need to be incubated on the plate for two hours; therefore this is the minimum time-
point for measurement. An activity assay, similar to that used to measure NE activity (section 
3.2.2) might be more appropriate, as it enables immediate determination of enzyme activity. 
However, to the author’s knowledge, there are currently no specific fluorogenic or 
colormetric substrates for MMP-9. Zymography is a semi-quantitative method to measure 
MMP-9 activity through the digestion of gelatin that is incorporated into a Tris-Glycine gel. 
Samples are temporarily denatured, separated on these gelatin gels, and then renatured and 
stained to reveal white bands on a dark background where MMP-9 has digested the gelatin. 
Pro- and active-MMP-9 concentration can then be semi-quantitatively determined by 
comparing them against an MMP-9 standard. This could be used to optimise conditions for 
the inhibitor: the inhibitor could be added to the renaturing buffer at different concentrations 
or for different lengths of time, and then the gel developed as normal. The intensity of the 
band can then be compared with samples renatured in buffer without inhibitor (from the 
same gel) to determine whether the inhibitor was working.  Although this will only provide 
semi-quantitative data, it may be a more appropriate way to optimize the conditions for the 
inhibitor. 
Given the variable results with the chosen inhibitors, it may have been a better approach to 
use more broad-spectrum inhibitors of MMP’s or serine proteases initially, prior to narrowing 
down to more specific inhibitors. This may have given better focus as to which specific 
proteases would best be targeted for inhibition, and provide a stronger basis for assessing 
the effectiveness of more specific inhibitors.   
6.4.4. Discrepancy in the effect of neutrophil supernatants 
One notable observation in the present chapter is that the effects of COPD neutrophil 
supernatants were dissimilar to those previously reported in Chapter 4. In Chapter 4, there 
were significant reductions in baseline airway patency, EC50 to CCh and maximal airway 
closure when PCLS were incubated with COPD neutrophil supernatants. In the present 
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chapter, not all of these effects were replicated. The supernatants used to investigate NE 
inhibition again caused reductions in maximal airway closure, but had no effects on either 
EC50 or baseline patency; and the supernatants used to investigate the effects of NAC and 
MMP-9 inhibition resulted in virtually no small airway function following overnight incubation 
with PCLS. This difference is difficult to reconcile, as neutrophils were treated in exactly the 
same way, and there were no significant differences in subject demographics of patients 
used between the Chapters 4 and 6. Therefore, this result most likely reflects the variability 
in the PCLS. In order to try and minimise the effects of variability between different animals, 
PCLS from two different rats were used when investigating the effects of supernatants from 
each patient, and at least four PCLS were used for each condition investigated. However, 
this method is clearly not sufficiently robust to adequately minimise airway/PCLS variability. 
Another caveat is that PCLS are grouped on Day 1 by airway closure at 10μM CCh, and not 
by EC50; therefore there may be differences that exist between the airways prior to any 
treatment. However, it would not be feasible to attempt to equally group PCLS based on 
both of these parameters. As such, increasing the number of rats per supernatant, and the 
number of PCLS per condition, may further minimise the variability between PCLS and thus 
provide more consistent results. 
6.4.5. Hypothesis: accept/reject 
The hypothesis at the beginning of this chapter was:  
“The antioxidant NAC, and/or inhibitors of NE and/or MMP-9 will inhibit small airway 
dysfunction and reduced PCLS viability in PCLS incubated in stimulated neutrophil 
supernatants from COPD patients.” 
With the exception of pre-incubation with NE inhibitor and its effects on restoring small 
airway function, the results of the present chapter mean that this hypothesis has to be 
rejected.  
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Chapters 4 investigated the effects of neutrophil products on rat PCLS, and reported that 
neutrophil supernatants from COPD patients induce aberrant small airway function and loss 
of PCLS viability. Chapter 5 examined two potential mechanisms (oxidative and elastolytic 
stress) that may contribute to neutrophil-induced dysfunction; and the present chapter 
(Chapter 6) attempted to attenuate the neutrophil supernatant-induced damage using 
protease inhibitors and antioxidants. The final chapter (Chapter 7) will therefore investigate 
small airway function in human PCLS from COPD patients, and determine whether or not 
this is concordant with the results obtained from Chapters 4 and 5.  
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Chapter 7.  
Small Airway Function in Human PCLS 
 204 
7. Small Airway Function in Human PCLS 
7.1. Introduction 
Small airways have been implicated as the main site of airflow obstruction in COPD (Hogg et 
al., 1968), and dysfunction of these airways has been significantly associated with decline in 
lung function (O'Donnell et al., 2004). Airflow resistance is inversely proportional to the radii 
of the airways raised to the fourth power; therefore even a small decrease in the airway 
lumen will result in a comparatively large increase in airflow resistance. Airway wall 
remodelling, as a result of fibrosis and hypertrophy of the various layers of the airway wall; 
occlusion of the airway lumen with inflammatory cells and exudates; and/or destruction of 
alveolar attachments, can all contribute to narrowing of the airway lumen and, thus, 
increased resistance to airflow. 
Despite their importance in the pathophysiology of COPD, small airways are notoriously 
difficult to investigate in vivo. Standard pulmonary function tests are not particularly reliable 
at specifically assessing small airway dysfunction; however single and, more recently, 
multiple breath nitrogen washouts; exhaled nitric oxide; and impulse oscillometry are used 
as non-invasive measures of small airway dysfunction in humans (Stewart et al., 2013). 
Imaging techniques, such as high resolution computed tomography (HRCT) and magnetic 
resonance imaging (MRI) are also used to assess and diagnose small airways disease. As 
described in previous chapters (Chapters 1, and 4-6), PCLS is an ex vivo preparation of lung 
tissue that includes functional small airways in their native microenvironment, which enables 
direct investigation of small airway dynamics, independent of in situ inflammatory responses 
that may confound their investigation.   
In Chapters 4-6, rat PCLS were used as an ex vivo test system to investigate small airway 
function in a “pathological” microenvironment, that may be extrapolated to indicate certain 
mechanisms of COPD pathophysiology; for example the effect of neutrophil activation. In 
order to investigate the relevance of this acute rat model to COPD, small airway function 
was assessed in the present chapter in PCLS from resected human lung tissue samples.  
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7.1.2. Hypothesis 
From the above introductory observations, the hypothesis of the present chapter was 
therefore that: 
“Ex vivo small airway function in human PCLS will differ between tissue from non-smokers, 
smokers and COPD patients, and this will correlate with lung function parameters.” 
7.1.3. Aims 
In order to investigate this hypothesis, the aims for this chapter were to: 
1. Generate PCLS from resected human lung tissue, and investigate small airway 
function. 
2. Assess any correlations between ex vivo small airway function and subject 
demographics. 
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7.2. Methods 
7.2.1. Subject selection 
Lung tissue samples were obtained from patients undergoing surgical resection at the Royal 
Brompton Hospital, London, which were determined macroscopically normal by a resident 
pathologist. Through accessing patient notes and lung function data, patients with COPD 
were categorised as those with FEV1: FVC ratio <0.7, and smoking history of >10pack years, 
as defined by GOLD, 2014. Smokers had >10 pack-year smoking history (50 pack-years, 
Table 7.1), but otherwise normal lung function; and non-smokers had variable, but negligible 
smoking history (two were never smokers, one patient smoked occasional cigars) and 
normal lung function. All subjects gave written, informed consent as approved by the Royal 
Brompton, Harefield and NHLI Research Ethics Committee (ethics number 10/H0504/9). 
7.2.2. Human tissue inflation and PCLS generation 
Human incubation buffer (human IB) comprised Roswell Park Memorial Institute (RPMI) 
1640 media supplemented with 100µg/ml (1% v/v) penicillin/streptomycin, 4mM (2% v/v) L-
glutamine, and 50µg/ml (0.5% v/v) gentamycin. Tissue inflation was undertaken on ice, in a 
small water bath filled with ice-cold slicing buffer. Evenly-spaced injections of ~100µl 3% (w/v) 
agarose were administered throughout the tissue until adequately inflated (approximately 1-
2ml/g tissue). Inflated tissue samples were then left to solidify. The outer membranous layers 
of the tissue were sliced off and the orientation of airways and blood vessels determined. 
Eight mm cores were cut through the tissue, and placed in slicing buffer prior to slicing. 
PCLS were generated as described previously (see Section 2.2.1.2), and were sliced at 400-
450µm thickness. PCLS were placed in individual wells of a 24-well plate in 1ml human IB 
and then washed as described previously. Contraction and relaxation analysis was 
performed as described previously (Sections 2.2.1.4 and 2.2.1.5).  
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7.2.3. Data Analysis 
As data sets were not assumed to be normally distributed, non-parametric statistical tests 
were used in all cases. However, for familiarity of presentation, data are presented as mean 
± SEM. Comparisons between subject demographics, and between airway function 
parameters were conducted using Mann-Whitney t-tests, or Kruskall-Wallis (ANOVA) tests 
followed by Dunn’s post-correctional tests. Correlations between small airway function and 
subject demographics were performed using Spearman’s rank correlation co-efficient. 
Concentration-response curves for contraction analyses were constructed by log-
transforming CCh concentration, and plotting against airway closure (Section 2.2.1.4). Non-
linear regression curves were then constructed, from which EC50 values were determined. 
The null hypothesis of no significant differences between groups was rejected at p<0.05. All 
statistical analysis was performed using GraphPad Prism v5.0 software. 
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 7.3. Results 
7.3.1. Subject demographics 
Subject demographics are shown in Table 7.1. Non-smoker subjects were approximately 25 
years younger than both smokers and COPD patients (p<0.05 vs. COPD patients); however 
smokers and COPD patients were matched for age and smoking history. Smokers and 
COPD patients had similar FEV1 % predicted, and both were higher than non-smokers. 
COPD patients did, however, have significantly lower FEV1/FVC ratio, compared with non-
smokers and smokers. Detailed patient history (including medication, diagnosis and reason 
for surgery) was unavailable for most subjects; however one non-smoking subject was 
diagnosed with pulmonary hypertension, and another with α1-AT deficiency. It is of note that 
with the COPD patients, despite FEV1/FVC values falling within the criteria of a COPD 
diagnosis, the FEV1% predicted values are very high. This may allude to a misdiagnosis; 
however, as mentioned previously, detailed patient history is not available for most patients, 
therefore this is difficult to check. It is, nevertheless, an important point to bear in mind when 
interpreting any future results.  
7.3.2. Airway closure of airways in human PCLS  
In response to CCh, airways in PCLS from all subject groups closed in a concentration-
dependent manner, with maximal increases above baseline of approximately 38-56% at 3-
10μM CCh. Despite there being no significant differences, airways in PCLS from COPD 
patients had ~1.5-fold higher maximal airway closure at 10μM CCh, compared with non-
smokers. All three subject groups had similar EC50 values within 50nM of each other (Table 
7.2, Figure 7.1).  
7.3.3. Passive airway reopening of airways in human PCLS 
Following CCh washout, airways in PCLS passively reopened to >95% of their original pre-
CCh patency (0%) by 60 min, and all had reopened to <50% maximal airway closure in <0 
min, as reflected by t1/2 values (Figure 7.2, Table 7.2)). Airways in PCLS from the single non-
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smoker available for use in the experiment reopened to ~10% larger than their pre-CCh 
patency almost immediately after washout, and then closed back to 0% over a further 40 
min. This was much quicker than airways in PCLS from smokers, which took ~20 min to 
reach their pre-CCh patency, and then continued to enlarge beyond their baseline patency 
over 60min. Airways in PCLS from two COPD patients took around 40 min to reach their pre-
CCh patency; however, unlike the other two subject groups, these airways did not enlarge 
beyond their pre-CCh patency, and, despite being very close, did not even reopen back to  
0% after 60 min.  
Table 7.1. Subject demographics for human PCLS experiments 
 Non-smokers 
Smokers 
(Current/Ex) 
COPD 
N 3 8 (2/6) 5 
Age            42 ± 6 74 ± 2 74 ± 3* 
Gender (m/f) 0/3  4/3$ 3/2 
Smoking history (Pack 
years) 
N/A#  50.8 ± 21.8 43.7 ± 9.3 
FEV1 (L)          2.5 ± 0.3  2.2 ± 0.3    1.9 ± 0.2 
FEV1 predicted (%)      75.0 ± 11.4         85.2 ± 5.4    90.8 ± 11.5 
FVC (L) 3.3 ± 0.4  2.8 ± 0.4   3.4 ± 0.3 
FEV1/FVC (L) 0.78 ± 0.07  0.77 ± 0.02   0.57 ± 0.04** 
Data are mean ± SEM. *p<0.05 non-smokers vs. COPD; **p<0.01 smokers vs. COPD. 
FEV1= Forced expiratory volume in one second. FVC= Forced vital capacity. 
#One patient smoked occasional cigars. $Some patient data unavailable. 
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Figure 7.1. CCh concentration-response curve of small airway closure in PCLS 
from human lung samples. Non-smokers (), n=3; smokers (), n=8; COPD (), n=4. 
Data are mean ± SEM. There are no significant differences between any data points.  
Figure 7.2. Passive reopening of small airways in PCLS from human lung samples, 
following CCh-washout. Non-smokers (), n=1; smokers (), n=4; COPD (), n=2. 
Data shown are mean ± SEM. There are no significant differences between any data 
points. 
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7.3.4. Correlations with lung function 
There were no significant correlations or trends between any lung function parameters and 
maximal airway closure (Table 7.3). An example for the FEV1/FVC ratio is shown in Figure 
7.3. 
7.3.5. Summary of results 
The results of the present chapter show: 
1. Small airways in PCLS from resected lung tissue from COPD patients have greater 
maximal airway closure than either smokers or non-smokers. 
2. Airways from all subject groups reopened >50% to their pre-CCh patency almost 
immediately after washout; however those from COPD patients took longer to reopen 
completely, compared with either non-smokers or smokers. 
3. There were no significant correlations between small airways function and subject 
demographics. 
 
Table 7.2. Function of small airways in human PCLS, in response to CCh  
 Airway Closure Airway Reopening 
Subject 
Group 
Maximal 
Closure (%) 
[CCh] for 
maximal 
closure (µM) 
EC50 (nM) 
 
T1/2 (min) 
 
Time to 
(0%) (min) 
Non-smokers 39.6 ± 6.5 3 233 ± 155 <0 <0 
Smokers 
(Current + Ex) 
47.2 ± 5.1 3 180 ± 55 
<0 22.2 
COPD 56.5 ± 9.7 10 206 ± 82 <0 - 
Data are mean ± SEM. T1/2= Time taken to reach 50% maximal airway closure. 
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Table 7.3 Correlations between ex vivo airway function and subject demographics 
Maximal airway 
closure vs. 
Spearman Rank 
Correlation 
Coefficient (r) 
P-value n 
Age 0.34 0.22 15 
Pack years 0.11 0.70 15 
FEV1 (L) -0.22 0.41 16 
FEV1 % predicted 0.29 0.34 13 
FVC (L) -0.07 0.80 16 
FEV1/FVC (L) -0.28 0.29 16 
FEV1= Forced expiratory volume in one second. FVC= Forced vital capacity. 
Figure 7.3. Relationship between lung function (FEV1/FVC) and small airway 
closure in a group of non-smokers (), smokers () and COPD patients (). No 
significant correlation (Spearman rank correlation coefficient).  
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7.4. Discussion 
The present chapter investigated the function of small airways in PCLS from resected tissue 
samples from non-smokers, smokers and COPD patients.  Despite being non-significant, the 
results indicate a trend for the sensitivity and maximal closure of small airways to cholinergic 
stimulation being greater in COPD patients, compared with either smokers or non-smokers. 
These results also suggest that this is an effect of disease state, rather than smoking history, 
as COPD patients’ airways were more hyperresponsive than smokers without airflow 
obstruction.  
7.4.1. Airway hyperresponsiveness in COPD 
Airway hyperresponsiveness has historically been associated with asthma; however, there is 
increasing evidence that it is also a prominent feature of COPD. In the GLUCOLD study (van 
den Berge et al., 2011, 2012), 94% of COPD patients were found to be hyperresponsive. In 
this same study, severity of AHR was significantly correlated with high sputum neutrophilia 
and worse airflow obstruction, as determined by lower FEV1 and FEV1/IVC ratios.  (Lancas 
et al., 2011) also demonstrated that parenchymal strips from COPD patients were 
hyperresponsive to cholinergic stimulation, compared with non-smoking controls; and also 
reported a significant reduction in elastic fibres in COPD parenchymal strips, compared with 
controls.  
7.4.2. Potential mechanisms 
7.4.2.1. Increase in smooth muscle mass 
There are a number of potential mechanisms that may contribute to airway 
hyperresponsiveness in COPD. Firstly, a number of studies have demonstrated increases in 
airway smooth muscle in COPD patients. Saetta et al., (1999), Bosken et al., (1990) and 
Cosio et al., (1980) have all histologically investigated small airways in lung sections from 
COPD patients and asymptomatic smokers, and found there was a significant increase in 
smooth muscle area in the former group, compared with the latter. A computational model of 
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small airway dynamics demonstrated that increased smooth muscle mass could cause 
airway hyperresponsiveness (Lambert et al., 1993); therefore, this is a feasible mechanism 
to explain the results of the present chapter. In order to explore this further, sections of 
PCLS could be stained for airway smooth muscle and the thickness quantified, to investigate 
whether or not this correlates with ex vivo small airway function. 
7.4.2.2. Reduced elastic recoil 
Another potential mechanism is reduced elastic recoil of the airways, caused by proteolytic 
destruction of the extracellular matrix. As described in more detail in previous chapters, a 
protease-antiprotease imbalance is one of the leading hypotheses regarding COPD onset 
and progression. Proteases, including elastases, collagenases and MMPs, degrade 
components of the extracellular matrix, which may alter airway dynamics. Airway closure is 
an active process that is dependent on a balance between the force of contraction elicited by 
shortening of the smooth muscle fibres, and the opposing forces generated by parenchymal 
attachments to the airways. Damage to these parenchymal attachments may reduce the 
load opposing smooth muscle contraction, leading to exaggerated narrowing of the airways. 
This was demonstrated by Khan et al., (2010): overnight incubation of mouse PCLS with 
elastase and/or collagenase resulted in increased velocity and magnitude of airway 
contraction. There is a reduction in the elastin fibres in the alveoli and small airway walls in 
COPD patients, compared with control subjects, and this reduction correlates with worsening 
lung function (Black et al., 2008). This loss of elastin is thought to contribute to reduced 
elastic recoil of the airways, which, alongside diminished alveolar attachments, leads to 
increased airway narrowing. In order to investigate this further in the present study, sections 
of PCLS could be stained for structural components of the airways, to assess whether or not 
there are any correlations between airway function and structural damage. 
The results of the present chapter also suggest that airways from smokers and COPD 
patients take longer to reopen than those from non-smokers. Although the numbers are very 
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low in these experiments, so no firm conclusions can be drawn, this would also be 
concordant with the results of the Khan et al study (2010), which also demonstrated reduced 
relaxation velocity in mouse PCLS treated with elastase and/or collagenase. Only passive 
relaxation was measured in the present study, so it would be interesting to also investigate 
the dynamics of drug-induced relaxation, or the effects of pre-treatment with drugs such as 
β2-adrenergic agonists, which induce smooth muscle relaxation. 
7.4.2.3. Increase in muscarinic receptors 
One other potential mechanism that may mediate airway hyperresponsiveness could be an 
increase in, or dysfunction of, muscarinic receptors. Cholinergic stimulation of airways is 
mediated by muscarinic receptors; in particular, in humans, M2 and M3 subtypes. Airway 
contraction is thought to be mediated predominantly by M3 receptors; however M2 receptors 
are thought to have indirect effects on airway contraction by inhibiting relaxation pathways 
(Fryer et al., 1998).  Therefore, increased numbers of these receptors could result in 
enhanced, or hypersensitive, contraction of the airways in response to cholinergic 
stimulation. To the author’s knowledge, there is currently no evidence to suggest that there 
is an increase in muscarinic receptor expression in COPD; however this is something that 
could be investigated by immunohistochemically staining sections of PCLS for the different 
receptor subtypes, and assessing whether or not there are differences between subject 
groups.  
7.4.3. Correlations with lung function 
The present study did not find any correlations with any lung function parameters. This may 
be due to low numbers of subjects, although the r-values were also very low. Increasing the 
number of experiments may allude to some correlations between ex vivo airway dynamics 
and subject demographics, although these may be more statistically significant than 
biologically/pathophysiologically significant. One possible issue that may be “masking” 
significant correlations is the inclusion of non-smokers and smokers who, by definition, have 
 216 
normal lung function. To circumvent this, COPD patients could be considered independently 
of the other two subject groups; however, at this stage, the numbers of COPD patients are 
too low. Another potential reason may be that airways from COPD patients do indeed have 
small airway disease, and are, therefore, already partially closed and/or less able to close in 
response to CCh stimulation, thus resulting in a lack of meaningful correlations. This was 
investigated herein, and there were no significant differences in the baseline airway lumen 
size between subject groups (data not shown), making this possibility unlikely, but not to be 
ruled out completely.  
7.4.4. Hypothesis: Accept/Reject 
The hypothesis of the present chapter was: 
“Ex vivo small airway function in PCLS will differ between tissue from non-smokers, smokers 
and COPD patients, and this will correlate with lung function parameters.” 
Although there were no significant results, there were some interesting trends with regards 
to disease state and small airway function. However, there were no correlations with patient 
demographics, so, at this stage, I can neither accept nor reject this hypothesis.  
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8. General Discussion 
8.1. Summary of results 
The present thesis investigated the role of neutrophil products primarily on rat small airway 
structure and function. Stimulated neutrophil supernatants from COPD patients reduced 
PCLS viability and caused reductions in maximal airway closure, EC50 to CCh, and baseline 
airway patency, compared with non-COPD neutrophil supernatants; however, there were no 
significant differences in protease composition of neutrophil supernatants between non-
smokers, smokers and COPD patients. In order to assess the contribution of different 
components of neutrophil supernatants to this aberrant function, PCLS were then incubated 
overnight with either H2O2 or PPE. Both H2O2 and PPE significantly reduced the maximal 
airway closure of small airways; however neither had any effect on either EC50 to CCh or 
baseline airway patency. H2O2 nevertheless significantly reduced viability of PCLS, whereas 
PPE had little or no effect. Aside from an NE inhibitor, which significantly attenuated the 
reduction in maximal airway closure, pre-incubation with protease inhibitors or antioxidants 
had no effect on the destructive effects of neutrophil supernatants. Finally, small airways in 
resected lung tissue from COPD patients displayed a trend towards having increased 
maximal airway closure and, thus, being more sensitive to CCh stimulation, compared with 
small airways from smokers and non-smokers. These combined observations merit some 
discussion of general principles, as outlined below. 
8.2. Use of PCLS as a model of small airways disease 
One of the objectives of this thesis was to establish whether or not PCLS could be used as a 
model of small airways disease (SAD), or at least the neutrophil-involved component of 
SAD. The pathophysiology of small airways disease in humans is complex and multifaceted, 
and ultimately results in increased narrowing of the airway lumen and, thus, increased 
airflow resistance. This can be due to proteolytic degradation of the attachments between 
the airway wall and the surrounding parenchyma, which can result in hypercontractility of the 
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airways due to the lack of parenchymal load opposing smooth muscle contraction; to mucus 
and inflammatory cell infiltrate occluding the airway lumen; and to remodelling and 
thickening of the airway wall through goblet and squamous cell metaplasia, smooth muscle 
hypertrophy and hyperplasia, and fibrosis (Baraldo et al., 2012).  
Of these mechanisms, the PCLS model in this thesis only addressed the destruction of the 
parenchymal attachments, and not the chronic remodelling aspect, which is in part due to 
the short exposure time of the PCLS to their relative insults, and the restricted range, and 
combination, of insults. The model in the present thesis was acute exposure of PCLS to 
either neutrophil supernatants, oxidative stress or elastolytic stress; therefore, there is, most 
likely, not enough time for these remodelling and repair processes to get underway. 
However, this may not be a limitation of the PCLS system in general, just the methodology 
used in the present thesis. In other studies, PCLS have been maintained in culture for up to 
5 days (Bergner et al., 2002); therefore, it may be possible to design a system to model 
more sub-acute exposure, involving low-level stresses over a longer time-frame, to 
reproduce some of the remodelling aspects of SAD pathophysiology.   
In addition, the present thesis only addressed airway function in response to cholinergic 
stimulation. This is physiologically relevant, as anticholinergics, such as tiotropium bromide, 
are a popular therapeutic strategy in the treatment of COPD (Montuschi et al., 2015). 
However, there are a number of other agonists that can mediate airway tone, including 5-HT, 
histamine, bradykinin, cysteinyl leukotrines (e.g. LTD4), and prostanoids (e.g. PGD2); and 
sensitivity to many of these factors is additionally enhanced by a pro-inflammatory 
environment. (Pelaia et al., 2008). Therefore, there are, more than likely, a number of 
additional agonists that modulate the aberrant airway tone observed in COPD that were not 
investigated in the present study. As such, it would be of interest to investigate the effect of 
neutrophil supernatants, H2O2 or PPE on airway function mediated by these other agonists, 
to identify whether or not particular agonist/receptor pathways are differentially affected in 
addition to the cholinergic pathway.  
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With regards to human PCLS, one of the advantages of the PCLS system is that it allows 
isolated investigation of small airway dynamics, without the potentially confounding impact of 
an inflammatory environment that would be present in in vivo studies. Therefore, the results 
obtained using PCLS, as a model, can be interpreted as being more due to long-term 
structural/physiological changes to the airways and/or the surrounding parenchyma, and 
more independent of the effects of inflammatory cells and/or an inflammatory environment. 
As such, PCLS may bridge a significant gap between current diagnostic and investigative 
tools with respect to small airways disease, as both airway function and histological structure 
can be assessed, whilst also being able to reconcile these results with actual patient data.  
One of the main disadvantages of the system is that the technique is invasive, as it requires 
lung tissue samples. Most patients also have significant co-morbidities, such as lung cancer, 
pulmonary hypertension or α1-AT deficiency; the effects of which are invariably difficult to 
predict accurately. In addition, a complete medical history is rarely provided, which makes it 
difficult to account for co-morbidities or drug intervention. In addition, lung tissue from 
patients with very severe disease and significant emphysema is very difficult to inflate. This 
potentially eliminates a whole cohort of patients that can be studied and, as these will be the 
subjects with the most severe disease, they would, in some ways, be the most interesting for 
our purposes.  
All of these factors should be taken into account when interpreting results using human 
PCLS. In order to circumvent this in the future, a larger cohort of patients should be used, so 
that variability due to co-morbidities is diluted. More extensive patient histories would also be 
advantageous with respect to possible sub-group analysis of the results.  
8.3. The use of neutrophils to model SAD pathophysiology 
One of the limitations of the present study with regards to modelling SAD is that only the 
effects of neutrophils were investigated. As described in Section 1.4.1, a number of 
additional inflammatory cells are thought to be involved in COPD pathophysiology, including 
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macrophages, T-cells, epithelial cells and fibroblasts; therefore there will be significant 
interplay between these cell types and, hence, their involvement in the development and 
progression of COPD. Nevertheless, it would be challenging methodologically to 
concurrently model the effects of different inflammatory cells, due to the number of variables 
it would entail. As such, any conclusions drawn from the present thesis should be 
considered in a wider context, taking into account the potential contribution of other 
inflammatory cells and mediators. However, one of the advantages of the PCLS system is 
that it does take in to account the potential involvement and interaction of lung structural 
cells, which are an important source of inflammatory mediators. This was demonstrated in 
the present thesis in Chapter 5, wherein the release of TNF-α and CINC-1 from PCLS 
following H2O2 or PPE exposure was investigated. As discussed in Chapter 5, this was not 
without its difficulties (namely, the presumed degradation of TNF-α and CINC-1 proteins by 
PPE); however, the PCLS system does provide a platform for investigating the role of 
structural cells in response to different stresses and their interaction with other inflammatory 
cells, and relating this with functional information. 
An additional limitation of the present thesis is that supernatants from the same number of 
neutrophils (10x106cells/ml) from non-smokers, smokers and COPD patients were 
investigated. There is evidence pertaining to a step-wise increase in the number of 
neutrophils in smokers, compared with non-smokers; and then COPD patients, compared 
with asymptomatic smokers, in sputum (Ilumets et al., 2008), BALF (Lofdahl et al., 2006), 
and bronchial epithelium (Di Stefano et al., 2009). As such, the characteristics of the PCLS 
system in the present thesis are not indicative of the in vivo environment. However, this 
system does enable investigation of inherent neutrophil defects or aberrant activity between 
the subject groups, without the confounding issue of different cell numbers; and the present 
thesis did display evidence for this in Chapter 4, whereby COPD neutrophil supernatants 
caused significant small airway dysfunction that neither smoker nor non-smoker 
supernatants could reproduce. In addition, when attempting to address this limitation, a 
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number of issues arose. Firstly, it was difficult to establish from the literature an appropriate 
ratio of neutrophil numbers between subject groups, as numbers varied considerably 
throughout the literature and from work in our own laboratory, in particular depending on 
where the count was obtained (i.e. sputum (Ilumets et al, 2008), BALF (Lofdahl et al, 2006), 
or airways (Di Stefano et al, 2009)). Secondly, the volume of supernatant would ideally need 
to stay constant; therefore neutrophils would have to be resuspended either more or less 
concentrated. It has been observed in our laboratory that when attempting to resuspend 
>10x106cells/ml, neutrophils tend to “clump” together and cannot be used; and, based on the 
minimal effects on airway function of supernatants from neutrophils stimulated with lower 
concentrations of fMLP, particularly in smokers and non-smokers (see Section 4.3.4.2), it 
was posited herein that diluting the neutrophils would result in very few observable effects. 
Therefore, it was difficult to develop a system whereby the relative numbers of neutrophils in 
non-smokers, smokers and COPD patients could be established.  
Another potential limitation in the present thesis is that the neutrophils were isolated from 
peripheral blood; therefore they may behave differently to neutrophils that have migrated into 
the lungs. Additionally, they were only exposed to one stimulus, fMLP, which, again, is 
probably not necessarily indicative of the environment in situ. However, neutrophils isolated 
from sputum or BALF will be in various states of activation and cell death; therefore, it would 
be difficult to ensure consistency between samples. As these neutrophils will be at least 
partly activated, it would be problematic to further stimulate them, and might also cause cell 
death. It may also be quite difficult to obtain adequate samples, particularly induced sputum 
from non-smokers, which would further complicate the experimental design. Overall, 
peripheral blood neutrophils are quiescent at the time of isolation; therefore, stimulation is 
relatively uniform and, importantly, can be controlled, as cells should be in similar activation 
states. The procedure is also relatively non-invasive, compared with induced sputum or 
bronchoscopy. Therefore, despite their limitations, peripheral blood neutrophils were a 
reasonable choice for the work in the present thesis. 
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8.4. The effect of other parenchymal structures on airway contraction 
One of the main advantages of the PCLS system is that airways are maintained in their 
native microenvironment. This environment will include intact parenchymal attachments to 
the airways, in addition to blood vessels also within the parenchyma. Particularly within the 
airway generations that are of interest in the present study, airways are often situated 
alongside blood vessels. Blood vessels also contain smooth muscle, and so may also be 
subject to any constrictor/relaxant mediators that are either released by neutrophils and 
thereby contained within the supernatants (see Table 1.1), or released from the lung tissue 
in response to the stresses added, such as prostaglandins and leukotrines.   
Cholinergic stimulation has vasodilatory effects via the release of NO from vascular 
endothelial cells that act on vascular smooth muscle (Furchgott et al., 1980).  Blood vessels 
in rat PCLS do dilate in response to acetylcholine, but only following contraction with a 
thromboxane mimetic, and this response is dependent on NO and endothelial-derived 
hyperpolarizing factor (EDHF) (Moreno et al., 2006). As such, it is a possibility that the 
experimental stresses imposed in the present thesis (e.g. neutrophil supernatants, PPE and 
oxidative stress), in addition to carbachol, may also affect vascular function. Therefore, 
altered blood vessel function may impact on the dynamics of small airway closure within the 
PCLS, and blood vessel contractility may alter airway calibre. To date, few studies have 
concurrently investigated both small airway and vascular function within the same PCLS 
(Perez et al., 2005, Perez et al., 2005), possibly as it requires a modified inflation technique 
using gelatin to perfuse the pulmonary vasculature. However, this may be of interest to 
investigate in any future work, and would be more representative of the in vivo environment, 
whereby the dynamics of these structures work in concert.  
8.5. The use of WST-1 as suitable viability assay 
Throughout this thesis, WST-1 has been used as a measure of PCLS viability. This assay 
measures mitochondrial function via the reduction of WST-1, a tetrazolium salt, into 
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formazan; which elicits a measureable colour change. This assay is simple, low cost, and 
takes very little time; thus was utilized throughout this study. However, the drawbacks of the 
use of this particular assay are that, as the PCLS are made up of multiple cell types, it was 
impossible to establish any heterogeneity in cell viability across these populations. There 
was often a disconcert between airway function and PCLS viability; suggesting that the 
airway smooth muscle cells were still quite viable in contrast to other cell types, which then 
decrease the “net” viability of the PCLS.  
One way to circumvent this in future experiments may be to use a universal contractile 
agonist, for example potassium (K+) that will indiscriminately depolarise smooth muscle. This 
will determine whether or not the smooth muscle is able to contract and is, as such, viable. 
K+ depolarises the smooth muscle cell membrane, opening voltage-gated Ca2+ channels that 
facilitate the influx of extracellular Ca2+, which, in turn, initiate smooth muscle contraction 
(see Section 1.5.1). Therefore, a high K+ solution will initiate smooth muscle contraction 
independent of agonist binding. This would allow distinction between aberrant smooth 
muscle contraction due to defective cholinergic stimulation (i.e. downregulation of muscarinic 
receptors), and that due to loss of viability in smooth muscle cells. In addition, TUNEL 
staining could be utilized on histological sections of PCLS in order to determine any 
heterogeneity between viability of cell types.  
8.6. The use of the rat to model human respiratory disease 
There may also be contention with regards to the use of rat tissue to model human disease. 
There are a number of anatomical differences between rat and human lungs, including 
different numbers of lobes: in the rat, there are one and four lobes comprising the left and 
right lungs, respectively (Kling, 2011); whereas in the human there are two lobes comprising 
the left, and three lobes comprising the right lung. Additionally, the airway branching pattern 
in human lungs is fairly symmetrical, dichotomous branching; whereas in rat there is a 
monopodial branching pattern (Yeh et al., 1979). There are also inevitable differences in 
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their functional responses to cytokines: rodent airways have also been shown to respond 
poorly to leukotrines (Held et al., 1999), which cause significant contraction human airways 
(Dahlén et al., 1980). With regards to more closely mimicking human airway function, guinea 
pigs would have been a more physiologically relevant model organism to use. Guinea pigs 
are not rodents (D'Erchia et al., 1996) and, like human airways, bronchoconstrict in response 
to leukotrines (Drazen et al., 1980). Guinea pig and human airways also respond similarly to 
electric field stimulation and capsaicin, compared with airways in rat and mice; again 
highlighting species differences with respect to neuronal innervation (Schleputz et al., 2012). 
However, guinea pig PCLS have not been as widely used, presumably due to the issue that 
the airways contract whilst generating the PCLS- a problem that has been encountered in 
our own laboratory, There has been some attempt to reconcile this issue by adding 
isoprenaline to the media, in order to prevent spontaneous airway closure (Ressmeyer et al., 
2006); however, in the present thesis, the addition of a bronchodilator may have affected the 
interpretation of results. 
However, there are advantages to using rats over other model organisms: they are 
inexpensive, easy to handle, quick to breed and mature, and large enough to be able to 
competently perform lung dissections and obtain PCLS. As all rats were the same strain, 
housed in the same environment, and treated similarly throughout their lifetime, this limits 
the effects of environmental and genetic factors potentially confounding any results.  This 
may even be an advantage over the use of human tissue samples, which, even if it were 
ethically viable to obtain samples from healthy, non-smoking individuals, would still be 
subject to genetic and environmental variability. As mentioned previously, all human lung 
samples used in the present thesis were obtained following lung resection for surgery or 
transplantation, which, by definition, indicates the presence of serious lung disease in the 
patient, not to mention any other co-morbidities. Therefore, human PCLS would be 
impractical for studying the effects of neutrophil supernatants, as the considerable amount of 
variability in both tissue and supernatant would confuse data interpretation without very large 
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sample sizes, which would also have been unfeasible in the time-frame of the present study. 
As such, the use of rats provides a reasonable alternative for study of small airway structure 
and function in the present thesis. 
8.7. Reproducibility of results 
Another limitation in the present thesis was the lack of reproducibility between experiments, 
most notably in the effects of COPD neutrophil supernatants in Chapter 4 compared with 
Chapter 6, whereby there was a reduction in EC50 and baseline airway patency in the former 
that was not observed in the latter. This is difficult to reconcile, as neither the rats nor the 
neutrophils were treated any differently between these experiments. One possibility is that 
the sample sizes are too low to account for the inherent variability between airways on lung 
slices, and between patients and their neutrophil supernatants. This may be in the number of 
PCLS used per condition, the number of rats used per supernatant, and/or the number of 
supernatants tested overall.  When testing drugs or invariable compounds (e.g. H2O2 and 
PPE), the conditions set out appeared to be adequate, as the number of PCLS/rats are only 
controlling for the variability in lung tissue. The experiments with the neutrophil supernatants 
are clearly far more complex, as the lung tissue, small airways, and neutrophil supernatants 
will have considerable variability. Consulting a statistician to determine the appropriate 
sample size for the number of PCLS per conditions, rats, and supernatants could help 
remedy this in future experiments. 
8.8. Clinical implications 
As mentioned previously, the work carried out in the present thesis represents one aspect of 
a complex, multifaceted disease; therefore, the clinical implications are limited. Neutrophil 
supernatants from COPD subjects had increased effects on small airway function, compared 
with neutrophil supernatants from non-smokers and smokers, which suggests innate 
differences in supernatant content. This may be important in COPD pathophysiology. H2O2 
and PPE mimicked some, but not all, of the effects of neutrophil supernatants. This suggests 
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that these mediators are involved in neutrophil supernatant-induced small airway 
dysfunction, but that there are other factors involved. Further analysis showed that, with the 
exception of NE, protease inhibitors and antioxidants had little or no effect on neutrophil 
supernatant-induced damage. Inhibition of NE did restore maximal airway closure, which 
indicates a restricted, but potential therapeutic effect; however, NE inhibitors have been 
used in a number of clinical trials and have shown little clinical efficacy (Kuna et al., 2012, 
Vogelmeier et al., 2012). Nevertheless, the work in the present thesis indicates that there are 
inherent differences in the degranulation products of neutrophils between COPD patients 
and smokers and non-smokers, owing to their differential effects on small airway function; 
however, none of the proteases measured in Chapter 3 seem to account for these 
differences. In addition, neither H2O2 nor PPE could completely reproduce the effects of the 
neutrophil supernatants. Therefore, this work suggests that there are additional neutrophil 
products responsible for the aberrant small airway function that may prove to be viable 
therapeutic targets in the future. 
8.9. Accept or reject overall thesis hypothesis 
The overall hypothesis for this thesis was: 
“Supernatants from fMLP-stimulated human neutrophils will significantly affect PCLS 
structure and small airway function in rat PCLS, and the effects of neutrophils from COPD 
patients will be more pronounced.  
In addition, these effects will be mediated by neutrophil proteases and/or oxidative stress, 
and addition of exogenous inhibitors or antioxidants will attenuate these effects.  
Finally, small airways in human PCLS will behave differently, compared with those from 
asymptomatic smokers and non-smokers” 
With regards to the first part of this hypothesis, fMLP-stimulated neutrophil supernatants did 
affect PCLS structure and viability and small airway function, and the effects of COPD 
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neutrophil supernatants were more pronounced, particularly with respect to EC50 to CCh and 
baseline airway patency. As such, this part of the hypothesis can be accepted. This 
suggests that the composition of COPD neutrophil supernatants are different to those of 
non-smokers and smokers, and this may be important in COPD pathophysiology. 
With regards to the second part of this hypothesis, H2O2 and PPE could partially reproduce 
the effects of neutrophil supernatants, with respect to maximal airway closure and PCLS 
viability (only H2O2). However, neither had any effect on the other airway parameters 
affected by neutrophil supernatants, and, with the exception of a NE inhibitor, protease 
inhibitors or antioxidants did not attenuate neutrophil-supernatant induced damage. As such, 
this part of the hypothesis can only be partially accepted. This suggests that oxidative stress 
and elastase may be involved in neutrophil supernatant-induced small airway responses; 
however additional mediators, and complex interactions between mediators, are likely to be 
involved. 
With regards to the final part of this hypothesis, small airways in PCLS from resected lung 
tissue from COPD patients displayed a trend for greater maximal airway closure; therefore 
this part of the hypothesis can be tentatively accepted. This suggests that small airways from 
COPD patients may be hyperresponsive; however increased sample sizes are required to 
validate this observation. 
8.10. Future work 
The acceptance and, more particularly, rejection of various aspects of the thesis hypothesis 
indicate avenues for future research, as outlined below.  
 Further characterise the protease composition of neutrophil supernatants, possibly 
using a high-throughput system such as MSD. This should enable assessment of a 
number of different proteases and/or mediators from one sample, without the fiscal 
and temporal constraints of optimizing and undertaking different assays for each 
protease. 
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 Measure the ROS content of the neutrophil supernatants, either directly or indirectly 
by measuring respiratory burst from neutrophils. This would allow assessment of 
whether or not ROS are a possible mediator in supernatant-induced airway 
dysfunction. 
 Further investigate mediator release from PCLS, following treatment with either 
neutrophil supernatants, H2O2 or PPE; in particular looking at lipid mediators. 
Measurement of PGE2 concentrations in PCLS supernatant was attempted as part of 
the work of this thesis using a commercially-available kit (Cayman Chemical); 
however, the results were inconclusive. Fluorescence-based immunoassays have 
been used successfully in the literature (Kirkby et al., 2013); therefore, these may be 
a better option. Additionally, experiments could be performed in the presence of 
indomethacin, a COX inhibitor that will block prostaglandin release. In order to 
circumvent the issue of degradation of mediators in the PCLS supernatant by 
proteases, PCLS could be homogenized and protein expression of mediators 
investigated using western blotting, or mRNA expression using PCR. 
 Further investigate the effects of H2O2 on small airway function, to try and reconcile 
its bronchoconstrictor effects, as discussed in the literature, and the effects observed 
in the present thesis. This would involve detailed time-courses and concentration-
responses, to elucidate whether the effects observed in the present thesis were a 
product of the decreasing viability of the PCLS, or whether H2O2 has a more complex 
involvement in mediating airway tone.  
 Perform detailed histological analysis to assess, in more detail, the viability of PCLS 
following the stresses induced in the present thesis. As the PCLS are a 
heterogeneous population of cells, it would be of interest to elucidate whether loss of 
viability is a uniform effect, or whether certain cell types are more susceptible. This 
may help explain some of the observed functional results; for example, the effect of 
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PPE, which significantly attenuated small airway closure, but had no effect on PCLS 
viability.  
 Further optimise and expand the inhibitors used in Chapter 6, in order to investigate 
further targets that may be causing small airway dysfunction. As discussed 
previously, NE was revealed as a relatively promising target from Chapter 6; 
however, NE activity was similar in supernatants from the three subject groups, 
suggesting it was not involved differentially in COPD supernatant-induced small 
airway dysfunction. This opens up the possibility of additional targets, that may be 
identified through, firstly, broad-spectrum inhibitors of particular protease classes 
(e.g. serine proteases), and then more specific inhibitors.  
 Increase the n-values for human PCLS samples, in order to validate (or otherwise) 
the observations in Chapter 7. 
 Investigate the effects of bronchodilators on human PCLS, to determine whether 
there are differences in responses between subject groups. In addition, use 
immunohistochemistry to investigate the numbers of muscarinic receptors on airway 
smooth muscle, and inflammatory cell infiltration into the airways, to see if either of 
these correlate with ex vivo airway function. Also, investigate the release of 
mediators in PCLS supernatant in response to different stimuli, e.g. LPS or H2O2, and 
determine if there are any differences between subject groups.  
 Finally, directly investigate the effects of sputum or BALF from COPD patients and 
controls on rat small airway function. These fluids should contain a variety of 
inflammatory cells and mediators that are upregulated in COPD, and therefore, would 
provide a more accurate microenvironment in which to incubate PCLS and examine 
small airway dysfunction in COPD.  
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